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A b strac t
Vitamin E has been shown to be beneficial in the prevention o f cardiovascular 
disease (CVD). The following research is concerned with assessing vitamin E status in 
healthy people and those with increased risk o f CVD, who may have an altered vitamin E 
status.
To understand the relationship between vitamin E intake, blood concentrations 
and metabolism healthy subjects were given varying single doses o f RRR a-tocopheryl 
acetate (a-TA) up to 780 mg (n=20). There was a greater uptake o f a-tocopherol in 
plasma and erythrocytes compared with platelets and lymphocytes. No dose-response 
relationship was observed, however there was a positive correlation between percentage 
increase in a-tocopherol concentration in plasma and erythrocyte with mg urinary a- 
carboxyethylhydroxychroman (a-CEHC) excreted. Less than 1% of a-TA was excreted 
as urinary a-CEHC.
Research into the absorption o f deuterium labelled (d6) a-TA showed a greater 
uptake into plasma and chylomicrons over 9 h when d6 a-TA was ingested with 17.5 g 
fat compared with 2.7 g fat (n=8). Furthermore, there was a greater uptake into 
chylomicrons over 9 h when d6 a-TA was ingested with toast and butter compared with 
cereal, cream and milk, both containing 17.5 g fat. This indicates the fat content and 
physical properties o f a meal affect a-tocopherol absorption.
The biokinetics o f newly absorbed d6 a-tocopherol into plasma, lipoproteins and 
blood cells was investigated in healthy subjects (11=12). d6 a-Tocopherol firstly entered 
the chylomicrons, followed by VLDL, then LDL and HDL. In platelets and lymphocytes 
there was a gradual increase in d6 a-tocopherol concentration. A third o f subjects 
exhibited a biphasic uptake o f d6 a-tocopherol in platelets, with an initial peak at 6 h.
Hypercholesterolemics are at increased risk o f CVD and have altered lipoprotein 
metabolism therefore they may have altered vitamin E biokinetics. To investigate this, 
hypercholesterolemic and normolipidemic males ingested 150 mg d6 a-TA (n=16). The 
d6 a-tocopherol uptake into plasma was similar but there was a lower uptake o f d6 a- 
tocopherol in low-density lipoprotein per g protein in hypercholesterolemics compared 
with normolipidemics. There was also a trend towards a lower uptake o f d6 a-tocopherol 
into erythrocytes, platelets and lymphocytes in hypercholesterolemics. A greater
percentage o f hypercholesterolemics exhibited a biphasic profile in the uptake o f d6 a- 
tocopherol into platelets compared with nonnolipidemics.
Cigarette smokers are subjected to increased free radical exposure and therefore 
may utilise more vitamin E. Steady-state vitamin E status was measured in cigarette 
smokers and non-smokers (n=30). Plasma and erythrocyte a and y-tocopherol levels were 
similar, however cigarette smokers had a lower concentration o f a-tocopherol in platelets 
and a- and y- tocopherol concentrations were lower in lymphocytes. Cigarette smokers 
excreted similar amounts o f urinary a-CEHC, but more y-CEHC compared with non- 
smokers.
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1.1 The discovery of vitamin E
In 1922 Evans and Bishop discovered a dietary factor essential for rat fertility, 
which was later classified as vitamin E. Twenty-four year’s later Evans et al (1936) 
isolated vitamin E from wheat germ oil, it was termed ‘tocopherol’ from the Greek 
meaning ‘to bring forth childbirth’ and later designated a-tocopherol. In the following 
years p-, y- and 5-tocopherol and four tocotrienols were also isolated. Researchers 
have since confirmed vitamin E as the most important in vivo lipid soluble antioxidant, 
protecting lipoproteins and cellular membranes from oxidative damage (Burton et al, 
1983; Tappel, 1962). More recently, researchers have described the involvement of a- 
tocopherol in cellular signalling and gene regulation (Azzi & Stocker, 2000). Vitamin 
E has also been proposed as beneficial in the prevention o f cardiovascular disease 
(Devaraj & Jialal, 1998; Gey et al, 1991; Kaul et al, 2001).
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1.2 Chemistry of vitamin E
Naturally occurring vitamin E consists o f four tocopherols (a, p, y and 5) and 
four tocotrienols (a, p, y and 5), they all have a chromanol ring and a hydrophobic C- 
16 phytyl tail (Figure 1.1). Tocopherols have a saturated phytyl tail whereas 
tocotrienols have three double bonds situated at carbons 3', T and 11'. The phytyl tail 
anchors vitamin E within membranes, positioning the chromanol ring at the 
hydrocarbon interface (Halliwell & Gutteridge, 1999).
Chromano 1 ring Phytyl tail
Tocotrienol
Figure 1.1 Chemical structure of tocopherol and tocotrienol isomers
Tocopherols and tocotrienols have a chromanol ring and phytyl tail. Tocopherols have a 
saturated phytyl tail, whereas tocotrienols have three double bonds. Tocopherols have three 
chiral centres at C2', C4' and C8'. There are 4 different isomers of tocopherol and tocotrienol; 
a; Rj and R2 = CH3, p; Rt = CH3 R2 = H, y; Ri = H R2 = CH3 and 5; Rj and R2 = H.
a-Tocopherol has three chiral centres on the C2' in the chromanol ring and 
C4' and C8' on the phytyl tail, either in the S or R configuration. Naturally occurring 
a-tocopherol has the R configuration at each chiral centre and hence is termed RRR-a- 
tocopherol (formerly d-a-tocopherol). a-Tocopherol can be synthesised by 
condensing trimethyl hydroquinone with isophytol. Synthetic a-tocopherol consists of
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approximately equal proportions o f the eight possible S and R configurations, and is 
termed all rac-a-tocopherol (formerly dl-a-tocopherol).
Burton and Ingold (1981) reported that the antioxidant capacity o f vitamin E is 
primarily determined by the bond dissociation energy o f the O-H bond. The 
chromanol ring stabilises the unpaired electron o f the a-tocopheryl radical. The 
stereoisomers of a-tocopherol have identical antioxidant activity but differ in their 
biologic activity (Herrera & Barbas, 2001). RflR-a-tocopherol, the most abundant 
form o f vitamin E in nature, has the highest biologic activity o f vitamin E based on rat 
foetal resorption-gestation assay and relative affinity for the hepatic a-tocopherol 
transfer protein (Bunyan et a l , 1961; Hosomi et al, 1997; Weiser et al, 1986; Weiser 
et al, 1996). y-Tocopherol has only 10% o f the biologic activity o f a-tocopherol 
(Bunyan et al, 1961).
Ingold et al (1987) synthesised deuterium labelled a-tocopherol. The 
deuterium can be situated on one, two or three methyl groups in the chromanol ring, 
these are termed d3, d6 or d9 a-tocopherol; figure 1.2 illustrates d9 a-tocopherol. The 
use o f deuterium labelled tocopherols has enabled investigators to simultaneously 
measure the RRR- and all rac-a-tocopherol bioavailability and biokinetics, both in the 
free and ester form (Cheeseman et al, 1995; Ingold et al, 1987a; Traber et al, 1988; 
Traber etal., 1990a).
cd3
Figure 1.2 Deuterium 9 labelled jR&R-oc-tocoplieroI
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1.3 Vitamin E intake
1.3.1 Food sources
Plant and products made from them are the predominant dietary source of 
vitamin E. Nuts, seeds, vegetable oils and some grains are rich sources o f vitamin E, 
differing in their proportions o f the different vitamin E homologues (Bauemfeind, 
1980). Wheat germ, safflower oil and sunflower oil are all rich sources o f a- 
tocopherol. The amount o f vitamin E within foods at the point o f consumption is 
difficult to assess as it depends upon the effects o f processing, storage and preparation 
(Expert Group on Vitamins and Minerals, 2003). y-Tocopherol is the most abundant 
form o f vitamin E within the American diet, due to their high consumption of com and 
soybean oil (Jiang et al., 2001; McLaughlin & Weihrauch, 1979; Swanson et al.,
1999). However, a lower proportion o f y-tocopherol rich oils are consumed within the 
UK (NDNS, 2003). Vitamin E supplements are widely available, both as RRR and all 
rac-a-tocopherol. These supplements are usually esterified with acetate or succinate at 
the reactive hydroxyl group within the chromanol ring, thereby increasing the 
molecule’ s stability and extending the products shelf life. RRR-a-tocopherol naturally 
occurs unesterified in food.
Previously, international units (IU) have been used to report vitamin E activity 
in foods. IU were assigned to vitamin E homologues stating the specific activity o f 1 
mg all raoa-tocopheryl acetate, therefore, 1 IU is equivalent to 0.67 mg RRR-a- 
tocopherol (Expert Group on Vitamins and Minerals, 2003). IU have since been 
superseded by RRR-a-tocopherol equivalents (a-TE) and RRR-a-tocopherol has been 
assigned an activity o f 1 mg a-TE per mg tocopherol. The relative activities o f the 
tocopherols and tocotrienols are listed in table 1.1.
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Table 1.1 RRR -a-tocopherol equivalents for the various vitamin E homologues adapted 
from Sheppard et al. (1993)
Vitamin E homologue Activity as a-TE (mg/ mg compound)
RRR-a-tocopherol 1.0
RRR-p- tocopherol 0.5
RRR-y- tocopherol 0.1
RRR-5- tocopherol 0.03
RRR-a-tocotrienol 0.3
RRR-P- tocotrienol 0.05
all rac-a-tocopheryl acetate 0.74
The activities of y and 8-tocotrienol are unknown
1.3.2 Government recommendations for daily vitamin E  intake
The Department o f Health report on dietary reference values for the United 
Kingdom, published in 1991, concluded that daily intakes o f 4 mg and 3 mg o f a-TE 
can be adequate for men and women respectively (Committee in Medical Aspects o f 
Food Policy, 1991). The Panel also reported that vitamin E requirements depend on 
dietary polyunsaturated fatty acid (PUFA) intake. PUFAs have a greater number of 
carbon double bonds in comparison to saturated and monounsaturated fatty acids and 
are thus more susceptible to oxidation. Vitamin E is utilised in the process o f 
preventing lipid peroxidation in vivo (Tappel, 1962). Muggli (1994) reported the mean 
dietaiy ratio o f mg a-TE : g PUFA in Britain to be over 0.6. This was reported as 
adequate, although there is no general agreement on what ratio to recommend 
(Committee in Medical Aspects o f Food Policy, 1991). In 2002 Brigelius-Flohe et al. 
reported that the United States and German governments had increased their dietary 
recommendations for vitamin E intake to 15 mg vitamin E/ day.
1.3.3 Vitamin E deficiency and toxicity
Plasma concentrations are often used to assess vitamin E status, these are 
influenced by lipid levels and hence are often expressed as a tocopherohcholesterol 
ratio. Plasma tocopherol concentrations less than 11.6 pmol per litre or < 2.25 pmol 
per mmol cholesterol indicate vitamin E deficiency (Thumham et al, 1986). A 
standard test for vitamin E deficiency is ex vivo oxidative susceptibility o f 
erythrocytes to dilute hydrogen peroxide (Farrell et al., 1977). Clinical manifestations 
o f vitamin E deficiency rarely develop from dietary inadequacy. The most common
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cause o f vitamin E deficiency is chronic malabsorption from an underlying 
gastrointestinal, pancreatic or hepatic origin. Conditions that result in vitamin E 
deficiency include; abetalipoproteinemia, chronic cholestatic hepatobiliary disorders 
and cystic fibrosis. A  genetic defect in the a-tocopherol transfer protein (a-TTP) 
results in vitamin E deficiency; this disorder is termed ataxia with isolated vitamin E 
deficiency (AVED). Severe vitamin E deficiency causes dysfunction in 
neuromuscular, vascular and reproductive systems and is characterised by 
spinocerebelar ataxia and myopathies (Sokol, 1993).
Vitamin E is considered to have low toxicity. A recent publication by the Food 
Standards Agency (2003) reported that 540 mg a-TE per day as. a safe upper level o f 
consumption over a lifetime (Expert Group on Vitamins and Minerals, 2003). There 
have been several large-scale supplementation studies from which data on the adverse 
effects o f vitamin E have been collated. The majority o f supplementation studies have 
not reported any adverse outcomes from vitamin E supplementation. The Alpha- 
Tocopherol, Beta-Carotene (ATBC) cancer prevention study investigated the effects 
o f 50 mg all rac-a-tocopherol in male cigarette smokers and an increase in mortality 
from haemorrhagic stroke in hypertensive smokers was observed (Leppala et al., 
2000). However, although biologically plausible, the significance o f this finding is 
uncertain. A meta-analysis conducted by Vivekananthan et al. (2003), which included 
four studies, revealed no significant difference in incidence o f all-cause strokes for 
subjects treated with vitamin E or controls.
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1.4 Cardiovascular disease
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in 
the Western world. CVD is a chronic, multi-factorial disease and the aetiology can be 
attributed to the accumulation o f risk factors. CVD encompasses coronary heart 
disease (CHD), stroke and peripheral vascular disease. In the UK it is the most 
common cause o f premature death and 110, 000 people die o f CHD each year 
(Department o f Health, 2000).
Atherosclerosis interlinked with thrombosis is fundamental in the pathogenesis 
o f CHD (Zaman et al., 2000). Considerable evidence suggests that oxidative stress and 
inflammation are central to atherosclerosis (Berliner et al., 1995; Ross, 1999). The 
development o f an atherosclerotic lesion is shown in figure 1.3. Possible causes of 
endothelial dysfunction leading to atherosclerosis include elevated and modified LDL; 
free radicals caused by cigarette smoking; hypertension, diabetes mellitus and genetic 
alterations (Ashwell, 1998; Griendling & Alexander, 1997; Steinberg, 1997; Talmud 
& Humphries, 2001).
Smooth-muscle
migration
Foam-cellformation T-cellactivation
Adherence and aggregation of platelets
Adherence and entry of leukocytes
Figure 1.3 A cross section of an artery illustrating atherosclerotic plaque progression
Fatty streaks initially consist of lipid-laden monocytes and macrophages (foam cells) together 
with T lymphocytes. Later they are joined by various numbers of smooth muscle cells. The 
steps involved in this process include smooth-muscle migration, T-cell activation, foam cell 
formation, platelet adherence and aggregation and the adherence and migration of leucocytes. 
Illustration from Ross et al. (1999)
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Raised plasma low-density lipoproteins (LDL) is a well recognised risk factor 
for CVD (Keys.A, 1970; Martin & et al, 1986; Rose & Shipley, 1986; Steinberg et al., 
1989). LDL, which may be oxidatively modified, can induce endothelial dysfunction 
(Griendling & Alexander, 1997; Stokes et al., 2002b). Furthermore, LDL can become 
trapped within the arterial wall, here they undergo further oxidation and are 
internalised into macrophages leading to the formation o f foam cells (Steinberg et al., 
1989). LDL are heterogeneous, and have been classified into sub populations; large 
buoyant, intermediate or small, dense LDL (Griffin, 1997). A predominance o f small 
dense LDL is considered more atherogenic than large, buoyant LDL (Berneis & 
Krauss, 2002; Griffin, 1999).
Epidemiological studies have associated cigarette smoking with CVD (Doll et 
al., 1994; Doyle et al., 1964). Several mechanisms for the increased risk have been 
proposed, these include; increased oxidative stress (Cross et al., 1998; Morrow et al.,
1995), disturbed lipoprotein metabolism by increasing insulin resistance and lipid 
intolerance (Eliasson et al., 1997). The products o f cigarette smoking damage vascular 
endothelium, leading to increased secretion of adhesion molecules which enhance the 
binding of platelets and monocytes (Blann et al., 1998) and increased platelet 
aggregation (Lehr et al, 1997; Rival et al., 1987).
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1.5 Cardiovascular disease: molecular functions of vitamin E
Vitamin E has traditionally been known as a lipophilic antioxidant, however a 
number o f non-antioxidant roles have been discovered, broadening the role o f a- 
tocopherol in disease prevention. a-Tocopherol has been shown to inhibit cells crucial 
in the progression o f atherosclerosis both directly and via the inhibition o f low-density 
lipoprotein (LDL) oxidation, suggesting a purpose for its selective retention within the 
body (Azzi et al., 2003).
1.5.1 a-Tocopherol as an antioxidant
Vitamin E is the principle chain-breaking antioxidant in cellular and 
intracellular membranes and lipoproteins halting lipid peroxidation (Burton et al., 
1983; Tappel, 1962). Polyunsaturated fatty acids within phospholipids are most 
susceptible to lipid peroxidation by free radical attack. The antioxidant function of 
vitamin E maintains the structural integrity o f cells.
The ability o f a-tocopherol to inhibit the oxidation o f LDL in vitro and ex vivo 
was the original rational behind the protective role o f vitamin E in CVD (Devaraj et 
al, 1997; Esterbauer et al, 1997). The oxidative modification o f LDL is considered a 
key step in the progression o f atherosclerosis (Ross, 1993; Ross, 1999; Steinberg et 
al, 1989).
a-Tocopherol inhibits lipid peroxidation by scavenging lipid peroxyl (LOO-) 
radicals faster than they can react with adjacent lipid moieties within membranes 
(Halliwell & Gutteridge, 1999), thus preventing propagation of a chain reaction. The 
hydroxyl group on a-tocopherol is responsible for lipid peroxyl scavenging activity as 
demonstrated in figure 1.4. During radical scavenging, a-tocopherol oxidises to an 
intermediate tocopheroxyl radical, which can be recycled or undergo further oxidation. 
The non-radical products o f tocopherol oxidation vary including a-substituted 
tocopherones and epoxy (hydroperoxy) tocopherone depending upon what the 
tocopheryl radical reacts with. These products readily hydrolyse to tocopheiylquinone 
and epoxyquinone respectively. a-Tocopheiylquinone is the primary product of 
tocopherol oxidation and has been detected in human tissues and plasma (Murphy & 
Kehrer, 1987; Vatassery, 1994). Some o f these tocopherylquinone products can be 
regenerated to a-tocopherol in vivo (Moore & Ingold, 1997).
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a-tocopheryl quinone
Figure 1.4 The role of a-tocopherol as a chain-breaking antioxidaut adapted from 
Halliwell and Gutteridge (1999).
a-Tocopherol can scavenge lipid peroxyl radicals (LIPID-OO*), react with 0 2‘* (superoxide 
radical) and quench singlet oxygen. The tocopheryl radical might also react with a further 
peroxyl radical to give non-radical products. The pathway of regeneration of a-tocopherol by 
ascorbate is also shown.
Within LDL membranes there is approximately ten molecules o f a-tocopherol 
for every 400 polyunsaturated, oxidisable lipid groups (Esterbauer et al, 1992). a- 
Tocopherol levels would be rapidly depleted unless physiological mechanisms existed 
to reduce the tocopheryl radical back to tocopherol. Moore and Ingold (1997) 
measured the conversion o f tocopherylquinone to tocopherol in humans by giving a 
male volunteer deuterium labelled tocopherylquinone and detecting deuterium labelled 
tocopherol. A number o f in vitro and indirect in vivo studies have demonstrated the 
ability o f ascorbate to convert the tocopheryl radical back to tocopherol (Kagan et al, 
1992; May et al, 1998). However, direct evidence to prove that this happens in vivo is
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limited (Hamilton et al., 2000). Ubiquinol can also recycle the tocopheryl radical and 
there is limited evidence that glutathione is also able to in some membranes, although, 
the ascorbate-dependent recycling system is likely to be the most important in vivo 
(Halliwell & Gutteridge, 1999).
Theoretical models and some in vitro studies have indicated that a-tocopheryl 
radicals may propagate lipid peroxidation within lipoproteins (Bowry et al., 1992; 
Bowry & Stocker, 1993; Neuzil et al., 2001). However, many researchers believe the 
importance o f pro-oxidation reactions o f a-tocopherol in vivo is questionable. In vivo 
a-tocopherol predominately acts as an antioxidant due to the continual presence o f co­
antioxidants, such as ascorbate, to convert the tocopheryl radical back to tocopherol 
(Azzi & Stocker, 2000; Frei et al., 1988).
1.5.2 Molecular functions o f  a-tocopherol
Vitamin E, specifically a-tocopherol, has the ability to influence cellular 
events by mechanisms not related to its antioxidant function (Table 1.2). The 
specificity o f a-tocopherol in these processes explains to a large extent why it is 
selectively retained within the body compared to other vitamin E homologues.
Atherosclerosis involves a combination o f oxidative and inflammatory 
processes with a-tocopherol playing an important role in inhibiting its progression 
(Kaul et a l, 2001). a-Tocopherol has been shown to reduce lipid peroxidation 
(Esterbauer et al., 1997) and to inhibit platelet adhesion and aggregation (Jandak et al, 
1989; Steiner, 1983; Steiner, 1991; Steiner & Anastai, 1976) and smooth muscle cell 
proliferation (Azzi et a l, 1998; Chatelain et al., 1993; Clement et al., 1997). It also 
exerts anti-inflammatory effects on monocytes (Cachia et al, 1998) and improves 
endothelial function (Faruqi et a l, 1994) in vitro and ex vivo.
A  large proportion of cellular events affected by a-tocopherol can be attributed 
to the inhibitory effect o f a-tocopherol on protein kinase C (PKC) activity. PKC is an 
enzyme with a central role in the regulation o f cellular signalling. a-Tocopherol 
inhibits PKC at a cellular level by activating protein phosphatase (PP2A) which in turn 
causes dephosphorylation o f PKC (Ricciarelli et al, 1998).
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Table 1.2 Summary of the functional properties of a-tocopherol encompassing 
antioxidant and molecular events in the prevention of cardiovascular disease adapted 
from Ricciarelli et al. (2001)
Functions of a-tocopherol Proposed mechanism
1. Protects LDL from oxidative damage Antioxidant
2. Reduces the respiratory burst in monocytes and neutrophils Decrease in PKC activity
3. Reduces the release of cytokines (IL-ip) from monocytes 5-lipoxygenase pathway
4. Decreases monocytes-endothelial adhesion NF-kB inhibition
5. Inhibits platelet adhesion and aggregation Decrease in PKC activity
6. Inhibits smooth muscle cell proliferation Decrease in PKC activity
7. Down regulates ox LDL scavenger receptors in macrophages Gene regulation
8. Enhances lymphocyte differentiation and proliferation Possibly antioxidant
1. (Devaraj et al, 1997; Esterbauer et al, 1997) 2. (Cachia et al, 1998; Devaraj et al, 1996)
3. (Devaraj & Jialal, 1999; Wu et al, 1999) 4.(Faruqi et al, 1994; Islam et al, 1998) 5.
(Jandak et al, 1989; Steiner, 1991; Steiner & Anastai, 1976) 6. (Chatelain et al, 1993) 7. 
(Devaraj et al, 2001; Teupser et al, 1999) 8. (Lee & Wan, 2002). LDL: low-density 
lipoprotein, oxLDL: oxdatively modified LDL: PKC: Protein kinase C, IL-ip: interleukin ip
1.5.2.1 a-Tocopherol prevents LDL oxidation
Oxidatively modified LDL (oxLDL) are central in the aetiology of 
atherosclerosis. OxLDL increase adherence o f monocytes to the endothelium and are 
taken up by macrophages within the arterial sub-endothelium forming foam cells 
(Steinberg, 1997). The ability o f vitamin E to inhibit LDL oxidation ex vivo has been 
extensively studied (Devaraj et al, 1997; Esterbauer et al., 1997).
1.5.2.2 Functional effects o f a-tocopherol on monocytes and macrophages 
Monocytes adhere to the endothelium and penetrate into the sub-endothelium
differentiating into macrophages. a-Tocopherol appeal's to influence monocytes and 
macrophages in a number o f ways. a-Tocopherol enrichment o f monocytes in vitro 
decreases monocytes-endothelial cell adhesion (Devaraj et a l, 1996; Devaraj & Jialal, 
2000; Martin et al, 1997). The mechanism for decreased monocytes-endothelial cell 
adhesion is due to a decrease in the expression o f cellular adhesion molecules on the 
monocytes by inhibiting NF-kB activation (Cominacini et a l, 1997; Islam et al, 
1998). Cell culture experiments have shown a-tocopherol inhibits superoxide anion 
production by impairing the assembly o f the NADPH-oxidase by a PKC dependant 
mechanism (Cachia et al, 1998; Devaraj et al, 1996). The release of superoxide 
anions from monocytes and neutrophils can induce LDL oxidation (Li & Cathcart,
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1994). Monocytes and macrophages also secrete several cytokines including 
Interleukin-ip (IL-1 P); these contribute towards the pathogenesis o f atherosclerosis 
(Bevilacqua et a l, 1984; Maziere et a l, 1996; Wu et al, 1999). a-Tocopherol inhibits 
the release o f IL-1 p via the inhibition o f the 5-lipoxygenase pathway (Devaraj et a l, 
1996; Devaraj & Jialal, 1999).
OxLDL are taken up by scavenger receptors on macrophages which ultimately 
forming foam cells. a-Tocopherol has been shown to down regulate the expression o f 
the cholesterol scavenger receptors SR-A and CD36 in monocytes and macrophages 
ex vivo (Devaraj et al, 2001; Teupser et a l , 1999). The possibility o f reduced oxLDL 
uptake into macrophages may reduce foam cell formation in vivo.
1.5.2.3 a-Toconherol inhibits smooth muscle cell proliferation
Smooth muscle cell proliferation is central in the progression o f 
atherosclerosis. a-Tocopherol inhibits vascular smooth muscle cell proliferation in cell 
culture by PKC inhibition (Boseoboinik et a l , 1991; Chatelain et a l , 1993; Tasinato 
eta l, 1995).
1.5.2.4 q-Tocopherol effects on platelet adhesion and aggregation
Platelet adhesion and aggregation is a key factor in thrombosis and CVD 
pathogenesis (Handin, 1996). a-Tocopherol modulates platelet adhesion and 
aggregation as demonstrated in supplementation studies and ex vivo experiments 
(Calzada et al., 1997; Steiner, 1991; Steiner, 1999). Several studies have shown that 
inhibition o f platelet aggregation occurs by a PKC dependent mechanism (Freedman 
et al, 1996; Freedman & Keaney, 2001; Mabile et al., 1999). Additionally the 
expression o f glycoprotein lib, a specific receptor for platelet aggregation, is down- 
regulated by a-tocopherol (Chang et al., 2000). a-Tocopherylquinone also inhibits 
platelet aggregation in vitro (Freedman & Keaney, 2001).
1.5.2.5 a-Tocopherol effects on lymphocyte differentiation and proliferation 
Peripheral lymphocytes, predominately T cells, localise to atherosclerotic
lesions during the pathogenesis o f atherosclerosis (Hansson, 1997; Song et a l, 2001). 
Within the arterial intima, lymphocytes secrete pro-inflammatory cytokines which
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activate macrophages (Bach et al., 1997). a-Tocopherol enhances lymphocyte 
differentiation and proliferation in vitro and ex vivo, possibly via interleukin-2 
production, which induces proliferation and differentiation (Beharka et al, 1997; 
Meydani et al, 1990; Meydani et al, 1986; Moriguchi & Muraga, 2000). a- 
Tocopherol protects lymphocytes from oxidative damage (Brennan et al, 2000; 
Metzger et al, 1980; Schneider et al., 2001). Lee & Wan (2002) hypothesised that this 
was the mechanism behind its effects on lymphocytes.
1.5.3 Functional properties o f  y-tocopherol
Researchers have predominately focused on a-tocopherol due to its selective 
retention within the body and its greater antioxidant capacity (Burton & Ingold, 1981; 
Traber & Kayden, 1989b). However, y-tocopherol represents the major dietary source 
o f vitamin E in the American diet (Jiang et al., 2001) and it has only recently been 
considered potentially important (Galli et al, 2003; Kontush et al, 1999; Ruiz-Rejon 
et a l , 2002).
Although a-tocopherol has a greater antioxidant capacity, y-tocopherol has a 
greater ability to neutralise the toxic nitrogen dioxide (Cooney et al, 1993). y- 
Tocopherol is able to form a stable nitro adduct, due to its unsubstituted carbon in the 
chromanol ring (Figure 1.1), compared with the relatively reactive nitrite ester formed 
from a-tocopherol reaction with nitrogen dioxide (Christen et al, 1997; Hoglen et al, 
1997). y-Tocopherol also inhibits platelet aggregation and delays thrombus formation 
in rats and ex vivo (Saldeen et al., 1999). It has been hypothesised that this occurs by a 
mechanism modulating nitric oxide rather than PKC (Liu et al, 2003). Both y- 
tocopherol and the y-tocopherol metabolite, 2,7,8-trimethy l-2-(P-carboxyethyl)-6- 
hydrochroman (y-CEHC), possess anti-inflammatory properties due to the inhibition 
o f cyclooxygenase activity in macrophages and epithelial cells (Jiang et al, 2000).
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1.6 Vitamin E and cardiovascular disease: observational and intervention 
studies
Antioxidant vitamins including vitamin E have been implicated in the 
prevention o f cardiovascular disease (CVD) for a number o f years (Ross, 1993; 
Steinberg et al, 1989). The more recent findings o f the involvement o f vitamin E in 
cellular events (detailed in section 1.5) are further reason to believe vitamin E has a 
central role in CVD prevention.
Observational studies have predominately shown that diets habitually high in 
vitamin E are inversely correlated with CVD mortality (Knekt et al, 1994; Kushi et 
al, 1996; Losonczy et al, 1996; Rimm et al, 1993; Sahyoun et al, 1996; Stampfer et 
al, 1993). This relationship is clearly illustrated in figure 1.4 from a study reported by 
Bellizzi et al (1994). However, there was no relationship found between dietary 
vitamin E and CVD mortality in the 25 year follow up o f the Seven Countries Study 
(Kromhout et a l , 1996).
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Figure 1.4 Relationship between coronary heart disease mortality rates and dietary a- 
tocopherol (mg/ habitual diet/ day).
• : European countries (Au; Austria, Be; Belgium, De; Denmark, Fi; Finland, Fr; France, Ge; 
Germany (West), Gr; Greece, Ir; Ireland, Is; Israel, It; Italy, NL; Netherlands, No; Norway, 
Po; Portugal, Sp; Spain, Sw; Sweden, Sz; Switzerland, UK; United Kingdom) A: Non- 
European countries (Al; Australia, Ca; Canada, lc; Iceland, Ja; Japan, Ma; Malta, NZ; New 
Zealand, US; United States). Correlation for all counties; r = -0.6, European countries; r = -
0.8. (Bellizzi et al, 1994)
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The relationship between plasma levels o f vitamin E and CVD is less clear. 
The WHO/ MONICA cross-cultural study reported an inverse correlation between 
plasma a-tocopherol levels and CVD mortality rates (Gey et al, 1991) and lower 
plasma vitamin E levels were observed in patients with coronary artery disease 
compared with controls (Singh et al, 1995). However, there are several studies that 
did not find an association between blood levels o f vitamin E and CVD (Hense et al, 
1993; Kok et al, 1987; Salonen et al, 1985). There is relatively small variation in 
plasma vitamin E levels within populations, thus correlations are less likely, compared 
with the greater variation observed in international studies (Gey et al, 1993). 
Interestingly, y-tocopherol levels in plasma have recently been shown to correlate 
inversely with CVD (Kontush et al, 1999; Ohrvall et al, 1996).
Observational studies have associated a-tocopherol with a reduction in CVD 
events, but they cannot provide a causal relationship. Table 1.3 shows a summary o f 
large vitamin E intervention trials that have been carried out during the last decade. 
These test the hypothesis that vitamin E can prevent LDL oxidation and cellular 
progression of atherosclerosis and therefore have a positive effect on either primary or 
secondary prevention o f CVD. The studies differ in their selection of subjects, the 
population and hence habitual diet and lifestyle, the type and dose o f vitamin E and 
whether combined with other antioxidant supplements, the study duration and the 
selected endpoints measured. The combination o f these differences make it difficult to 
compare and interpret the collective outcomes. Collectively the study outcomes are 
inconsistent between a positive effect and no effect after vitamin E supplementation 
(Table 1.3).
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Table 1.3 Summary of large primary and secondary intervention trials with a- 
tocopherol and cardiovascular disease events adapted from Kinsky (2003)
Study
(country)
No. 
(CVD events)
Study
design CVD events reported Primary _____________  endpoint
Linxian
/’/'ii • \
27,056 1° 30 mg* Death from stoke +(China) (523) 5-8 years
ATBC 29,133 1° 50 mg Death from all CVD <->/-(Finland) (1723) 5-8 years Non-fatal MI
ASAP 520 1° 270 IU*
Death from all CVD
(Finland) (6) 6 years Change in intima- media thickness
+
PPP 4495 1° 300 mg Death from all CVD <->(Italy) (109) 3.6 years Non-fatal MI and stoke
VEAPS 353 1° 400 IU Change in intima- < >(USA) 3 years media thickness
CHAOS 2002 400-800 IU Decrease in non-fatal
(England) pre-existingatherosclerosis
2° 1.4 years MINo effect on fatal CVD
+
GISSI 11,324 O O 250 IU No effect on fatal and <->(Italy) recent MI Z 3-5 years non-fatal CVD
HOPE 9541 400 IU No effect on fatal and(USA/
Canada)
pre-existing CVD 
or diabetes
2° 4.5 years non-fatal CVD <->
SPACE 196 800 IU Decrease in CVD(Israel) renal disease 2° 1.4 years +
HPS
(England)
20,536 
> risk CVD l°/2°
660 IU* 
5 years
No effect on fatal and 
non-fatal CVD
Linxian China trial (Blot et al, 1993; Mark et al, 1998). ATBC; Alpha Tocopherol Beta 
Carotene (Virtamo et al, 1998). ASAP; Antioxidant Supplementation in Atherosclerosis 
Prevention (Salonen et al, 2000). PPP; Primaiy Prevention Project (Collaborative group of 
the primaiy prevention project, 2001). VEAPS; The Vitamin E Atherosclerosis Prevention 
Trial (Hodis et al, 2002). CHAOS; Cambridge Heart and Antioxidant Study (Stephens et al, 
1996). GISSI; Gruppo Italinao per lo Studio Della Soprawivenza nellTnfarto Miocardico 
(Gruppo Italiano per lo Studio della Soprawivenza nellTnfarto miocardico, 1999). HOPE; 
Heart Outcomes Prevention Evaluation (The Heart Outcomes Prevention Evaluation Study 
Investigators, 2000). SPACE; Secondary Prevention Antioxidants of Cardiovascular disease in 
End stage renal disease (Boaz et al, 2000). HPS; Heart Protection Study (Heart Protection 
Study Collaborative Group, 2002)
CVD: cardiovascular disease, MI: myocardial infarction, l°/2°: primaiy or secondary 
prevention study design, aT: a-tocopherol, IU: international unit, * Combined 
supplementation with other antioxidants, + positive effect, -  negative effect, no effect
CVD is a chronic multifactorial disease that starts in childhood and slowly 
progresses through life (Ross, 1999). The intervention studies tabled were carried out 
predominantly in middle-aged people and it is veiy likely that the stage o f the disease 
was reasonably advanced in the study populations and is known to be so in the 
secondary prevention trials. The antioxidant and molecular functions o f vitamin E,
18
Chapter 1
detailed in section 1.5, implicate its involvement in the early stages o f the disease, 
protecting the endothelium and LDL from oxidative damage (Simon et al, 2001). 
Therefore, as stated by Brigelius-Flohe et al (2002), subjects with pre-existing CVD 
are not the ideal target group for vitamin E supplementation. Supplementation from an 
early age is also not feasible as the number o f CVD events would be very small in the 
early stages of the disease to effectively measure outcome. The end points measured 
were predominately CVD events rather than atherosclerosis progression itself. 
Although, the VEAPS and ASAP trials both reported the progression of 
atherosclerosis by measuring change in intima media thickness, the VEAPS study 
reported no effect, whereas the ASAP study reported a retarded progression with 
vitamin C and E supplementation (Hodis et al, 2002; Salonen et al, 2000).
The studies summarised in table 1.3 were predominately carried out in 
populations with adequate vitamin E status as measured by baseline plasma vitamin E. 
It has been reported that individuals with plasma vitamin E concentration < 27.5 pM 
may be at greater risk o f CVD (Gey et al, 1993). The studies do not distinguish 
between those with low or high baseline plasma vitamin E. This may have masked any 
effect of supplementation in those with sub optimum levels before supplementation. 
The genetic background o f the subjects was also not generally considered. There are 
known polymorphisms that respond differently to diets and could therefore have had 
quite a large influence on sub groups within the studies (Paoloni-Giacobino et al, 
2003).
The a-tocopherol dose varied between all rac and RRR- isoforms and the 
amount taken varied considerably from 30 mg to 800 IU between studies (Table 1.3). 
all rac and RRR a-tocopherol are equally absorbed, however, all rac a-tocopherol is 
metabolised to a greater extent (Traber et al, 1998a), thus producing a larger 
concentration o f metabolites within the body compared with supplementation with 
RRR a-tocopherol. Within the studies the amount absorbed between subjects would 
have also varied due to the well-documented variable amount o f vitamin E absorbed 
and the large inter-individual variation in absoiption. Vitamin E needs to be consumed 
with fat for optimal absorption (Cohn et al, 1992b; Cohn, 1997); this was not always 
considered in the trials. As a consequence the amount o f vitamin E entering the 
systemic circulation would not have been homogenous within the studies.
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A number o f the studies gave vitamin E in combination with other antioxidants 
such as vitamin C, (3-carotene or selenium. The ability o f vitamin C to regenerate the 
tocopheryl radical to tocopherol in vivo is generally accepted and believed to be 
influential in the ability o f a-tocopherol to act optimally (Hamilton et al., 2000). The 
ASAP study used combined vitamin E and C supplementation and they reported 
retarded progression of carotid atherosclerosis (Salonen et a l, 2000).
Several systematic reviews and meta-analyses have reported on the collective 
outcome o f the intervention trials. They conclude that the trials have failed to 
unequivocally demonstrate that vitamin E supplementation has a positive role in 
slowing the progression o f CVD (Asplund, 2002; Hooper et a l, 2001; Pryor, 2000; 
Vivekananthan et al., 2003). This is in contrast with the positive findings o f 
observation studies and summarised in table 1.4 by a meta-analysis o f both 
observation and intervention studies.
20
Chapter 1
Table 1.4 Meta-analysis of effect of high versus low vitamin E intake on cardiovascular 
disease mortality for observational and intervention studies from Hooper et al. (2001)
Study High vitamin E 
(n/total)
Low vitamin E 
(n/total)
Odds ratio 
(95% Cl)
Odds ratio 
(95% Cl)
Observational studies
Knekt (>3 IU) 58/1709
Kushi (>30 III) 50/6897
Sahyoun (>30 ill) 22/145
Stampfer {-200 IU) 17/17 449
Rimm (‘-400 IU) 16/7982
Losonczy (?) 19/359
Subtotal {95% Cl) 182/34 S41
Test for heterogeneity d-0-3 
Test for overall effect p=0*0002
Intervention studies
AT8C (50 IU)
GlSSI (300 IU)
PPP {300 IU)
HOPE (400 IU) 
CHAOS (>400 IU} 
SPACE (800 IU) 
Subtotal (95% Qi)
Test for heterogeneity p 
Test for overall effect p
853/14 564 
310/5660 
22/2231 
342/4761 
53/1035 
9/97 
1589/28348 
:0-68 
0-
98/1709 
52/6897 
26/145 
25/17449 
26/7982 
1082/10819 
1309/45001
870/14 569 
329/5664 
26/2264 
328/4780 
44/967 
15/99 
1612/28343
0-58 (0*41.-0-80] 
0-96 [0-65-1*42] 
0-82 [0-44-1-52] 
0-68 [0-37-1-261 
0-61 f 0-33-1-15] 
0-50 [0-32-0-80] 
0-67 10-54-0-831
0-98 [0-89-1-08} 
0-94 [0-80-1-10]
0-86 [0-48-1-52]
1-05 10-90-1-23] 
1-13 [0-75-1-73 ] 
0-57 10-24-1-38] 
0-98 [0-92-1-06}
0-1 0-2 
Favours high 
vitamin E
I I
5-0 10-0 
Favours low 
vitamin E
Knekt (Knekt et al, 1994), Kushi (Kushi et al, 1996), Sahyoun (Sahyoun et al, 1996), 
Stampfer (Stampfer et al, 1993), Rimm (Rimm et al, 1993), Losonczy (Losonczy et al,
1996). ATBC; Alpha Tocopherol Beta Carotene (Virtamo et al, 1998). GISSI; Gruppo 
Italinao per lo Studio Della Soprawivenza nell’Infarto Miocardico (Gruppo Italiano per lo 
Studio della Soprawivenza nell'Infarto miocardico, 1999). PPP; Primary Prevention Project 
(Collaborative group of the primary prevention project, 2001). HOPE; Heart Outcomes 
Prevention Evaluation (The Heart Outcomes Prevention Evaluation Study Investigators,
2000). CHAOS; Cambridge Heart and Antioxidant Study (Stephens et al, 1996). SPACE; 
Secondary Prevention Antioxidants of Cardiovascular disease in End stage renal disease 
(Boaz et al, 2000). IU: international unit, CI: confidence interval
The observational studies may represent the beneficial effect of lifelong high 
habitual intake of vitamin E compared with comparatively short-term high dose 
supplementation, however, observational studies are inherently confounded by other 
lifestyle and dietary factors. Although the intervention trials may have reduced the 
confounding factors, there are discrepancies between their study design and the theory 
behind vitamin E’s role in CVD prevention.
The lack o f a conclusive positive effect o f vitamin E on CVD prevention has 
lead some researchers to question the underlying hypothesis o f LDL oxidation in the 
pathology o f atherosclerosis (Jialal & Devaraj, 2003). However, CVD is multifactorial
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and the expectation that one micronutrient can slow the progression o f atherosclerosis 
may have been unrealistic.
Knowledge o f the regulation and biokinetics of vitamin E within the body and 
the molecular effects of vitamin E on various cell types involved in atherosclerosis has 
been rapidly increasing, however, it is still not fully elucidated. It is important to 
understand these aspects o f vitamin E in order to interpret the past intervention studies 
and possibly for the design o f future studies. It may not be possible to conduct the type 
o f study required to conclusively determine the role of vitamin E in CVD prevention, 
as mentioned by Pryor (2000). As yet, there is no agreed biomarker to accurately 
determine vitamin E status (Morrissey & Sheehy, 1999) and until this is resolved it 
will prove difficult to assess the effect o f vitamin E status in disease states. Likewise, 
until an optimal vitamin E status is determined it is unknown who may benefit from an 
increased intake o f vitamin E. Plasma vitamin E concentration is not an ideal 
biomarker and therefore the cut off, >27.5 pM for adequate vitamin E status, as 
suggested by Gey et al (1993) may be too simplistic (discussed in detail in section 
1.9.1).
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1.7 Vitamin E absorption and biokinetics
Vitamin E, a lipophilic compound, is associated with lipoproteins during 
absorption and transport within the hydrophobic environment o f the systemic 
circulation. Vitamin E status is closely regulated. The relative proportions of vitamin 
E isoforms within the diet are not reflected in plasma or tissue concentrations (Jiang et 
al., 2001; Traber & Kayden, 1989b). Plasma vitamin E concentration is a saturable 
process and large supranutritional doses o f a-tocopherol only result in a 2-3 fold 
increase from baseline concentration (Dimitrov et al., 1991; Jialal et a l , 1995).
7.7.7 Absorption o f  vitamin E
Vitamin E absoiption is reliant on the same intraluminal, membrane and 
intracellular events that are required for lipid absoiption. Lipids must be emulsified 
and hydrolysed before they can penetrate across the brush border membrane o f the 
enterocytes, this is dependent upon pancreatic function, biliary secretion and 
micellular formation (Carey et al, 1983). No specific transport proteins have been 
identified to facilitate vitamin E absorption into enterocytes.
The stomach has an important role in fat digestion, it mechanically breaks up 
large lipids into smaller particles. There is no appreciable metabolism o f a-tocopherol 
within the stomach and gastric emptying o f vitamin E follows lipids (Borel et al,
2001). Partially digested food leaves the stomach and enters the small intestine 
triggering the secretion o f bile into the lumen. Mixed micelles form and are composed 
o f monoglycerides, fatty acids (from lipid hydrolysis) and biliary secretions. Vitamin 
E is solubilised within these micelles (Carey & Small, 1970; Kayden & Traber, 1993). 
Patients with cholestatic liver disease or biliary obstruction are unable to secrete bile 
and thus cannot effectively absorb lipids, or vitamin E, due to the inability to form 
mixed micelles (Jeffrey et al, 1987; Sokol et al, 1983).
Pancreatic secretions include pancreatic lipase and esterase, these hydrolyse 
lipids and cleave tocopheryl esters respectively, enabling tocopherol absorption (Carey 
et al, 1983; Muller et al, 1976). The importance o f pancreatic secretions is 
demonstrated in patients with cystic fibrosis, who are unable to produce sufficient 
pancreatic secretions and consequently vitamin E passage through the brush border is 
impaired (Harries & Muller, 1971).
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Vitamin E is believed to enter the enterocytes with lipids by passive diffusion. 
This process is non-saturable, non-carrier mediated and unaffected by metabolic 
inhibitors (Hollander et al., 1975; Traber et al., 1990b). Following investigations into 
patients with coeliac disease it has been proposed that the main site for vitamin E 
absorption is in the proximal small intestine (Muller et al, 1974).
Vitamin E absorption is affected by the amount and composition of lipid with 
which it is ingested. Bile micelles with lipids have a greater capacity to solubilise 
vitamin E than pure bile salt micelles in vitro (Cohn et al, 1992b). However, the 
amount o f fat required for maximal vitamin E absoiption is currently undetermined 
(Melia et al, 1996; Parks & Traber, 2000). Long chain polyunsaturated fatty acids 
(PUFA) ingested with vitamin E reduce its absorption compared to ingestion with 
saturated fatty acids and medium chain triacylglycerol (Gallo-Torres, 1970; Meydani 
et al, 1987; Tijburg et al, 1997; Weber et al., 1964). It was hypothesised that vitamin 
E is utilised within the intestine to protect PUFAs from oxidative damage and 
subsequently there is less vitamin E available for absorption.
Once within the enterocytes, vitamin E is incorporated into chylomicrons with 
the newly absorbed lipid (Bisgaier & Glickman, 1983). Although the mechanism of 
chylomicron assembly has been thoroughly investigated, it remains unknown how 
vitamin E is incorporated into the chylomicrons (Brigelius-Flohe et al., 2002). 
Chylomicrons are secreted into the mesenteric lymph and then into the systemic 
circulation via the thoracic duct. Patients with abetalipoproteinemia are unable to 
assemble chylomicrons, and as a consequence vitamin E accumulates within the 
enterocytes. The ingested vitamin E cannot be transported without chylomicron 
production, hence plasma vitamin E concentrations are extremely low (Kayden, 1972; 
Muller et al, 1974).
There are only a few human studies which have attempted to measure the 
fractional dose o f vitamin E absorbed (Kelleher & Losowsky, 1970; MacMahon, 
1970) (Blomstrand & Forsgren, 1968), the investigators used faecal recovery o f 
radioactive a-tocopherol or collected lymph via a thoracic duct cannula. Investigators 
agree that vitamin E absorption is incomplete, however the amount absorbed is very 
variable. Using the faecal recovery o f radioactive a-tocopherol, vitamin E absorption 
has been estimated to be between 50 -  86% (Kelleher & Losowsky, 1970; MacMahon, 
1970). These values are likely to be greater than the actual amount as any losses o f
24
Chapter 1
radioactivity are included in the calculated amount absorbed (Kayden & Traber, 
1993). Measurement o f vitamin E absorption by thoracic duct cannulation in two 
cancer patients showed that 21% of free tocopherol was absorbed over a 24 hour 
period (Blomstrand & Forsgren, 1968). It is currently unknown why vitamin E is only 
partially absorbed, considering lipid absorption is almost complete (Carey et ah, 
1983).
The effect o f the dose o f dietary vitamin E on the absorption efficacy is also 
not known and the studies performed so far are few and inconclusive. Traber et al 
(1986b) reported that increasing amounts o f a-tocopherol supplementation decreased 
the percentage o f dose absorbed in animals. However, a dose-response increase in 
newly absorbed a-tocopherol into plasma was observed up to 150 mg.
Several studies have investigated the plasma appearance o f various forms o f 
vitamin E, they have unanimously concluded that RRR-a-, all rac-a- and y-tocopherol 
are absorbed without discrimination (Traber et a l , 1990a; Traber & Kayden, 1989b). 
Cheeseman et al (1995) demonstrated that the absoiption o f RRR-a-tocopherol was 
not different when orally administered as the free phenol, acetate or succinate ester.
Individuals vary greatly in their rate and magnitude o f lipid and vitamin E 
absorption (McNamara et al, 1987; Roxborough et al, 2000). This inter-individual 
variation is a result o f the gastrointestinal handling o f lipids and tocopherols. This 
encompasses variability in the secretion o f bile and pancreatic lipases and processes 
involved in the packaging o f chylomicrons and their release into the systemic 
circulation. Genetic variation has been proposed as the major determinate o f variation 
in lipid metabolism (Ye & Kwiterovich, 2000). Within the enterocytes, polymorphism 
in apo B or the chylomicron assembly protein, microsomal transfer protein, may 
influence the rate o f chylomicron secretion and therefore appearance of newly 
absorbed a-tocopherol in the systemic circulation (Bergeron & Havel, 1997; Hussain, 
2000; Peacock et al, 1995). Fatty acid composition impacts on the postprandial 
handling o f dietaiy triglycerides (Tinker et al, 1999) and would therefore presumably 
impact upon vitamin E transport (Parks & Traber, 2000).
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1.7.2 Vitamin E transport within chylomicrons
Vitamin E incorporated within chylomicrons enters the systemic circulation 
via the lymphatic pathway, illustrated in figure 1.5. Chylomicrons are substrates for 
endothelial bound lipoprotein lipase, which catalyses triglyceride hydrolysis, 
facilitating the transfer o f lipid products and vitamin E to peripheral tissue (Nelsson- 
Ehle et al., 1980; Traber et al., 1985). The importance o f this pathway is demonstrated 
in patients with lipoprotein lipase deficiency who have low vitamin E levels within 
adipose tissue but have higher than normal levels in plasma (Kayden, 1983). The loss 
of triglycerides from chylomicrons and the acquisition o f apolipoprotein E from high- 
density lipoproteins (HDL) lead to the formation of chylomicron remnants. During 
this process excess surface area is created from the chylomicrons and the resultant 
phospholipids, apolipoproteins and vitamin E are transferred to HDL (Traber & 
Kayden, 1989a). Finally the liver takes up the chylomicrons remnants, which are 
thought to still contain a substantial proportion of the newly absorbed vitamin E 
(Traber & Sies, 1996).
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BLOOD
Figure 1.5. Scheme of the absorption of vitamin E into the systemic circulation, adapted 
from Traber & Kay den (1989a)
VE: vitam in E, CM: chylom icron, HDL: high-density lipoprotein, Apo E: apolipoprotein E 
The enterocytes w ithin the intestine secrete vitam in E within chylom icrons into the lymphatic 
circulation; they enter the blood via the thoracic duct. A large proportion o f  the ingested 
vitam in E is excreted in the faeces w ithout being absorbed. The chylom icrons are catabolised 
w ithin the circulation by lipoprotein lipase, which transfers fatty acids and vitam in E to 
peripheral tissues. The resultant chylom icron rem nants have excess surface area, which is 
transferred to HDL along w ith vitam in E. The chylom icron rem nants acquire apolipoproteins 
E from HDL and are subsequently taken up into the liver.
1.7.3 Selective secretion of RRR-a-tocopherol into very low-density lipoproteins 
(VLDL); the role of a-tocopherol transfer protein (a-TTP)
The liver has a central role in maintaining plasma vitamin E concentrations and 
the selective retention o f R&K-a-tocopherol within the body as illustrated in figure 1.6 
(Traber et al., 1990c; Traber et al., 1990a; Traber & Kayden, 1989b). a- and y- 
Tocopherols are equally absorbed into chylomicrons, however, VLDL only contain a- 
tocopherol (Traber & Kayden, 1989b). Using deuterium labelled RRR-a- and all rac- 
a-tocopherol investigators have established that RRR-a-tocopherol compared with 
other stereoisomers is selectively secreted in VLDL (Traber et al., 1988; Traber et al., 
1990a).
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Vitamin E isomers other than RRR a-tocopherol are presumed to be excreted 
in bile or by routes as yet undetermined (Brigelius-Flohe et al, 2002). Bjorneboe et al 
(1987) gave an intravenous injection o f chylomicrons labelled with [3H]a-tocopherol 
into rats, 14-20% o f the label was excreted in the bile within the first 24 hours. 
Increases in bile tocopherol concentrations have also been shown in humans following 
300 mg a- and y-tocopherol supplementation (Traber & Kayden, 1989b). The 
mechanism by which vitamin E is secreted into bile is not known. Mustacich et al 
(1996) demonstrated that a-tocopherol secretion into bile requires micro tubules and 
suggested a relationship between the phospholipid phosphatidylcholine and biliary 
output o f a-tocopherol. Interestingly, it has been demonstrated that a-tocopherol 
secreted into the bile o f rats was reabsorbed into the enterohepatic circulation along 
with phosphatidylcholine (Mustacich et al, 1998) and enterally infused 
phosphatidylcholine inhibited a-tocopherol absorption (Koo & Noh, 2001). The exact 
meaning o f these findings is not clear and further studies are needed to elucidate 
vitamin E excretion in bile and its reabsorption.
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Figure 1.6 Scheme of the transport and uptake of a-tocopherol within the systemic 
circulation adapted from Traber & Kayden (1989a)
a-T : a-tocophero l, VE: vitam in E, a-T T P : a-tocophero l transfer protein, VLDL: very low- 
density lipoprotein, LDL: low -density lipoprotein, HDL: high-density lipoprotein.
Follow ing chylom icron rem nant uptake, the liver secretes VLDL. a-T ocopherol transfer 
protein (a-T T P ) selectively transfers R R R -a-tocopherol into VLDL during its assembly. The 
other hom ologues o f  vitam in E are excreted, presum ably into bile. W hilst in the circulation 
V LD L is catabolised to LDL by lipoprotein and hepatic lipase. A pproxim ately ha lf o f  VLDL 
is converted to LDL the rem ainder is taken up by the liver. During catabolism  o f  VLDL, 
excess surface area and a-tocophero l is transferred to HDL. Peripheral tissues take up a -  
tocopherol w ithin LDL via the LDL receptor.
The discrimination between the different homologues and stereoisomers is 
dependant upon the hepatic a-tocopherol transfer protein (a-TTP), a protein that has 
been purified and characterised in human liver (Kuhlenkamp et al., 1993). a-TTP 
belongs to a family o f cytosolic lipid-binding and transfer proteins known as the Sec 
14 protein family (Kaempf-Rtzoll et al., 2003b). a-TTP preferentially binds RRR-a- 
tocopherol, the fully methylated chromanol ring, the phytyl side chain and R 
configuration at the C2 position being essential in the binding o f tocopherol (Burton et 
al., 1998; Hosomi et al, 1997; Ingold et al, 1987b). The relative affinities o f the 
different vitamin E homologue and stereoisomers for a-TTP have been determined by 
Hosomi et al. (1997) as shown in table 1.5.
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Table 1.5 Relative affinities calculated from the degree of competition for a-tocopherol 
transfer protein (a-TTP) adapted from Hosomi et al. (1997)
V itam in E Relative affinity
R R R -a-T  ocopherol 100%
SR R -a-T ocopherol 11%
P-Tocopherol 38%
y-Tocopherol 9%
5-Tocopherol 2%
a-T ocotrienol 12%
Trolox* 9%
* Trolox is a tocopherol analogue w ithout a phytyl side chain
a-TTP transfers a-tocopherol between intrahepatic compartments. It has been 
demonstrated that it transfers a-tocopherol between liposomes and mitochondria in 
vitro (Mowri et al, 1981). The mechanism by which a-TTP might add RRR-a- 
tocopherol to VLDL during its assembly remains unknown. Using brefeldin to disrupt 
the Golgi apparatus, Arita et al (1997) showed that inhibition o f VLDL assembly did 
not affect a-tocopherol secretion. They speculated that a-tocopherol is not assembled 
into VLDL in the liver cell but rather becomes associated with VLDL after it is 
secreted. They also reported inhibition o f a-tocopherol secretion by 25- 
hydroxycholesterol, a potent modulator o f cholesterol metabolism, linking a- 
tocopherol secretion to cellular cholesterol metabolism and/ or transport. Oram et al, 
(2001) suggested that this pathway may involve the ATP-binding cassette transporter 
A l (ABCA1), a transport protein for cholesterol and phospholipids.
There are a number o f identified genetic defects in a-TTP within the human 
population. Ataxia with vitamin E deficiency (AVED) is a syndrome characterised by 
neurological abnormalities characteristic o f those associated with vitamin E deficiency 
(Sokol, 1993). Patients with AVED have extremely low plasma vitamin E levels, even 
though they are able to absorb vitamin E and have normal transport within 
chylomicrons. However, they have an impaired ability to incorporate vitamin E into 
VLDL (Traber et al, 1990c). Transfer o f vitamin E between lipoproteins is important 
in a-TTP deficient patients who depend upon this transfer process to incorporate 
vitamin E from chylomicrons into their VLDL, LDL and HDL (Schuelke et al., 1999; 
Traber, 1994).
Plasma levels of vitamin E are tightly regulated, large intakes of vitamin E do 
not increase plasma concentration greater than ~80 pM (Dimitrov et a l , 1991; Jialal et
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al, 1995). This saturable process is believed to be due to the saturation o f a-TTP 
within the liver and hence the inability to incorporate additional a-tocopherol into 
VLDL (Traber, 1994).
1.7.4 Post hepatic transport o f  a-tocopherol within lipoproteins
a-Tocopherol associated with VLDL is secreted from the liver into the 
systemic circulation during the fasted state. VLDL is catabolised by lipoprotein lipase 
and hepatic lipase, illustrated in figure 1.6, approximately half o f secreted VLDL are 
converted to LDL whereas the remainder are returned to the liver (Parhofer et al, 
1991). During VLDL catabolism some a-tocopherol is transferred to HDL and 
peripheral tissues, however the majority o f a-tocopherol stays within the delipidated 
VLDL and either returns to the liver or remains in the LDL.
a-Tocopherol associated with LDL is taken up by peripheral tissues via the 
LDL receptor (Cohn & Kuhn, 1989). Fibroblasts expressing the LDL receptor have 
been shown to take up a-tocopherol in vitro (Traber & Kayden, 1984). Wantanabe 
rabbits with defective LDL receptors do not have reduced tissue concentration of 
vitamin E (Cohn et al, 1992a). Therefore, although considered an important pathway, 
LDL receptor uptake is not crucial in maintaining tissue a-tocopherol concentration.
a-Tocopherol is constantly exchanged between lipoproteins via the action o f 
phospholipid transfer protein (PLTP) (Kostner et al, 1995). a-Tocopherol readily 
exchanges from HDL to other lipoproteins (Traber et al, 1992b). This is less rapid 
with chylomicrons and VLDL, but during delipidation excess surface is created 
allowing the exchange o f tocopherol between lipoproteins. Furthermore, HDL has 
been shown to be a more effective donor o f a-tocopherol to erythrocytes compared 
with other lipoproteins (Kayden & Bjornson, 1972; Kostner et al, 1995).
1.7.5 Uptake o f  vitamin E into blood cells and peripheral tissues
The mechanisms that regulate peripheral cellular uptake and tissue 
concentration o f vitamin E are not fully elucidated. The rate at which newly absorbed 
vitamin E is taken up by tissues varies. For example, plasma and erythrocytes have 
relatively quick turnover, whereas this process is slower in muscles and the brain 
(Burton & Traber, 1990; Traber et al, 1994). Vitamin E uptake from lipoproteins
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involves a number o f mechanisms, listed in table 1.6, and it is a combination o f these 
that regulate vitamin E status.
Table 1.6 Mechanisms of vitamin E uptake into blood cells and peripheral tissues
Vitamin E uptake mechanism Cell/ Tissue
1. Lipoprotein lipase Peripheral
2. Chylomicron remnant uptake Liver
3. Tocopherol binding protein Erythrocytes
4. LDL receptor Lymphocytes and Peripheral
5. Scavenger receptor class B type 1 receptor Peripheral
6. Phospholipid transfer protein Endothelium
7. Passive diffusion Lipoproteins and cells
1. (Sattler et al., 1996; Traber et al, 1985) 2. (Traber & Sies, 1996) 3. (Wimalasena et al, 
1982) 4. (Cohn & Kuhn, 1989; Traber & Kayden, 1984) 5. (Mardones et al, 2002) 6. (Kostner 
et al., 1995) 7. (Oram et al, 2001; Traber et al., 1992b)
Vitamin E distribution in blood cells has only been documented for 
erythrocytes. Monocytes, neutrophils, lymphocytes and platelets are all functionally 
affected by vitamin E but little is known about uptake mechanisms. Uptake by these 
blood cells is presumed to occur during cell formation and/ or passive diffusion from 
circulating lipoproteins. Lymphocytes have LDL receptors, therefore presumably 
obtain vitamin E from internalising LDL (Norman et al., 1999; Wilund et al, 2002). 
Erythrocytes do not have LDL receptors and it has been suggested neither do platelets, 
and therefore obtain their vitamin E from a different pathway (Kaempf et al, 1994).
Vitamin E binding sites have been identified and characterised for erythrocytes 
and are thought to facilitate the transfer o f vitamin E from plasma to the erythrocytes 
(Kitabchi & Wimalasena, 1982b; Wimalasena et al., 1982). Vitamin E binding sites 
have been reported for other peripheral cells such as liver, cultured aortic endothelial 
cells and rat adrenal cells (Dutta-Roy, 1999; Kitabchi et al, 1980; Kunisaki et al., 
1993). However, (Kitabchi & Wimalasena, 1982a) reported from preliminary studies 
that neither platelets nor polymorphonuclear cells have tocopherol binding.
The scavenger receptor class B type 1 receptor (SR-B1), a membrane bound 
protein, selectively transports cholesteryl esters from HDL into cells and is capable of 
transferring vitamin E (Goti et al, 2001; Mardones et al, 2002). This has been shown 
by uptake from HDL in various cultured cells and SR-B1 knockout mice have reduced 
concentration o f a-tocopherol in bile and some tissues but not others (Mardones et al,
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2002).Vitamin E status has been shown to up and down regulate SR-B1 protein levels 
within liver tissue (Witt et al, 2000).
The ATP-binding cassette transporter A l (ABCA1), an ATP-binding cassette 
protein, transports cellular cholesterol and phospholipids to lipid-poor HDL 
apolipoproteins and facilitates cellular a-tocopherol secretion (Oram et al, 2001). It is 
possible that ABCA1 co-transports a-tocopherol, cholesterol and phospholipids to the 
cell surface where the lipid complex is solubilised and removed by apolipoproteins 
(Oram & Vaughan, 2000). Oram et al (2001) suggested that SR-B1 and ABCA1 
operate together to transport a-tocopherol between tissues by the HDL reverse 
cholesterol transport pathway. HDL in vitro is capable of removing a-tocopherol from 
cells by passive diffusion as well as by the aforementioned active processes.
Genetic polymorphisms in certain genes can influence lipoprotein metabolism 
and therefore vitamin E tissue uptake and biokinetics (Ye & Kwiterovich, 2000). 
These encompass apolipoproteins, lipid processing enzymes and lipoprotein receptor 
genes. Together these would ultimately affect a-tocopherol concentration in tissue and 
may account for the inter individual variation in response to vitamin E 
supplementation (Roxborough et al, 2000).
7.7.6 Intracellular distribution and regulation o f  a-tocopherol
Intracellular a-tocopherol transport, resulting in the accumulation o f a- 
tocopherol in certain cellular and intracellular membranes, is only partially 
understood. a-Tocopherol distribution is influenced by its lipid solubility and is hence 
associated with membrane and tissue lipid (Blatt et al, 2001). The lipophilic nature o f 
a-tocopherol means that it requires specific transfer proteins for transport through the 
hydrophobic cell compartments. Dutta-Roy et al (1994) reported that a-tocopherol 
accumulates within the cells where oxygen radical production is greatest and thus 
where it is required most as an antioxidant namely in the mitochondria membrane and 
the endoplasmic reticulum. There are a number o f tocopherol binding proteins (TBP) 
that have been identified, it is unclear how many exist and which mechanisms regulate 
tocopherol transfer between peripheral cells (Dutta-Roy, 1999).
a-TTP is involved in the selective retention o f RRR a-tocopherol within the 
body (Burton et al, 1998; Hosomi et al, 1997; Ingold et al, 1987b). a-TTP, although
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predominately found within hepatocytes it is also expressed in the human brain and 
placenta, the rat brain, spleen, lung and kidney and the mouse uterus (Copp et a l , 
1999; Hosomi A et al, 1998; Kaempf-Rtzoll et al, 2002; Kaempf-Rtzoll et al, 
2003a). An intracellular 15 kDa TBP that specifically binds a-tocopherol is present in 
all major tissues and it seems likely that it is a general intracellular carrier o f a- 
tocopherol (Dutta-Roy et al, 1993; Dutta-Roy, 1999). The mechanism of how this 
TBP transports intracellular a-tocopherol is still unknown.
A 46 kDa TBP, the tocopherol associated protein (TAP), has recently been 
described (Zimmer et al, 2000). TAP is reportedly expressed in all tissues although it 
is most abundant in the brain, liver and prostate (Brigelius-Flohe et a l , 2002; Zimmer 
et al, 2000). In the presence o f a-tocopherol, TAP translocates to the nucleus and 
activates reporter gene transcription (Yamauchi et al, 2001). Porter (2003) reported 
that TAP is identical to supernatant protein factor, which stimulates the synthesis o f 
cholesterol. Further studies are needed to clarify the role o f TAP (Manor, 2003).
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1.8 Vitamin E metabolism and urinary excretion
Vitamin E is metabolised in the liver and specific metabolites have been 
detected in plasma and mine (Galli et al, 2002; Schultz et al, 1995). It is 
hypothesised that they are excreted into bile and reabsorbed via the intestine into the 
systemic circulation before urinary excretion (Hattori et al, 2000; Lodge et al, 2001).
The sole vitamin E metabolite products initially identified had an oxidised 
chromanol ring, these were derived from vitamin E acting as an antioxidant (Burton & 
Ingold, 1993; Simon et al, 1956). The primary oxidation product is 
tocopherylquinone, reduced to tocopherylhydroquinone (Siegel et al, 1997), this and 
other tocopherol oxidation products are conjugated to yield the glucuronate (Drevon, 
1991). These products are excreted into bile or further degraded in the kidneys to 
tocopheronic acid and excreted in the urine (Burton & Ingold, 1993; Simon et al, 
1956). Due to the great interest in the antioxidant function o f vitamin E, early studies 
investigating vitamin E metabolism concentrated on these oxidised products, urinary 
tocopheronolactones, the so called Simon metabolites (Brigelius-Flohe & Traber, 
1999; Burton & Ingold, 1993; Simon et al, 1956). However, Schultz et al (1995) 
reported tocopheronolactone was actually a product of oxidation during sample 
preparation within the laboratory and not an in vivo oxidation product. There is still 
some disagreement on the ex vivo oxidation o f carboxyethyl hydroxychromans 
(CEHC) to tocopheronolactone (Pope et al, 2000).
1.8.1 Metabolism o f  vitamin E to carboxyethy hydroxychromans
Schultz et al (1995) described a urinary metabolite o f vitamin E with an intact 
chromanol ring, which was identified as 2,5,7,8-tetramethyl-2 (2'-carboxyethyl)-6- 
hydroxychroman (a-CEHC), shown in figure 1.8. Eleven years earlier 8-CEHC was 
the first urinary metabolite o f vitamin E to be discovered with an intact chromanol 
ring (Chiku et al, 1984). y-CEHC was first described as a-LLU, a novel natriuretic 
factor that inhibits the 70 pS ATP-sensitive K+ channel in the thick ascending limb 
cells o f the kidney (Wechter et al, 1996). a- and y-Tocotrienols are excreted as a- and 
y-CEHC (Lodge et al., 2001). a- and y-CEHC have been identified within both the 
urine and plasma of humans (Galli et al, 2002; Schultz et al, 1995). Previously, a- 
CEHC was only detected following supplementation (Schultz et al, 1995). The 
development o f more sensitive detection assays revealed that a-tocopherol is
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metabolised to a-CEHC without supplementation (Galli et al., 2002; Radosavac et al., 
2002; Stahl eta l, 1999; Swansong al, 1999).
The HepG2 cells, a human hepatoblastoma cell line, are capable of 
synthesising the CEHC metabolites and have been instrumental in characterising the 
metabolic pathway of vitamin E (Birringer et al, 2001; Parker & Swanson, 2000). 
Birringer et al (2001) used HepG2 cells to demonstrate that tocopherols are 
metabolised by side chain ©-oxidation and consecutive (3-oxidation o f the phytyl tail 
followed by stepwise removal o f two- or three-moieties, ultimately yielding the 3'- 
carboxychromanol metabolite. Figure 1.8 shows the intermediate products that have 
been identified. Songtag and Parker (2002) reported that the initial oxidation o f the 
terminal methyl group is catalysed by cytochrome P450 isoform 4F2. They 
demonstrated that the previously proposed CYP 3A does not possess tocopherol ©- 
hydroxylase activity, whereas CYP 4F2 exhibited clear NADPH-dependant ©- 
oxidation o f a- and y-tocopherol. CYP 4F2 catabolism demonstrated in vivo and in 
vitro discrimination between a- and y-tocopherol, with greater rate o f oxidation for y- 
tocopherol (Songtag & Parker, 2002). The enzyme systems that degrade the side chain 
have yet to be identified.
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CYP induced co-oxidation
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coo,h
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COOH a-CEHC
Figure 1.7 Tocopherol metabolism to carboxyethyl hydroxychroman adapted from 
Birringer et al. (2001)
Side chain degradation starts with the co-hydroxylation catalysed by a cytochrome P450 enzyme 
in microsomes. The hydroxyl group is further oxidised to a carboxylic residue in the cytosol. 
Subsequent p-oxidation is thought to take place in perisomes. Metabolites identified so far are 
a-CMHHC, a- y- and 8-CMBHC (Pope et al, 2001) and a- y- and 8-CEHC. CYP: 
cytochrome
37
Chapter 1
1.8.2 The involvement o f  a-tocopherol transfer protein in vitamin E metabolism
Since RRR-a-tocopherol is selectively retained within the body it is degraded 
to a-CEHC to a lesser extent than the other isoforms o f vitamin E (Lodge et al, 2001; 
Swanson et al, 1999; Traber et al, 1998a). It is generally believed that a-TTP 
mediates this through the removal o f -K&R-a-tocopherol from the metabolism pathway 
(Schuelke et al, 2000). Swanson et al. (1999) reported that a substantial amount o f 
dietary y-tocopherol is excreted as y-CEHC, whereas most a-tocopherol consumed is 
retained within the body.
Schuelke et al. (2000) detected high concentrations o f urinary a-CEHC in 
patients with defective a-TTP despite the fact that they had extremely low plasma 
vitamin E concentrations. This study supports the case that vitamin E metabolism does 
not require a-TTP as there was no difference in a-CEHC excretion in a-TTP deficient 
patients following a//-rac-a-tocopherol or RRR-a-tocopherol supplementation.
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1.9 Assessing vitamin E status
Vitamin E status can be assessed by measuring dietary intake, clinical 
examination or biochemical or physiological biomarkers. Dietary measurement is 
limited by inadequate food databases, the large variability o f vitamin E within foods 
and the inherent problems of people reporting dietary intake. Clinical examination 
lacks sensitivity, vitamin E deficiency syndromes develop over long periods o f time 
and symptoms o f overt toxicity remains unknown (Expert Group on Vitamins and 
Minerals, 2003). Reliable biomarkers o f vitamin E status need to ensure sufficient 
sensitivity to detect greater a-tocopherol usage and increased requirements within 
selected tissues. It is not possible in many cases to obtain this information from 
humans, therefore indirect biomarkers o f tissue a-tocopherol status, that can be 
obtained non-invasively, are used (for example blood, mine and saliva). Assumptions 
are made when using these indirect biomarkers to assess a-tocopherol status in 
individuals and how this may relate to disease risk.
Vitamin E is predominately located within biological membranes and adipose 
tissue. Vitamin E prevents phospholipid peroxidation thereby protecting membrane 
integrity. a-Tocopherol has important non-antioxidant functions, these processes 
would be compromised by vitamin E inadequacy which may increase disease risk. 
Hence it is important to have reliable indices of vitamin E status. Vitamin E status 
encompasses vitamin E adequacy in all cellular and intracellular membranes o f all 
tissues. There is no storage organ that releases vitamin E on demand. The bulk of 
vitamin E within the body is localised in adipose tissue, but is not readily mobilised 
(Schaefer et al, 1983; Traber & Kayden, 1987). There is limited information on the 
vitamin E content o f human tissues and the rate o f turnover. Burton et al (1998) 
reported a fast turnover o f vitamin E in plasma and liver with the slowest being in 
adipose tissue and nerves, as determined by uptake of deuterium labelled a-tocopherol 
in terminally ill patients.
Certain tissues are exposed to greater oxidative stress and therefore may 
require greater amounts o f vitamin E, for example, skeletal muscle after strenuous 
exercise, the lungs o f cigarette smokers and atherosclerotic arteries with chronic 
inflammation. It is not clear whether sites o f increased vitamin E usage become 
deficient in vitamin E or if there is increased mobilisation o f vitamin E to the site.
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Evidence so far is contradictory, there is more a-tocopherol in atherosclerotic plaque 
compared with healthy arterial tissue (Iuliano et al., 2003). However, cigarette 
smokers have lower vitamin E concentration in alveolar fluid compared with non- 
smokers (Pacht et al., 1986). Understanding how different tissues respond to oxidative 
stress in vivo, their ability to retain or mobilise vitamin E (Elsayed, 2001) and how 
vitamin E is regulated between tissues is fundamental in the interpretation o f 
biomarkers o f vitamin E status.
a-Tocopherol status is affected by dietaiy intake (total vitamin E and ratio o f 
isoforms ingested), a-tocopherol usage (either oxidised or metabolised) and the 
availability and efficiency o f other compounds to recycle oxidised vitamin E (such as 
ascorbic acid and glutathione). a-Tocopherol is selectively retained within the body 
and therefore its status should be considered separately to other isoforms of vitamin E. 
Researchers are still in the early stages of determining the importance o f y- 
tocopherols’ role within the body (at present government recommendations do not 
include y-tocopherol), in the future, attention may be focused at detennining y- 
tocopherol status and requirements (Committee in Medical Aspects o f Food Policy, 
1991; Galli et al, 2003).
1.9.1 Biomarkers o f  a-tocopherol status
Plasma concentrations o f a-tocopherol are commonly used to assess vitamin E 
status. However, it is generally recognised that steady-state plasma a-tocopherol is not 
an ideal indicator o f vitamin E status as plasma vitamin E is closely regulated. The 
relative proportions o f vitamin E isoforms within the diet are not reflected in plasma 
or tissue concentrations (Jiang et al., 2001; Traber & Kayden, 1989b). Plasma vitamin 
E concentration is a saturable process (Dimitrov et al., 1991; Jialal et al, 1995), 
influenced by plasma lipids (Horwitt et al, 1972; Thumham et al, 1986) and there is 
limited evidence to show that it is not sensitive to altered vitamin E concentrations 
within cells or tissues (Mezzetti et al, 1995; Simon et al., 1997). Plasma vitamin E is 
often corrected for cholesterol to remove the confounding effect o f plasma lipids. The 
consequence o f higher circulating a-tocopherol, due to raised plasma lipids, on tissue 
uptake is not fully understood.
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Steady-state plasma a-tocopherol concentration is the combined total o f a- 
tocopherol within lipoproteins. The primary function o f lipoproteins is to transport 
lipids to and from peripheral tissues. a-Tocopherol is there to protect lipids from 
peroxidation and a-tocopherol distribution is primarily due to its lipid solubility (Blatt 
et ah, 2001). a-Tocopherol content o f LDL may be a useful biomarker o f vitamin E 
status, although, interestingly in unsupplemented individuals it does not correlate with 
plasma a-tocopherol (Ziouzenkova et a l , 1996).
Tissue a-tocopherol uptake and retention is a complex process and not directly 
related to plasma levels (detailed in section 1.7.5). Simon et al (1997) reported similar 
plasma a-tocopherol corrected for cholesterol in normocholesterolemic and 
hypercholesterolemic men, however, there was significantly lower a-tocopherol 
concentration in the erythrocytes o f hypercholesterolemic subjects. Steady state levels 
o f plasma a-tocopherol corrected for cholesterol have been reported to be similar in 
cigarette smokers and non-smokers (Dietrich et al, 2003; Duthie et al, 1993; 
Marangon et al, 1998). Mezzetti et al (1995) reported that plasma a-tocopherol was 
not related to a-tocopherol levels within arterial tissue and Pacht et al (1986) reported 
lower a-tocopherol within the alveolar fluid o f cigarette smokers despite similar 
plasma levels. Two studies investigating the biokinetics of a-tocopherol in cigarette 
smokers compared with non-smokers have demonstrated that cigarette smokers utilise 
a-tocopherol differently to non-smokers and this difference cannot be detected in 
steady state plasma a-tocopherol (Munro et al, 1997; Traber et al, 2001).
Researchers have been interested in the vitamin E content o f erythrocytes and 
their susceptibility to oxidation as an indicator o f vitamin E deficiency (Miyake et al, 
1991). a-Tocopherol is located within the membranes of erythrocytes and may 
therefore better represent a-tocopherol status in cellular membranes. It has been 
proposed that erythrocyte a-tocopherol is a better indicator o f vitamin E status in 
hypercholesterolemic and obese subjects compared with plasma a-tocopherol 
concentration (Nishida et al, 1982; Simon et al, 1997). However, a-tocopherol 
concentration within erythrocytes is not specific enough in cigarette smokers. The 
majority o f studies have reported erythrocyte a-tocopherol in cigarette smokers and 
non-smokers to be similar’, whereas biokinetic studies have shown them to differ in
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their handling o f a-tocopherol (Brown et al, 1997; Brown et al, 1998; Duthie et al, 
1991; Munro et al, 1997; Traber et al, 2001). Further research is required to 
determine whether erythrocyte a-tocopherol is related to other tissue a-tocopherol 
utilisation and concentration.
a-Tocopherol concentration in platelets has been proposed as a useful 
biomarker o f vitamin E status, by Lehmann (1981) and Vatassery et al (1983), as they 
are not influenced by plasma lipid levels. a-Tocopherol concentration within platelets 
may reflect a direct functional biomarker o f vitamin E as platelet adhesion and 
aggregation are influenced by a-tocopherol (Steiner, 1983). It is unknown if increased 
usage of vitamin E within the body results in less a-tocopherol within platelets and is 
currently undetermined how vitamin E concentration within platelets is reflected in 
other tissue levels.
Kaempf et al (1994) proposed that cells with LDL receptors, such as 
lymphocytes, might be more useful biomarkers o f vitamin E status than erythrocytes 
or platelets. Lehmann et al (1988), Meydani et al (1990) and Lenton et al (2000) are 
the only investigators who have measured the a-tocopherol content o f lymphocytes. 
a-Tocopherol concentration within lymphocytes may represent a functional biomarker 
o f vitamin E status in relation to chronic inflammation (Lehr, 2000; Ross, 1999). It is 
not known if a-tocopherol content in lymphocytes reflects that in other tissue levels. 
a-Tocopherol concentrations within other mononuclear and polynuclear leucocytes 
have also received veiy little attention. Due to the low circulating volume of 
leucocytes, compared with erythrocytes, large blood samples are required to measure 
vitamin E concentration, which is not always practical.
a-Tocopherol concentration within adipose tissue is a long-term indicator o f 
vitamin E intake (Handelman 1994). Adipose tissue a-tocopherol is not readily 
mobilised and therefore does not represent a sensitive indicator of vitamin E status. 
Tissues could be vitamin E deficient but the a-tocopherol but levels within adipose 
tissue may remain unchanged for a number o f months or years.
Vitamin E metabolites (tocopherylquinone or a-CEHC) may prove to be useful 
biomarkers o f vitamin E status. Tocopherylquinone (TQ) is the primary product o f 
tocopherol oxidation in vivo. TQ levels could be an indicator o f greater oxidative 
stress, and thus an increased requirement for vitamin E. The measurement o f TQ needs
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great care (especially when measuring a-T:a-TQ ratio) as any oxidation o f tocopherol 
during sample preparation would produce inaccurate data. Tocopherolactone, a urinary 
metabolite o f TQ, has been suggested as a biomarker for vitamin E oxidation in vivo 
(Pope et al, 2000). However, it remains unclear whether or not it is an artefact o f 
CEHC extraction. Schultz et al (1995) proposed urinary a-CEHC as an indicator of 
adequate vitamin E status on the premise that a-tocopherol is only metabolised when 
plasma levels exceed 7-9 pmol/ g lipid. Since this suggestion was made, a-CEHC has 
been shown to be produced without supplementation and in AVED patients who have 
a defective a-TTP and extremely low plasma vitamin E levels (Schuelke et al, 2000). 
In a healthy population it is unknown whether people deficient in vitamin E still 
produce a-CEHC. The regulation o f a-CEHC production is not fully understood, 
however it can be hypothesised that extent o f a-CEHC metabolism, in people with 
functioning a-tocopherol transfer protein (a-TTP), may represent the amount o f 
vitamin E excess to requirements within the body (Schuelke et al, 2000; Schultz et 
al, 1995). a-CEHC probably indicates a-TTP function and dietary intake but may not 
be reflective o f tissue vitamin E status hence more research is required into a-CEHC 
regulation before it can be considered a useful biomarker.
The requirement for vitamin E and uptake by different tissues will vary 
between individuals due to the diverse functionality o f vitamin E. There is large inter­
individual variation in the absorption o f vitamin E and uptake into erythrocytes as 
described by Roxborough et al (2000). The variations observed include differing 
activity o f enzymes and proteins involved in chylomicron packaging, cellular and 
tissue uptake, metabolic rate, blood volume, lipid concentration in blood and ratio o f 
lipoproteins (Brigelius-Flohe et al, 2002; Ye & Kwiterovich, 2000). These factors 
could indictate a large variation in requirements for a-tocopherol for optimal supply of 
vitamin E to all tissues.
In conclusion, no single biomarker for a-tocopherol status is known to be 
representative o f a-tocopherol status and the measurement o f a number o f biomarkers 
are needed to observe whether vitamin E biokinetics and tissue levels are altered in 
different sub populations and disease states. It is important to gain an understanding o f 
vitamin E status to further elucidate the role o f a-tocopherol in preventing disease 
progression. It is also important to understand the extent o f inter-individual variation
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in the healthy population as this may mask small differences in vitamin E biomarkers. 
It is difficult to estimate vitamin E requirements on a physiological basis until we have 
a clear understanding o f how different tissues respond to vitamin E intakes, their 
ability to retain vitamin E and how the mobilisation o f vitamin E is regulated.
Chapter 1
1.10 Aims and objectives of the current research
It has been well documented that vitamin E is essential for optimal health. 
Vitamin E protects biological membranes from free radical damage and lipid 
peroxidation, maintaining membrane integrity. There is also mounting evidence for 
the role of vitamin E in preventing the pathogenesis of cardiovascular disease (CVD), 
both as an antioxidant and at a molecular level.
Optimal vitamin E status has yet to be defined, this is primarily due to the 
difficulties in assessing vitamin E status within humans. The majority of studies have 
used steady-state plasma vitamin E levels to assess vitamin E status, however, plasma 
vitamin E concentration is hepatically regulated, saturable, influenced by plasma lipids 
and limited evidence shows that it is not sensitive to altered concentrations in cells or 
tissues. A number of steady-state and functional biomarkers have been suggested, 
although these have not been properly standardised and are not universally accepted. 
Urinary metabolites (a- and y- CEHC) have been suggested as potential biomarkers of 
adequate vitamin E status, however, there is limited information on the exact 
metabolic pathways and the amount of a-tocopherol converted to a-CEHC. At present 
there is no adequate biomarker to reliably and accurately measure vitamin E status. 
Throughout the work presented in this thesis a combination of biomarkers will be used 
to assess vitamin E status.
It is important to understand and be able to determine vitamin E status when 
investigating possible factors relating to disease risk. Scientific publications covering 
vitamin E status in people with increased risk of CVD are limited. Some risk factors 
for CVD such as dislipidemia and cigarette smoking may predispose these people to 
an altered vitamin E status. To examine vitamin E within these sub populations further 
investigation into vitamin E status in healthy individuals is first required.
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1.10.1 Research aim
The aim of this research was to use a more holistic approach in assessing 
vitamin E status, the purpose being to gain a greater understanding of vitamin E status 
in the healthy population and in those with an increased risk of CVD with a possible 
altered vitamin E status.
1.10.2 Research objectives
1. To investigate the response of vitamin E concentration within blood components 
and urinary excretion of vitamin E metabolites to supplemental a-tocopherol in 
healthy volunteers.
2. To compare the biokinetics of supplemental a-tocopherol between 
hypercholesterolemic and normolipidemic volunteers
3. To determine steady-state levels of vitamin E status in cigarette smokers compared 
with non-smokers.
46
C h a p t e r  2
M a t e r i a l s  a n d  M e t h o d s
Chapter 2
2.1 Materials
The reagents used for sample isolation and assays in the studies reported in 
Chapters 3, 4, 5, 6 and 7, are listed below;
L-ascorbic acid (Sigma-Aldrich Chemical Co., Poole, UK)
Acetonitrile HPLC grade (Fisher Scientific Ltd, Loughborough, UK)
Bio-Rad Protein assay dye reagent concentrate (Bio-rad laboratories Gmbh, Muchen) 
Butylated hydroxytoluene (Sigma-Aldrich Chemical Co., Poole, UK)
Citric acid (Fisher Scientific Ltd, Loughborough, UK)
Cholesterol reagent (ACE™, Alfa Wasserman B.V., 3440 AL Woerden, The 
Netherlands, supplied by Randox laboratories ltd, Antrim, UK)
Copper sulphate (CuS04) (Sigma-Aldrich Chemical Co., Poole, UK)
Cotinine (Sigma-Aldrich Chemical Co., Poole, UK)
Creatinine kit (Randox laboratories ltd, Antrim, UK)
Deferoxamine mesylate (DFO) (Sigma-Aldrich Chemical Co., Poole, UK) 
Diethylenetriaminepentacetic acid (DTPA) (Sigma-Aldrich Chemical Co., Poole, UK) 
Diethylether (J.T. Baker, Scientific Chemical Suppliers ltd)
Diammonia hydrogen orthphosphate (BDH, Poole, UK)
1-Dodecane sulfonic acid sodium salt for ECD (Sigma-Aldrich Chemical Co., Poole, 
UK)
Ethanol (absolute) (Hayman Ltd, Witham, Essex, UK)
Folin Ciocalteu reagent (BDH, Poole, UK)
High-density lipoprotein kit (Randox laboratories ltd, Antrim, UK)
Histopaque-1077 (Sigma-Aldrich Chemical Co., Poole, UK)
Lithium perchlorate 99.9 % (Sigma-Aldrich Chemical Co., Poole, UK)
Low-density lipoprotein kit (Randox laboratories ltd, Antrim, UK)
Optiprep™ (XIS-SHIELD Poc AS, Oslo, Norway)
Methanol (LC-MS Chromasolv) (Riedel-deHen from Sigma-Aldrich Chemical Co., 
Poole, UK)
Methanol HPLC grade (Fisher Scientific Ltd, Loughborough, UK)
Metaphosphoric acid (MPA) (Sigma-Aldrich Chemical Co., Poole, UK) 
Perfluorodecalin (Fluorochem, Derbyshire, UK)
Phosphate-buffered saline (PBS) tablets (Oxoid Ltd, Basingstoke, Berkshire, UK)
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Phosphate-buffered saline (PBS) tablets (Oxoid Ltd, Basingstoke, Berkshire, UK) 
Potassium bromide (KBr) (Fisher Scientific Ltd, Loughborough, UK)
Potassium hydroxide (KOH) (BDH, Poole, UK)
Sodium acetate (Sigma-Aldrich Chemical Co., Poole, UK)
Sodium azide 99.5 % (Fisher Scientific Ltd, Loughborough, UK)
Sodium bromide (NaBr) (Fisher Scientific Ltd, Loughborough, UK)
Sodium carbonate (NaC03) (Sigma-Aldrich Chemical Co., Poole, UK)
Sodium dodecyl sulphate (SDS) (BDH, Poole, UK)
Sodium potassium tartrate (Sigma-Aldrich Chemical Co., Poole, UK) 
Tris[hydroxymethyl]aminomethane 99% (Sigma-Aldrich Chemical Co., Poole, UK) 
Triglycerides reagent (ACE™, Alfa Wasserman B.V. 3440 AL Woerden, The 
Netherlands, supplied by Randox laboratories ltd. Antrim, UK)
Trolox (6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) 97% (Sigma- 
Aldrich Chemical Co., Poole, UK)
Urinary protein kit (Randox laboratories ltd., Antrim, UK)
Vitamin E capsules (Holland and Barrett, Nuneaton, Warwickshire) Ingredients listed
were RRR-a-tocopheryl acetate, gelatine and glycerine shell and soya bean oil.
a-CEHC (>99 %) BSAF, Germany
a-Tocopherol (>99 %) (Fluka Biochemika, Switzerland)
p-glucuronidase (Sigma-Aldrich Chemical Co. Poole, UK)
y-CEHC (>99 %) (Cayman chemicals, USA)
y-Tocopherol (>99 %) (Fluka Biochemika, Switzerland)
5-Tocopherol (>90 %) (Sigma-Aldrich Chemical Co. Poole, UK)
RRR-a-5, 7-(CD3)2-tocopheryl acetate (d6) a gift from Cognis Nutrition and Health 
all rac-a-5 (CD3)-tocopheryi acetate (d3) a gift from Cognis Nutrition and Health
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2.2 Methods
2.2.1 Subjects
Subjects were recruited by poster advertisements placed around the University 
of Surrey and Guildford town centre, emails were sent to university staff and 
advertisements were placed in a number of local newspapers. Subjects were required 
to complete a personal information sheet (Appendix I), those reporting gastrointestinal 
problems or any other problems that could possibly affect the studies were not used. 
Subjects were excluded if they took dietary supplements within 6 months before the 
study period. Subjects recruited were aged between 20 and 60 years.
The University of Surrey Advisory Committee on Ethics approved the studies 
documented within this thesis. Subjects supplied written, informed consent before 
starting a study, they were reimbursed to cover time and inconvenience incurred by 
participating in a study. The studies took place in the Clinical Investigation Unit at the 
University of Surrey.
2.2.2 Dietary intake
Habitual dietaiy intake was recorded using previously validated EPIC 7-day 
food diaries (Bingham et al., 1997). The diaries were analysed using Diet 5 for 
Windows (USDA release 12, 1998, Robert Gordon University), this software did not 
distinguish between the different forms of vitamin E within the diet.
2.2.3 Twenty-four hour urine collection
Volunteers were provided with a 2.5 litre container containing 0.5 g sodium 
azide as preservative. They were instructed to start collecting once their first morning 
urination had been discharged and continue collecting until after the first urination the 
following morning. Volunteers were requested to keep the sample out of direct 
sunlight and the container was collected from the subject before mid-day. The volume 
was recorded and two 50 ml aliquots were taken and kept at -20°C until analysis, the 
samples were analysed within six months.
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2.2.4 Blood collection
A suitably trained person drew the blood samples from an antecubital vein in 
the forearm of subjects, in the studies described in Chapters 3, 5, 6 and 7. For the 
study detailed in Chapter 4, the blood samples were taken from an intravenous cannula 
inserted into an antecubital vein in the forearm under local anesthetic by a trained 
doctor. The blood samples were aliquoted into 10 ml tubes containing 
ethylenediaminetetraacetic acid (EDTA). Subjects were requested to fast (no food or 
drink except water) for 12 h before the start of each study.
2.2.5 Plasma isolation
For the isolation of plasma from whole blood the EDTA tubes containing the 
blood samples were centrifuged at 1550 g for 10 minutes at 4 °C. The plasma was 
carefully removed for lipoprotein isolation, as detailed in section 2.2.9.
During the studies detailed in Chapters 3, 5, 6 and 7 plasma was isolated after 
the removal of platelets and erythrocytes (as illustrated in figure 2.1), to minimize the 
amount of blood required from the volunteers.
Plasma samples were aliquoted into cryo tubes, containing 10 pi butylated 
hydroxytoluene (BHT) (1 mg/ ml ethanol), snap frozen in liquid nitrogen and stored at 
-80 °C until analysis; the samples were analysed within six months.
2.2.6 Platelet isolation
Platelets were isolated from whole blood using a method described by 
Lehmann et al (1988) (Lehmann et al., 1988). Ten ml whole blood was centrifuged at 
280 g for 14 minutes at a pre-cooled temperature of 2 °C. The platelet rich plasma was 
transferred into a flat-bottomed glass tube and subsequently spun at 1120 g for 15 
minutes at 2 °C, the bottom layer was used to isolate erythrocytes (section 2.2.7). The 
platelet poor plasma was transferred into a cryo tube (and stored at -80 °C until 
analysis), leaving a visible opaque disc of platelets at the base of the tube. A 2 ml Tris 
buffer (134 mmol/L NaCl, 5 mmol/L KC1 and adjusted to pH 7.4 with HC1) was added 
and gently aspirated with a Pasteur pipette to agitate the platelets. The platelets were 
spun at 1120 g for 15 minutes at 2 °C. The supernatant was removed leaving the 
washed platelets at the base of the tube, 1 ml Tris buffer was aliquoted into the tube
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with the platelets and gently aspirated with a Pasteur pipette. The platelets were 
aliquoted equally, in duplicate, into cryo tubes (containing lOpl BHT (1 mg/ ml 
ethanol)), snap frozen in liquid nitrogen and stored at -80 °C until analysis. Samples 
were analysed within six months.
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Figure 2.1 Summary of blood separation procedures for the isolation of plasma, 
erythrocytes, platelets and lymphocytes from whole blood.
2.2.7 Erythrocyte isolation
Erythrocytes were isolated from the infranatant after the platelet rich plasma 
was removed (illustrated in figure 2.1). The sample was centrifuged at 1550 g for 10 
minutes at 4 °C. The plasma was removed and the leucocytes ‘buffy coat' discarded. 
The erythrocytes were washed by addition o f 4 ml saline, then mixed by inversion. 
The erythrocytes and saline solution was centrifuged at 700 g for 10 minutes at 4 °C, 
the supernatant was then discarded. This washing process was repeated twice. The 
washed packed cells (erythrocytes) were measured for haematocrit. Through capillary 
action the erythrocytes travelled up the capillary tube, these capillary tubes were
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placed in a haemo centrifuge (Heraeus Biofuge, Kendro laboratory products GmbH, 
Germany) and centrifuged at 13,000 g for 10 minutes. The percentage haematocrit was 
determined by placing the capillary tube against a chart supplied by the manufacturers 
and reading the percentage packed cells. The remaining erythrocytes were equally 
aliquoted into cryo tubes (containing 10 pi BHT (1 mg/ ml ethanol) and 10 pi 
deferoxamine mesylate (DFO) (1 mg/ ml ethanol)), snap frozen in liquid nitrogen and 
stored at -80 °C until analysis. Samples were analysed within six months.
2.2.8 Lymphocyte isolation
Lymphocytes were isolated from whole blood using Histopaque-1077, 
a solution of polysucrose and sodium diatrizoate, adjusted to the density of 1077 g/ ml 
as instructed by the manufacturers. During centrifugation, erythrocytes and 
granulocytes are aggregated by polysucrose and rapidly sediment, whereas, 
lymphocytes and other mononuclear cells remain at the plasma- Histopaque-1077 
interface. The manufacturers state a 68 ± 13% recovery of lymphocytes from whole 
blood.
Ten ml Histopaque-1077 was aliquoted into a 50 ml centrifuge tube and 
allowed to reach room temperature before 10 ml whole blood was carefully layered on 
top, so as not to disturb the Histopaque-1077. The tube was centrifuged at 400 g for 30 
minutes at room temperature. The plasma layer was removed to within 0.5 ml of the 
opaque interface, the 0.5 ml near the opaque interface was discarded. The opaque 
interface, which contained the lymphocytes, was carefully transferred into a second 
falcon tube, taking care not to remove any of Histopaque-1077 from the layer below. 
The lymphocytes were washed with phosphate buffered saline (PBS; lmg /ml in 
distilled water). A 10 ml aliquot of PBS was added to the lymphocytes and centrifuged 
at 250 g for 10 minutes at room temperature. The supernatant was removed leaving the 
lymphocyte pellet at the base of the tube. Five ml PBS was aliquoted into the tube and 
the lymphocytes were gently aspirated with a Pasteur pipette, this was then spun at 
250 g for 10 minutes at room temperature. The washing process was repeated twice 
more. After the final wash 0.5 ml PBS was added to the lymphocyte pellet at the base 
of the tube and gently aspirated with a Pasteur pipette. The lymphocytes in PBS were 
aliquoted into a cryo tube (containing lOjul BHT (1 mg/ ml ethanol), snap frozen in
53
Chapter 2
liquid nitrogen and stored at -80 °C until analysis, samples were analysed within six 
months.
2.2.9 Isolation o f lipoproteins from plasma
For the study detailed in Chapter 4 chylomicrons were isolated from plasma 
directly obtained from whole blood. Whereas for the studies reported in Chapters 5 
and 6, lipoproteins were isolated from frozen plasma retrieved from the procedure to 
isolate lymphocytes (shown in figure 2.1).
2.2.9.1 Isolation of chylomicrons
The isolation of chylomicrons from plasma was performed by a method 
adapted from Weintraub et al. (1987b). In reusable Beckman ultracentrifuge tubes (16 
x 76 mm) 4 ml plasma was overlaid with 4 ml 0.9% sodium chloride solution (density 
(d) — 1.006 g/ ml). The samples were placed into a 70.1 Ti Beckman Coulter rotor 
then centrifuged at 110,000 g for 15 minutes at 21°C, max acceleration, deceleration 5 
(Beckman Opima XL-1000 ultracentrifuge, USA) to float the chylomicron particles (d 
-  0.095 -  1.006 g/ml). The top 1 ml, chylomicron fraction, was recovered with a 
syringe and needle into a 1 ml volumetric flask. For the study detailed in Chapter 4 
chylomicrons were isolated from fresh plasma and subsequently aliquoted equally into 
cryo tubes (containing 10 pi BHT (1 mg/ ml ethanol)), snap frozen in liquid nitrogen 
and stored at -80 °C until analysis; samples were analysed within six months. In the 
studies detailed in Chapters 5 and 6 the chylomicrons were isolated from frozen 
plasma and were analysed immediately for cholesterol, triacylglycerol, protein and 
vitamin E content.
2.2.9.2 Isolation of very low-densitv lipoproteins (VLDL). low-densitv lipoproteins 
(TDD and high-densitv lipoproteins (HDD bv sequential ultra centrifugation
For the isolation of VLDL and IDL, LDL and HDL the chylomicron free 
plasma was retrieved, obtained as described in section 2.2.9.1, a steel cannula was 
placed (2.5 mm diameter) into the tube and 4 ml of plasma drawn up using a syringe. 
VLDL and IDL, LDL and HDL were subsequently isolated by sequential ultra 
centrifugation from this plasma at their respective hydrated densities: VLDL and IDL
54
Chapter 2
(d 1.006 -  1.019 g/ ml), LDL (d 1.019 -  1.0639 g/ ml) and HDL (d 1.210 g/ ml). 
Density solutions (sodium bromide; NaBr 1.019 g/1 and 1.182 g/ ml) were confirmed 
by a digital density meter (Parr Scientific, UK). Appendix II details the formula use to 
make density solutions.
To isolate VLDL and IDL, 4 ml chylomicron free plasma was transferred into 
Beckman Ultraclear centrifuge tubes (16 x 76 mm), 0.32 ml NaBr solution (1.182 g/ 
ml) was added to adjust density to 1.019 g/ml, the volume was made up to 11 ml with 
6.68 ml NaBr solution (1.019 g/ ml). The tubes were mixed by inversion then placed 
into a 70.1 Ti Beckman Coulter rotor and centrifuged at 15,000 g for 20 h at 15°C, 
max acceleration and max deceleration (Beckman Opima XL-1000 ultracentrifuge, 
USA) to float the VLDL particles (d 1.006 -  1.019 g/ ml). The top 2 ml were 
recovered with a syringe and needle into a 2 ml volumetric flask taking care not to 
disturb the lipoproteins in the infranatant, a further 1 ml was discarded.
To isolate LDL, 2.94 ml NaBr solution (1.182 g/ ml) was added to the tube and 
the density of the solution adjusted to 1.063 g/ ml. With a glass pipette the gelatinous 
pellet was disrupted. The tubes were mixed by inversion then centrifuged under the 
same conditions used for VLDL isolation. The LDL particles (d 1.019 -  1.063 g/ ml) 
floated to the top. The top 2 ml was recovered with a syringe and needle into a 2 ml 
volumetric flask taking care not to disturb the lipoproteins infranatant.
To isolate HDL, 2.1125 g potassium bromide was added to the infranatant 
adjusting the density of the solution to 1.21 g/ ml. The tubes were mixed by inversion 
then centrifuged under the same conditions used for VLDL and LDL isolation. The 
top 1 ml was recovered with a syringe and needle into a 1 ml volumetric flask.
Aliquots of the isolated lipoprotein fractions were immediately analysed for 
cholesterol, triacylglycerol, protein content and vitamin E.
2.2.9.3 Separation of LDL subclasses by self generated gradient of iodixanol
A method described by Davies et a l (2003) was used for the separation of 
LDL subclasses from plasma. According to this method 7.8 ml 9 % iodixanol/ PBS 
solution was transferred into a Beckman Optiseal™ centrifuge tube (16 x 67 mm). In a 
separate tube 2.8 ml plasma and 0.7 ml Optiprep (60 % Iodixanol w/v) were mixed by 
inversion. Using a steel cannula (2.5 mm diameter) and syringe, 3 ml of 
plasma/iodixanol solution was under-layered into the centrifuge tubes containing the
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9% iodixanol solution, care was taken not to introduce air bubbles. Optiseal plugs 
were placed on the tubes and secured using the Beckman plug sealer. The tubes were 
left to settle for 30 minutes before being placed in the Beckman NVT65 near-vertical 
rotor. Bronze spacers were placed over the tubes and tightened to a torque of 180 inch 
pounds. The samples were centrifuged at 341,000 g for 3 hours at 16 °C, acceleration 
and deceleration programs 5 (Beckman Opima XL-1000 ultracentrifuge, USA).
Tubes were removed from the rotor, taking care not to disturb the gradient. The 
top 500 pi was discarded before fractionation to minimize the contamination from 
chylomicrons or VLDL. The tubes were placed in a Beckman Fraction Recovery 
System and the tubes were pierced by a needle assembly attached to an infusion pump. 
The gradient was upwardly displaced by a dense, hydrophobic displacement fluid 
(Perfluorodecalin), and 300 pi fractions were collected using RediFrac fraction 
collector (Pharmacia Biotech). The fractions were frozen and stored at -80 °C until 
analysis, the samples were analysed within six months.
The cholesterol content of the LDL sub fractions were measured as described 
in section 2.2.11. The cholesterol values were plotted on a graph to determine the 
individual profiles and adjacent fractions were pooled together for vitamin E analysis, 
as shown in appendix III.
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2.2.10 Determination o f  plasma and lipoprotein triacylglycerol
Plasma and lipoprotein triacylglycerol concentrations were measured 
automatically by the SPACE biochemical analyser (Alfa Wasserman, The 
Netherlands), using ACE™ Triglycerides reagent. The reactions involved are outlined 
below:
Triacylglycerol  leases ^  g|yCeroj _j_ fatty acids
slvcerol kinase
Glycerol + ATP ^  glycerol-3-phosphate + H20 2
glycerol-3-phosphate
Glycerol-3-phosphate + 0 2 — °--^ ase >  dihydroxyacetone phoshate + H20 2
peroxidase
2 H20 2 + 4 Aminoantipyrin + 4-chlorophenol   >  quinoneimine + HCI + 4 H20
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The end product, quinoneimine was measured at 505 nm/ 692 nm and its 
concentration was directly proportional to triacylglycerol concentration. The range of 
quantitation of the assay was 0.02 - 1 1 .4  mmol/ L. Quality control samples were 
inserted at the beginning of every assay; if the value fell outside 2 standard deviations 
of the mean the assay was repeated. The inter-assay coefficient of variation (CV) for 
QCs was less than 2 %.
2.2.11 Determination o f plasma and lipoprotein cholesterol
Plasma and lipoprotein cholesterol concentrations were measured 
automatically by the SPACE biochemical analyser (Alfa Wasserman, The 
Netherlands), using ACE™ Cholesterol reagent. The reactions involved are outlined 
below:
cholesterol esterase 
Cholesterol ester + H20 2 ---------------->  cholesterol + fatty acids
cholesterol oxidase 
Cholesterol + 0 2 ^  cholestene-3-one + H2 O2
2 H20 2 + phenol + 4- Aminoantipvrin peroxidase^  qUinoneimine + H20
The end product, quinoneimine was measured at 505 nm/ 692 nm and was
directly proportional to cholesterol concentration. The limit of quantitation for the 
assay is 19.3 m m ol/1. Quality control samples were inserted at the beginning of every 
assay; if the value fell outside 2 standard deviations of the mean the assay was 
repeated. The inter-assay coefficient of variation (CV) for QCs was less than 2 %.
2.2.12 Determination o f low-density lipoprotein (LDL) cholesterol
Plasma LDL cholesterol were measured automatically by the SPACE 
biochemical analyser (Alfa Wasserman, The Netherlands), using ACE™ LDL 
cholesterol reagents.
In the initial reaction eliminated chylomicrons, VLDL and HDL
cholesterol esterase 
Cholesterol ester + H20 2 ---------------->  cholesterol + fatty acids
cholesterol oxidase 
Cholesterol + 0 2 ---------------->  cholestene-3-one +H20 2
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cholesterol oxidase 
2 H20 2  >  2 H20  + 0 2
Then LDL cholesterol was released by detergents in reagent 2
cholesterol esterase 
Cholesterol ester + H20 2 ^  cholesterol + fatty acids
cholesterol oxidase 
Cholesterol + 0 2  >  cholestene-3-one +H20 2
peroxidase
2 H20 2 + 4-Aminoantipyrine + TOOS >  quinonine pigment + 4 H20
TOOS; N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3 -methylaniline
The intensity of the quinonine pigment was directly proportional to cholesterol 
concentration at 600nm. Quality control samples were inserted at the beginning of 
every assay; if the value fell outside 2 standard deviations of the mean the assay was 
repeated.
2.2.13 Determination ofhigh-density lipoprotein (HDL) cholesterol
Plasma HDL cholesterol were measured automatically by the SPACE 
biochemical analyser (Alfa Wasserman, The Netherlands), using ACE™ HDL 
cholesterol reagents.
In the initial reaction eliminated chylomicrons, VLDL and LDL
cholesterol esterase 
Cholesterol ester + H20 2 -------------- >  cholesterol + fatty acids
cholesterol oxidase 
Cholesterol + 0 2  >  cholestene-3-one +H20 2
cholesterol oxidase 
2 H20 2  >  2 H20  + 0 2
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Then HDL cholesterol was released by detergents in reagent 2
cholesterol esterase 
Cholesterol ester + H20 2 -------------- ^  cholesterol + fatty acids
cholesterol oxidase 
Cholesterol + 0 2  >  cholestene-3-one +H20 2
peroxidase
2 H20 2 + 4-Aminoantipyrine + HDAOS -------------- >  quinonine pigment + 4 H20
HD AOS; N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline
The intensity of the quinonine pigment was directly proportional to cholesterol 
concentration at 600nm. Quality control samples were inserted at the beginning of 
every assay, if the value fell outside 2 standard deviations of the mean the assay was 
repeated.
2.2.14 Determination o f  protein in platelets and lymphocytes
The isolated platelets and lymphocytes (isolation procedure detailed in sections
2.2.6 and 2.2.8) were defrosted at room temperature then sonicated for 3 minutes to 
ensure a homogenous sample. Lymphocytes were diluted 1 in 3 with PBS before 
analysis. Samples were analysed in duplicate and the mean values was used.
The protein content in platelets and lymphocytes was determined automatically 
by SPACE biochemical analyser (Alfa Wasserman, The Netherlands) using a 
colorimetric urinary protein kit (validated for use in platelets and lymphocytes as 
described in section 2.2.14.1). The method is based on the formation of pyrogallol red 
complexes with proteins in an acid environment containing molbdate ions, whose 
optical density at 600nm is directly proportional to the protein concentration of the 
samples.
2.2.14.1 Validation of urinary protein kit with the modified Lowry protein assay
The urinary protein (UP) kit was designed to measure protein in ui'ine, 
however, due to the high sensitivity of the assay it was used to measure the protein 
content in the isolated platelets and lymphocytes in the investigations described in this 
thesis. The method was validated as the protein in platelets is suspended in a Tris 
buffer and the lymphocytes in PBS. The modified Lowry protein assay was used to
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validate the protein measurement by the urinary protein kit as it is a sensitive assay 
(Lowry & Rosebrough, 1951).
The modified Lowry protein assay was carried out as follows; 2 ml Biuret 
reagent (100 ml 2 % Na2 CC>3 in 0.1 M NaOH w/v solution, 1 ml 2 % NaK Tartrate 
w/v solution and 1 ml 1 % CuS04 w/v solution) was added to 400 pi standards, quality 
controls and samples, then vortexed and left to stand for 10 minutes. Folin Coicalteu 
reagent was diluted 1:1 with distilled water, 200 pi was then added to the standards, 
QCs and samples and immediately vortexed. They were left to stand for 30 minutes 
and the absorbance at 750 nm was then measured on a spectrophotometer (Beckman 
Du 650, USA). A standard curve was generated from standards, protein concentration 
for QCs and samples were calculated from the equation of the standard curve. 
Standards were prepared from a 1 mg/ ml human albumin stock solution, provided 
with the urinary protein kit, diluted with distilled water to range from 0 - 5 0  pg 
protein.
The validation of the urinary protein kit to accurately measure protein in 
platelets and lymphocytes was performed by measuring the protein content in six 
platelet and six lymphocyte samples (n = 12), using the UP kit and the modified 
Lowry protein assay. A close correlation was observed between the two methods (r2 = 
0.94). The Bland and Altman test was used to assess the agreement between methods; 
the mean difference was 0.017 g protein with 95 % confidence interval of + 0.38 or - 
0.18 mg/ ml protein (Bland & Altman, 1986).
The reproducibility of the UP kit to measure protein in platelets and 
lymphocytes was determined by the coefficient of variation, with an n of 12 over the 
course of 3 days. The coefficient of variation for platelet and lymphocyte protein was
4.5 and 5.3 %, respectively.
2.2.15 Determination o f protein in lipoproteins
The protein content of lipoproteins were measured using the method 
described by Bradford (1976). Bio-Rad protein assay dye reagent concentrate was 
diluted 1 : 5 with distilled DDI water then filtered through a nylon membrane filter 0.2 
pm (47 mm Whatman, Maidstone, UK). Standard protein solutions were diluted from 
stock solution of 1 mg/ ml human albumin serum with PBS, to a range from 0.05 to
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0.5 mg/ ml. Into a microtiter 96 well plate 10 pi of standards and samples were 
dispensed in triplicate. To each well 200 pi of diluted dye reagent was added, then 
mixed in microplate mixer for 10 seconds. Samples were left to incubate at room 
temperature for 5 minutes. Absorbance was measured at 620 nm on a 
spectrophotometer equipped with Genesis II software (Windows ™ based, version
3.05 Labsystems Multiskan, Biochromatic). A standard curve was generated in 
Microsoft Excel and the linear equation was used to calculate the concentration of 
samples.
2.2.16 Ascorbic acid extraction from plasma
A method described by (Omaye et al., 1987) was used for the isolation of 
ascorbic acid was isolated from fresh plasma by the addition of 1 ml 5 % 
metaphosphoric acid in 1 mM diethylenetriaminepentacetic acid (made fresh daily) to 
1 ml plasma, mixed by inversion and spun at 700 g for 5 minutes at room temperature. 
The supernatant was equally aliquoted into 0.5 ml tubes. The samples were stored at - 
80°C until analysis. Samples were analysed within six months.
2.2.17 Ascorbic acid quantification with HPLC with electrochemical detection
A method described by Omaye et al. (1987) was used for HPLC quantification 
of ascorbate. The ascorbic acid samples were defrosted at room temperature. To 10 pi 
sample, 10 pi 1 mM DTPA and 74 pi mobile phase (see below for composition) were 
added together and the mixture was vortexed. A 20 pi aliquot was analysed by HPLC 
with electrochemical detection (ECD). The HPLC system was a 2690 Waters Alliance 
System (Waters Ltd, Elstree, UK) comprising a solvent delivery system, online 
degasser, peltier-cooled autosampler (set at 4 °C), controller and column oven (set at 
25°C) in conjunction with an LC-4C amperometric ECD (Bioanalytical Systems, 
Lafayette, USA) equipped with a glassy-carbon working electrode and a Ag/AgCl/gel 
reference electrode operating with an applied potential of + 0.5 V. The mobile phase 
consisted of 40 mM sodium acetate, 0.51 mM DTPA, 1.5 mM 1-dodecane sulfonic 
acid sodium salt for ECD and 7.5 % (v/v) methanol adjusted to pH 4.75 with glacial 
acetic acid, flow rate was delivered at 1 ml/ min. The ascorbic acid was separated 
using a Supelcosil™ LC-8 column (150 x  4.6 mm 5pm) (Supelco, USA).
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Chromatogram peaks were processed using Waters Millennium ®32 software and 
quantitated using an external calibration curve prepared with ascorbic acid standards. 
Calibration curve consisted of 0.25, 0.5, 0.75 and 1.0 mnoles generated from different 
injection volumes of alO pM ascorbic acid stock solution.
2.2.18 Vitamin E extraction from blood components by solvent extraction
All vitamin E extractions from biological samples were carried out by 
the following method adapted from Burton et al. (1985). For analysis by LC/MS 
plasma was diluted 1 : 5 with PBS prior to vitamin E extraction. Platelet and 
lymphocyte samples were sonicated for 3 minutes prior to vitamin E extraction to 
ensure homogeneity of the sample.
Into a glass screw top tube, 5 pi internal standard (500 pM 5-tocopherol for 
HPLC analysis, 10 pM d3 all rac-a-tocopherol for LC/MS analysis) was added at the 
start of each extraction, followed by 25 pi BHT (1 mg/ ml ethanol), lOOpl sample and 
900 pi 0.1 M sodium dodecylsulphate. Samples were vortexed, then 2 ml absolute 
ethanol was added. Samples were vortexed, then 4.5 ml hexane was added and 
subsequently vortexed. The samples were centrifuged at 700 g for 3 minutes at 5 °C. 
Three ml of the hexane upper layer was aliquoted from each sample into a new glass 
tube using a displacement pipette. The hexane was dried down completely under 
nitrogen. For analysis by HPLC, 100 pi absolute ethanol was immediately added to 
the dried sample. For analysis by LC/MS, 500 pi absolute ethanol was immediately 
added to the dried plasma sample while 200 pi absolute ethanol was added for all the 
other dried blood component samples. Samples were extracted in duplicate and quality 
controls were extracted with each extraction. Fifty pi reconstituted sample was placed 
into Waters vials for analysis, kept at 4 °C until analysis which took place within 24 
hours of extraction.
2.2.19 Vitamin E extraction by saponification
The vitamin E content of the vitamin E capsules used in the studies detailed in 
Chapters 3, 4, 5, and 6 were analysed by the following method adapted from Kayden 
etal. (1983).
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Approximately 10 mg oil was placed into a glass screw top tube, 900 pi water 
(1 % ascorbic acid) and 2 ml ethanol (1 % ascorbic acid) were added and the tube was 
vortexed. Subsequently 0.3 ml saturated KOH was added and vortexed. The samples 
were incubated at 70 °C for 30 minutes, then rapidly cooled on ice. After cooling, 25 
pi BHT and 1 ml water (1 % ascorbic acid) were added to the samples and vortexed. 
Four ml hexane was added, samples were vortexed then allowed to separate. The top 3 
ml of the hexane layer was transferred to a new glass tube using a displacement 
pipette. The hexane was completely dried down under nitrogen. Approximately 10 ml 
absolute ethanol was used to reconstitute the oils extracted from the vitamin E 
capsules in order to perform HPLC analysis. Approximately 5 ml absolute ethanol was 
used to reconstitute the hydrolysed d6 7?7?7?-a-tocopherol and d3 all rac-oc-tocopherol 
standards for the preparation of stock solutions.
2.2.20 Vitamin E  quantification using HPLC with electrochemical detection
Vitamin E was quantified by HPLC with electrochemical detection 
(ECD) using a method adapted from Podda et al. (1996). The vitamin E concentration 
of plasma, erythrocytes, platelets and lymphocytes isolated for the studies detailed in 
Chapters 3 and 7 were quantified using the following method.
The HPLC system used was the same as described in section 2.2.17. The 
mobile phase consisted of 99 % methanol, 1% water and 0.1 % lithium perchlorate 
filtered through 0.2 pm pore size nylon membrane filters (47 mm Whatman 
Maidstone, UK). The tocopherols were separated using a reverse phase Waters 
Spherisorb® ODS-2 column (250 mm x  4.6 mm, C l8, 5pm particle size) at a flow 
rate of 1.5 ml/ min. Tocopherols peaks were identified from retention times, 5-, y- and 
a-tocopherol eluted at 9.2, 10.9 and 12.9 minutes respectively. Chromatogram peaks 
were identified and quantified using internal standard (6-tocopherol) with Waters 
Millennium ®32 software. Quality control samples were inserted at the beginning of 
every assay, and the inter-assay coefficient of variation (CV) for the assay was 12 %.
a-, y- and 8-Tocopherol standards were made up from pure oils (a-, y- 
tocopherol > 99%, 8-tocopherol > 90%) diluted in absolute ethanol. The exact 
concentrations were determined by measuring their absorbance on a 
spectrophotometer and their concentrations were calculated using Beer-Lamberts law
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(absorption/ extinction coefficient = concentration), wavelength and extinction 
coefficients were ascertained from Kofler et al. (1962) and are reported in table 2.1. 
Standard tocopherol solutions were stored at -20 °C and their concentrations were 
regularly checked.
Table 2.1 Physiochemical data for a-, y- and 8-tocopherol
Substance Molecularweight
Wavelength 
A,max (nm)
Extinction coefficient (e) for 
ethanol solutions (M"1 cm'1)
a-Tocopherol 430.7 292 3270
y-Tocopherol 416.7 298 3810
8-Tocopherol 402.7 298 3520
From Kofler et al. (1962)
2.2.20.1 Validation of 8-tocopherol as an appropriate internal standard
Previous researchers have quantified tocopherols using an external calibration 
curve (Podda et a l , 1996). Quantification using an external calibration curve cannot 
take into account losses incurred during the extraction process, hence an internal 
standard method was developed to quantify a- and y-tocopherol. 8-Tocopherol was 
validated as an appropriate internal standard; its retention time was at least one minute 
less then a- and y-tocopherol, the compounds of interest, therefore the peaks did not 
overlap, as was the case with p-tocopherol.
Response calibration curves were linear from 0.2 to 60 pM tocopherol in 
sample (equivalent to 0.002 to 0.40 pmoles injected) illustrated in figure 2.2. Recovery 
of a-, y- and 8-tocopherol was 99, 98 and 95 % respectively.
Ratio (area y-tocopherol/ area 8-tocopherol) Ratio (area a-tocopherol/ area 8-tocopherol)
Figure 2.2 Response calibration curves for a- and y-tocopherol in ethanol
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The comparison between quantification within an internal standard and 
quantification using an external calibration curve, was carried out simultaneously in 
20 plasma samples. There was a close correlation between the two methods (r2 =
0.86). The Bland and Altman test was used to assess the agreement between methods; 
the mean difference was 0.8 pM a-tocopherol with 95 % confidence interval of + 10.0 
or - 8.4 pM a-tocopherol (Bland & Altman, 1986). Although the agreement was poor, 
the coefficient of variation between duplicates was consistently larger when measured 
by external curve compared with the internal standard quantification, 5.6 %and 3.2 % 
respectively (20 duplicate samples). Therefore, the external curve was less accurate 
and less precise.
2.2.21 LC/ MS quantification o f  vitamin E
LC/MS quantification of vitamin E was carried out by the method described by 
Hall et al. (2003). Deuterium labelled (d6 RRR-a-tocopherol) and unlabelled (dO) a- 
tocopherol were quantified by LC/MS in the studies detailed in Chapters 4, 5 and 6. dO 
and d6 a-Tocopherol were present in the biological samples after supplementation, d3 
all rac a-tocopherol was the internal standard.
The HPLC system was a 2695 Waters Alliance System (Waters Ltd, Elstree, 
UK) comprising a solvent delivery system, online degasser, peltier-cooled 
autosampler (set at 4 °C), controller and column over (set at 25 °C). The mobile phase 
consisted of 100% LC/MS grade methanol. The tocopherols were separated using a 
reverse phase Waters Symmetry® column (2.1 mm x  50 mm, C l8, 2.5 pm particle 
size) at a flow rate of 0.3 ml/ min. Tocopherols eluted at 2.2 minutes.
The HPLC system was coupled with a Micromass LCT™ time-of-flight (TOF) 
mass spectrometer (Micromass UK Ltd, Manchester, UK). The LCT™ consisted of an 
orthogonal ion extraction (Z-Spray) source equipped with an electrospray inlet. The 
ions are transferred via a dual hexapole pusher region where the ions are deflected into 
the analyser flight tube at a rate of 20 KHz (50 ps flight time). Ion arrival times are 
recorded using a multichannel plate detector linked to a 3.6 GHz time to digital 
converter (TDC). RF lenses transfer ions from source to the TOF mass analyser. 
Ionisation parameters were as follows; negative ion electrospray ionisation (ESI-), 
desolvation gas temperature 250 °C, source temperature 120 °C, capillary voltage,
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2800 V, sample cone voltage -35 V, extraction cone voltage 3 V, RF lens 450. TDC: 
start mV 800 and stop mV 181. Ions in the range of 350 -  500 m/z were collected 
from 1.5 to 3.5 minutes following injection and acquired at 4000 FWHM resolution. A
0.95 ms scan time was used with a 0.05 ms inter-scan delay. Ions generated by dO, d3 
and d6 a-tocopherol were 429.37, 432.39 and 435.41 m/z respectively. The identified 
peaks were integrated and amounts calculated from response curves generated from a 
range of standards using Mass Lynx 4© software.
The standards underwent the same extraction procedure as the samples, 
differing amounts of dO and d6 a-tocopherol were aliquoted in duplicate, 5 pi of 10 
pM d3 all rac-a-tocopherol (internal standard) and 100 pi PBS were added and the 
extraction procedure was carried out as detailed in section 2.2.18. Reconstituted 
ethanol standards were stored at -80 °C for a maximum of two months.
A d6 a-tocopherol standard curve extracted from PBS did not agree with one 
extracted from erythrocytes, therefore was not used. A consequence of this was dO a- 
tocopherol could not be quantified in the samples.
d3 and d6 a-Tocopherol standards (> 98 % isotopically pure) were prepared 
from their tocopheryl acetates as described in section 2.2.19, dO was prepared from 
pure a-tocopherol oil (> 99% purity); standards were diluted in absolute ethanol. The 
exact concentrations were determined by measuring their absorbance on a 
spectrophotomer and calculating their concentration using beer-Lamberts law 
(absoiption at 298nm / extinction coefficient e 3270 = concentration), wavelength and 
extinction coefficients were ascertained from Kofler et a l (1962). Standard tocopherol 
solutions were stored at -20  °C, their concentrations were regularly checked.
2.2.21.1 Development of liquid chromatography time-of-flight mass spectrometric 
fLC TOF MS) method to detect deuterium labelled tocopherols
A LC TOF MS method was developed to quantitatively measure deuterium 
labelled tocopherols in biological samples (Hall et a l , 2003). Previous methods have 
been published for gas chromatography MS (Ingold et a l,  1987b) and LC MS utilising 
either single or triple quadrupole instruments (Kalman et a l, 2003; Lauridsen et a l, 
2001; Mother et a l,  2002). TOF Mass spectrometers are very sensitive with high mass 
accuracy.
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The LC TOF MS instruments and procedure are detailed in section 2.2.21. To 
optimise conditions the TOF MS was tuned by continuous infusion of a 10 pM dO a- 
tocopherol into the spectrometer. Ionisation was tested in both positive and negative 
ion mode of electrospray and atmospheric pressure chemical ionisation, negative ion 
electrospray produced the maximal signal and was therefore used. Optimum 
conditions are described in section 2.2.21. TOF MS produces a single ion of exact 
mass, the mass for dO (429.3742) corresponds almost exactly to the [M - H] 
calculated mass of a-tocopherol (429.3733). Figure 2.3 shows the typical total ion 
chromatogram and m/z scans following the injection of 0.5 pmoles of dO, d3 or d6 a- 
tocopherol.
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Figure 2.3 Typical total ion chromatogram and m/z scans following the injection of 0.5 
pmoles of dO, d3 or d6 a-tocopherol
A lineal* response was observed up to 15 pmoles of dO, d3 and d6 a-tocopherol 
pure standards in ethanol. Figure 2.4 shows the calibration curves for peak area verses 
concentration. The d6 a-tocopherol response is considerably lower than dO and d3 a - 
tocopherol. Injections of 150 pmoles or greater a-tocopherol resulted in saturation of
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the detector, resulting in a non-linearity. The TOF MS has a low dynamic range 
(approximately 3 orders of magnitude), therefore the extracted biological samples 
were diluted to be within the range of the instrument, so preventing saturation by dO 
a-tocopherol.
8000 -1 ♦
7000 - 
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| 5000 - y /
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a. y
3000 -
2000 '  *
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Figure 2.4 Calibration curves for peak area versus concentration of dO, d3 and d6 a- 
tocopherol
An internal standard, d3 all rac-a-tocopherol, was used for the quantification 
of dO and d6 RRR-a-tocopherol in biological samples. A matrix ion and an ion 
suppression effect from the extraction procedure was observed when spiked samples 
were compared with ethanol standards. To overcome this, standards underwent 
identical extraction procedure as the biological samples (detailed in section 2.2.21). 
The identified peaks were integrated and amounts calculated from response curves 
generated from the range of standards using Mass Lynx 4© software. Figure 2.5 
illustrates the response curve for dO and d6 a-tocopherol, the curves are non-linear and 
fit a polynomial equation for quantitation. Response for dO and d6 a-tocopherol were 
calculated by the equation below whereby the unknown was replaced by either dO or 
d6 a-tocopherol.
Response = Area unknown x (d3 concentration / d3peak area)
♦ d3 r2 = 0.9986
♦ dO r2 = 0.9993
♦ d6 r2 = 0.9987
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Figure 2.5 Response curves used for the quantification of dO and d6 a-tocopherol
The limits of detection and quantification were calculated using pure ethanol 
standards and blood components spiked with varying concentrations of d6 a- 
tocopherol prior to extraction. The limit of detection (LOD) was determined from the 
amount of tocopherol injected with a signal to noise ratio of 5:1. For ethanol standards 
LOD was 5 ffnols, whereas for plasma, erythrocytes and platelets it was 15, 30 and 15 
finds respectively. The limit of quantification (LOQ) was determined from the lowest 
point in the standard response curve in which an amount can be accurately and 
reproducibly determined. The LOQ for plasma, erythrocytes and platelets was 50, 100 
and 50 finds respectively.
To assess the precision of the TOF MS plasma, erythrocytes and platelet 
tocopherol extractions were analysed for within day and between day variation. 
Within day variation was determined by tocopherol extractions measured eight times, 
coefficient of variation ranged from 3 to 7 % for dO and d6 a-tocopherol. Between day 
variation was determined by tocopherol extractions measure eight times over a period 
of 4 weeks, coefficient of variation ranged from 3 to 10 % for dO and d6 a-tocopherol.
The accuracy of the TOF MS to quantify tocopherols was determined by 
measuring plasma extractions spiked with d6 a-tocopherol ranging from 1-15  pM in 
12 samples. The accuracy was found to be 98 ± 8 % of the calculated concentration. 
The TOF MS quantification of tocopherols was validated with HPLC-ECD analysis of
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dO a-tocopherol. HPLC-ECD is unable to distinguish between the different species of 
a-tocopherol. Plasma and platelet samples were extracted separately, 8-tocopherol 
was added as an internal standard for HPLC-ECD analysis, whereas d3 all rac-a- 
tocopherol was added as an internal standard for TOF MS analysis. The 
concentrations from the HPLC-ECD and TOF MS closely correlated (r2 = 0.94). The 
Bland and Altman test was used to assess the agreement between methods; the mean 
difference was + 3.6 pM a-tocopherol with 95 % confidence interval of + 8.2 or - 2.1 
pM a-tocopherol (Bland & Altman, 1986).
2.2.22 Quantification o f vitamin E urinary metabolites
Urinary metabolites of a- and y-tocopherol, 2,5,7,8-tetramethyl-2 (2'- 
carboxyethyl)-6-hydroxychroman (a- CEHC) and 2,7,8-trimethyl-2- (2'- 
carboxyethyl)-6~hydroxychroman (y-CEHC) were measured by HPLC with 
electrochemical detection (ECD), as described by Lodge et al. (2000).
The urine samples were defrosted at room temperature. To a 5 ml aliquot of 
urine, 400 pi of freshly made enzyme solution (4mg P-glucuronidase in 450 pi 0.1 M 
acetate buffer with enzyme activity; 1850 units) and 10 pi Trolox (1 mg/ ml ethanol as 
internal standard) was added and then the mixture was gently shaken. The samples 
were incubated at 37 °C for 4 hours, then cooled on ice. Once cooled 50 pi 
concentrated HC1 was added and samples gently shaken. Using an automated glass 
volumetric pipette 15 ml diethyl ether was added to the samples. Samples were then 
vortexed and mixed by inversion. The samples were centrifuged at 700 g for 1 minute 
at 4 °C. Ten ml diethyl ether was removed with an automated glass volumetric pipette 
into a separate tube. The diethyl ether was dried down completely with nitrogen, the 
samples were re-suspended with 100 pi ethanol for HPLC analysis.
The HPLC system was a 2690 Waters Alliance System (Waters Ltd, Elstree, 
UK) as described in section 2.2.2.17 in conjunction with an LC-4C amperometric 
ECD (Bioanalytical Systems, Lafayette, USA). The mobile phase was delivered at a 
flow rate of 0.4 ml/ min and consisted of a gradient with Mcllvaine buffer (0.01 M 
citric acid, 0.02 M diammonia hydrogen orthphosphate, 0.1 % lithium perchlorate in 
distilled water and adjusted to pH 4.15 with 12 M HC1 (0.2 g of preservative sodium
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azide was added) and acetonitrile (ACN) with 0.1 % lithium perchlorate, gradient 
detailed in table 2.2.
Table 2.2 Mobile phase gradient used to separate urinary metabolites and trolox
Time (min) Mcllvaine buffer ACN
0-6.5 80 20
1 minutes to change
7.5-19.5 60 40
4 minutes to change
23.5-30 5 95
1 minutes to change
31-35 80 20
The metabolites and trolox were separated using a reverse phase Sepserv 
ES1000™, column (250 mm x 4 mm, C18, 5pm particle size). Peaks were identified 
from retention times: Trolox, a-CEHC and y-CEHC eluted at 21, 24.5 and 28 min, 
respectively.
The peaks were identified using Waters Millennium®32 software then 
quantitated using the peak area of trolox. The area of trolox peak was known to equate 
to 0.01 mg therefore the concentration of a-CEHC and y-CEHC could subsequently be 
calculated; (0.01/ (Trolox pea k a rea / CEHC peak area )) x trolox response factor = mg CEHC 
in original 5 ml urine sample. The response factor to trolox was approximately 0.9 for 
y-CEHC and 0.7 for a-CEHC calculated from calibration curves.
Samples were extracted in duplicate and quality controls were extracted with 
each extraction. Quality control samples were inserted at the beginning of every assay, 
and the inter-assay coefficient of variation (CV) for the assay was 16 %.
2.2.23 Determination o f urinary creatinine
Urinary creatinine was measured automatically by the SPACE biochemical 
analyzer (Alfa Wasserman, The Netherlands), using a colorimetric kit supplied by 
Randox (County Antrim, UK). The urine samples were diluted 1 in 50 with distilled 
water before analysis. The creatinine in alkaline solution reacts with picric acid to 
form a coloured complex. The amount of the complex formed was directly 
proportional to the creatinine concentration.
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2.2.24 Cotinine measurement by HPLC with UV detection
Urinary cotinine (a nicotine metabolite) was measured by HPLC with UV 
detection by a method adapted from Greaves et al. (2001). Urinary cotinine was 
measured to confirm cigarette smoking status in Chapter 7. The urine samples were 
defrosted at room temperature; a 2 ml aliquot of urine was transferred into a glass 
screw top tube. Fifty pi 150 % NaOH was added to the urine and shaken to mix. Using 
a glass volumetric pipette, 8 ml dichloromethane was added, vortexed then mixed by 
inversion. The samples were centrifuged at 1,100 g for 2 minutes at room temperature. 
With care, 4 ml of the infranatant was transferred to a new tube using a glass 
volumetric pipette. This was then dried under nitrogen and reconstituted in 100 pi 20 
% methanol 80 % water solution.
The HPLC system was a 2690 Waters Alliance System (Waters Ltd, Elstree, 
UK) as described in section 2.00 in conjunction with a Waters 2487 dual X absorbance 
UV detector (Waters Ltd, Elstree, UK). The mobile phase was delivered at a flow rate 
of 1 ml/min and consisted of 64 % water, 20% methanol, 12 % 0.4 mM sodium 
acetate (pH 4.3), 4 % ACN. A C l8, Discovery™® column was used to separate the 
cotinine. Absorbance was taken at 260 nm, peaks were identified from the retention 
time, cotinine eluted at 11.5 minutes. The peaks were identified using Waters
• • O ')
Millennium® software then quantitated using an external calibration curve. Cotinine 
standards were made up from pure cotinine. An external calibration curve, which 
ranged from 0.2 to 1.0 pg, was used. Limit of detection of assay is reported to be 10 
pg/ L with a signal to noise ration of 5 (Greaves et a l, 2001).
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2.3 Statistical analysis
Results were analysed using GraphPad InStat® (version 3.01, 32 bit for 
Windows 95/ NT (1998) San Diego, USA) and STATISTICA (version 5.1 for 
Windows, StatSoft Inc (1997) Tulsa, OK, USA). Pearsons correlation coefficient as 
used to test the association between two sets of data, expressed as r2 the product 
moment coefficient; Spearman rank order correlation was used if the data was not 
normally distributed. Basic descriptive statistics, unpaired and paired t tests, one-way 
analysis of variance (ANOVA) or two-way repeated measures ANOVA were 
performed as appropriate. Post hoc analysis of effects was carried out using Tukey’s 
Honestly Significant Difference test as required. Statistical significance was assumed 
if p < 0.05 and a trend towards significance if p < 0.10 and > 0.05.
In Chapters 3, 5 and 6 area under the curve (AUC) was calculated by trapezoid 
method and for Chapter 6 power calculations were conducted using an internet based 
power calculator at www.health.ucalgaiy.ca/~rollin/stats/ssize.
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C h a p t e r  3
U r i n a r y  a -  a n d  y - C E H C  e x c r e t i o n  a n d  
p l a s m a ,  e r y t h r o c y t e ,  p l a t e l e t  a n d  
l y m p h o c y t e  a -  a n d  y - t o c o p h e r o l :  R e s p o n s e  
t o  v a r y i n g  s i n g l e  d o s e s  o f  v i t a m i n  E
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3.1 Introduction
Vitamin E is essential to health, it acts as an antioxidant maintaining the 
integrity of biological membranes and there are important non-antioxidant roles 
emerging for a-tocopherol (Azzi et a l, 2003; Wang & Quinn, 1999). This chapter 
investigates the uptake of vitamin E within plasma, erythrocytes, platelets and 
lymphocytes and the urinary excretion of vitamin E metabolites, in response to 
varying single doses of a-tocopheryl acetate. Investigations into a possible dose- 
response relationship between vitamin E in blood components (other than plasma) and 
urinary vitamin E metabolites (CEHC) have not previously been undertaken.
Presently, there is no universally accepted biomarker for reliable and accurate 
measurement of vitamin E status (Morrissey & Sheehy, 1999). A number of steady- 
state and functional biomarkers have been suggested, these include vitamin E 
concentration in erythrocytes, platelets, lymphocytes and urinary CEHC excretion 
(Lehmann et a l, 1988; Schultz et a l, 1995; Vatassery et a l,  1983). A better 
understanding of the response in blood components and urinary metabolites to vitamin 
E supplementation within healthy people is required to further elucidate vitamin E 
regulation.
Steady-state plasma a - and y-tocopherol concentrations are frequently used to 
assess vitamin E status (Hense et a l, 1993; Salonen et a l, 1985; Winklhofer-Roob et 
a l, 1997). Plasma vitamin E concentration represents the combined total of vitamin E 
within circulating lipoproteins (Traber, 1994). The vitamin E content of lipoproteins is 
predominately due to their chemical composition rather than the presence of transport 
proteins, as may be the case in peripheral tissues (Blatt et a l,  2001; Perugini et a l, 
2000). There are several confounding factors that reduce the sensitivity of plasma as a 
biomarker for vitamin E status; it is a saturable system (Dimitrov et a l,  1991), 
subjected to hepatic regulation (Traber et a l, 1990a; Traber & Kayden, 1989a) and 
influenced by plasma lipids (Horwitt et a l, 1972; Thurnham et a l, 1986). Vitamin E 
within erythrocytes is membrane bound and these cells possess tocopherol binding 
proteins (Kitabchi & Wimalasena, 1982b), it has therefore been proposed that vitamin 
E concentration within erythrocytes is a better indicator of tissue vitamin E status than 
plasma (Simon et a l,  2001). Lymphocytes have LDL receptors and are thought to 
obtain their vitamin E by internalisation of LDL. It is currently unknown how platelets 
obtain their vitamin E. Both platelets and lymphocytes are functionally affected by
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vitamin E and therefore vitamin E concentration within these cells may represent a 
function biomarker of vitamin E. Vitamin E regulation and distribution between the 
aforementioned blood components is poorly understood.
Within the liver, a - and y-tocopherol are metabolised to 2,5,7,8-tetramethyl-2- 
(2'-carboxyethyl)-6-hydroxychroman (a-CEHC) and 2,7,8-trimethyl-2- (2'- 
carboxyethyl)-6-hydroxychroman (y-CEHC) respectively. The hepatic a-tocopherol 
transfer protein selects i?£R-a-tocopherol for secretion within VLDL, while the other 
forms of vitamin E are presumed to be metabolised and excreted into bile (Hattori et 
a l , 2000; Mustacich et a l , 1998). The vitamin E metabolites present in plasma (Galli 
et a l, 2002; Stahl et a l,  1999) are thought to be reabsorbed from the intestine into the 
systemic circulation. The proportion of vitamin E metabolites not reabsorbed by this 
route and excreted into the faeces is currently unknown. Vitamin E metabolites within 
plasma are excreted in the urine after kidney filtration. It has been proposed that 
urinary vitamin E metabolites might reflect vitamin E regulation within the liver 
(Lodge et a l, 2001).
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3.2 Aim and hypothesis
At present there is no adequate biomarker to reliably and accurately assess 
vitamin E status. This is, in part, due to the limited information available about the 
regulation of vitamin E and the extent of a-tocopherol metabolism to a-CEHC. a- 
CEHC has been proposed as a biomarker for adequate vitamin E status, however, 
relatively little is known about a-CEHC formation and excretion in response to 
vitamin E supplementation, and therefore further investigation into factors affecting its 
excretion are needed. Plasma is frequently used to assess vitamin E status. Vitamin E 
levels within erythrocytes, platelets and lymphocytes have been proposed as potential 
biomarkers for vitamin E status. Limited information exists on dose-response uptake 
of a-tocopherol into blood components and the extent of a-tocopherol metabolism to 
a-CEHC.
Instead of plasma, vitamin E levels within erythrocytes, platelets, lymphocytes 
and urinary CEHC excretion, could potentially be used as biomarkers of vitamin E 
status. However, before they can be used as biomarkers, an understanding of the 
relationship between supplementation and vitamin E concentration and formation 
urinary CEHC excretion must be established.
The current study aims to;
1. Determine the response of vitamin E concentration within plasma, erythrocytes, 
platelets and lymphocytes, and the urinary excretion of CEHC metabolites to 
varying single doses of a-tocopheryl acetate.
2. Establish whether there is a relationship between vitamin E levels in plasma, 
erythrocytes, platelets and lymphocytes and the urinary excretion of CEHC 
metabolites.
3. Determine the percentage of a-tocopheryl acetate dose excreted as urinary a- 
CEHC.
It is hypothesised that a dose-dependent increase in a-tocopherol within 
plasma, erythrocytes, platelets and lymphocytes, and urinary a-CEHC will be 
observed. It is also hypothesise that a peak in urinary a-CEHC will be observed on the 
same day of a-tocopheryl acetate ingestion, as reported for other forms of vitamin E.
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3.3 Study design
Twenty healthy subjects (7 males and 13 females) were recruited from the 
university and advertisements in local newspapers. Selection criteria stated subjects 
must not have been taking dietary supplements (6 months prior to the study), were 
non-smokers and had no gastrointestinal disorders as determined by a written 
questionnaire. Subjects with blood lipid abnormalities were excluded (selection 
criteria was cholesterol < 6 mmol/1 and triglycerides <1.5 mmol/1).
The vitamin E doses given to the subjects were 130, 195, 390 and 780 a a- 
tocopheryl acetate. Five subjects were randomly assigned to each a-tocopheryl acetate 
dosage.
Figure 3.1 illustrates the study protocol. Subjects were requested to complete a 
7-day food diary finishing on day 5 of the study. The subjects collected 24 h urine 
collections for two days prior to ingesting the a-tocopheryl acetate capsule, the day 
the capsule was consumed and the subsequent two days. The subjects were instructed 
to consume the a-tocopheryl acetate capsule with a fat containing breakfast on day 3, 
but otherwise the subjects ate ad libitum. A fasted 20ml blood sample was taken 24 
hours prior to and 24 hours following ingestion of the a-tocopheryl acetate capsule.
I  o  1
1 2 3 4 5
'----- Y----- ' ------V----- ' V-----y----- ' V-----V----- ' '-----V----- '
24 hr urine collection each day
20ml blood sample 0 >  a-Tocopheryl acetate; either 130, 195, 390 or 
▼ 780 mg
Figure 3.1 Schematic figure of study protocol
The subjects were requested to complete a food diary during the study period. The subjects 
collected 24 h urine collections for five days, on days 2 and 4 a fasted blood sample was 
taken. On day 3 the subjects ingested the a-tocopheryl acetate capsule (either 130, 195, 390 
and 780 mg a-tocopheryl acetate)
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The completed food diaries were analysed for the average daily nutrient intake 
as detailed in section 2.2.2. Plasma, erythrocytes, platelets and lymphocytes were 
isolated from the fasted blood samples and a- and y-tocopherol were subsequently 
measured, as detailed in sections 2.2.4 -  2.2.8. Plasma cholesterol and triacylglycerol 
were measured as detailed in section 2.210 and 2.2.11. Creatinine and a - and y-CEHC 
were measured from aliquots of the 24 hour urine collections as detailed in sections 
2.2.3, 2.2.22 and 2.2.23. The mean value from day 1 and 2 urine collections were used 
for the baseline value.
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3.4 Results
The vitamin E content of the ‘Holland and Barrett’ a-tocopheryl acetate 
capsules was analysed, after saponification (method detailed in section 2.2.19). The oil 
contained 97% a-tocopherol and 3 % y-tocopherol, as a consequence the precise doses 
given to the subjects were 130 and 4 mg, 195 and 6 mg, 390 and 12 mg, 780 and 24 
mg a-tocopheryl acetate and y-tocopheryl acetate respectively. From here onwards the 
doses of vitamin E will be expressed as mg a-tocopheryl acetate only for clarity.
3.4. J Subject characteristics
Twenty healthy normolipidemic subjects participated in the study, there were 
five subjects in each of the four a-tocopheryl acetate dosage groups. During the study 
period no one reported any side effects or withdrew from the study. Table 3.1 shows 
the subject characteristics of each group and mean values for all twenty subjects. Age, 
body mass index, plasma cholesterol and triacylglycerol concentrations, and habitual 
dietary vitamin E intakes were not significantly different between groups as analysed 
by one-way ANOVA (Table 3.1). None of the subjects consumed greater than 10 mg 
vitamin E a day from their habitual diet during the study period.
Table 3.1 Subject characteristics for each group and total
Group
a-TA
Gender
M/F
Age
(Years)
BMI
(kgm"2)
Cholesterol 
(mmol/1)
TAG 
(mmol/1)
Vitamin E intake 
(mg/ day)
130 mg 
n = 5 1/4 42 ±6 24.5 + 1.3 4.5 ± 0.4 1.1 ±0.1 6.65 + 1.04
195 mg
n = 5 2/3 34 + 5 22.8 ±1.2 4.6 ± 0.3 1.1 ±0.2 5.26 ± 0.62
390 mg 
n = 5 3/2 39 + 6 25.2 + 2.2 4.7 ± 0.3 1.0 ±0.1 6.77 ±0.81
780 mg 
n = 5 1/4 40 ±5 24.2 ±1.0 4.6 ± 0.4 1.0+ 0.1 5.27 ±0.31
Total 
n = 20 7/ 13 39 ±3 24.2 ± 0.7 4.6 ± 0.2 1.1 ±0.1 6.00 ± 0.48
Values expressed as mean ± SEM. a-TA: mg of a-tocopheryl acetate in each dose, M: male, 
F: female, BMI: body mass index, TAG: triacylglycerol
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3.4.2 Baseline values
Table 3.2 shows the mean baseline a - and y-tocopherol concentrations in 
plasma, erythrocytes, platelets and lymphocytes for each of the four dosage groups 
and the combined subject total. The mean baseline a-tocopherol concentration in 
plasma was 23.1 pM (rangel6.8-31.1 pM) for all subjects. There was significantly 
greater a-tocopherol in each blood component compared with y-tocopherol as 
analysed by paired t-test (p < 0.0001). Baseline a- and y-tocopherol concentration in 
plasma, erythrocytes, platelets and lymphocytes were similar in each of the four 
groups of five subjects. Baseline values for the seven males and thirteen females were 
not significantly different from each other (data not shown).
Table 3.2 Mean baseline a- and y-tocopherol concentrations in blood components for 
each group and total
Group Plasma Plasma Erythrocytes Platelets Lymphocytes
a-TA pmol/1 pmol / mmol C pmol/PCV pmol/ g protein pmol/ g protein
130 mg a-T 23.1 ±3.3 5.1 ±0.4 4.0 ± 0.3 1.29 ±0.24 2.46 + 0.30
_____ Y-T 1.57 + 0.28 0.34 ± 0.04 0.37 ±0.05 0.14 ±0.03 0.21 ± 0.06
195 mg a-T 22.3 ± 1.4 5.1 ±0.5 3.5 + 0.2 1.09 + 0.23 2.17 ±0.17
y-T 1.55 + 0.16 0.33 ± 0.02 0.29 + 0.04 0.09 ± 0.03 0.29 ± 0.05
390 mg a-T 22.9 ±1.5 4.9 + 0.4 3.7+ 0.4 1.24 ±0.25 2.34 ±0.16
y-T 1.55 + 0.05 0.34±0.03 0.33 ± 0.04 0.11 ±0.03 0.29 + 0.03
780 mg a-T 25.5 ± 0.7 4.7 + 0.5 3.7 ±0.4 1.10 + 0.21 2.32 ± 0.54
y-T 1.35 ±0.07 0.31 ±0.03 0.27 ± 0.03 0.08 + 0.02 0.23 ± 0.04
Total a-T 23.1 ±1.3 5.0 ± 0.2 3.7 ± 0.2 1.18 ± 0.11 2.32 + 0.15
y-T 1.51 ±0.08 0.33 ± 0.07 0.31 ±0.09 0.10 ±0.06 0.26 ± 0.08
Values are expressed as mean ± SEM. a-TA: mg of a-tocopheryl acetate in each dose, a-T:
a-tocopherol, y-T: y-tocopherol, C: cholesterol, PCV: packed cell volume
Table 3.3 shows the mean baseline urinary excretion of a- and y-CEHC over 
24 hours and corrected for creatinine for each group and the combined subject total. 
Urinary excretion of y-CEHC was significantly greater than a-CEHC in all subjects as 
analysed by paired t-test (p < 0.001). Baseline urinary excretion of a - and y-CEHC 
were similar in each of the four groups. Baseline values for the seven males and 
thirteen females were not significantly different from each other (data not shown).
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Table 3.3 Mean baseline" urinary a- and y- CEHC excretion for each group and total
Group a- CEHC a- CEHC y- CEHC y- CEHC
a-T pg/ 24 h mg/ g creatinine jig/ 24 h mg/ g creatinine
130 mg 349 ± 80 0.35 + 0.12 652 + 130 0.63+0.15
195 mg 349 ±50 0.37 + 0.10 471+61 0.51 ±0.16
390 mg 205 ± 60 0.19 + 0.07 380 + 97 0.34 + 0.06
780 mg 339 + 91 0.30 + 0.03 448 ± 70 0.42 ± 0.04
Total 302 ±33 0.30 + 0.04 479 ± 48 0.48 ± 0.06
Values expressed as mean ± SEM. a-TA: mg of a-tocopheryl acetate in each dose group 
" Baseline 24 h urinary a- and y-CEHC excretion were the mean from day 1 and 2 collections
3.4.2.1 Baseline correlations
Table 3.4 shows a correlation matrix for baseline a-tocopherol concentration 
in plasma, erythrocytes, platelets, lymphocytes and baseline urinary excretion of a- 
CEHC. There were no correlations between a-tocopherol concentration in plasma 
with a-tocopherol concentration in erythrocytes, platelets or lymphocytes or urinary 
excretion of a-CEHC. There was a negative correlation between a-tocopherol in 
erythrocytes and urinary a-CEHC excretion and a positive correlation between a- 
tocopherol in erythrocytes and platelets.
Table 3.4 Correlation matrix for baseline a-tocoplierol concentration in plasma, 
erythrocytes, platelets, lymphocytes and urinary a-CEHC excretion (n = 20)
Plasma 
a-T/ mmol C
Erythrocytes 
a-T/ PCV
Platelets 
a-T/ g pro.
Lymphocytes 
a-T/ g pro.
a-CEHC/ 
24 h
Plasma 
a-T/ mmol C -
r2 = 0.01 
p = 0.67
r2 = 0.00 
p = 0.90
r2 = 0.01 
p = 0.57
r2 = 0.00
p = 0.81
Erythrocytes 
a-T/ PCV
r2 = 0.01 
p = 0.67 -
r2 = 0.25 
p = 0.03
r2 = 0.06 
p = 0.29
r2 = 0.24 
p = 0.03
Platelets 
a-T/ g pro.
r2 = 0.00 
p = 0.90
r2 = 0.25 
p = 0.03 -
r2 = 0.02 
p = 0.57
r2 = 0.00 
p = 0.89
Lymphocytes 
a-T/ g pro.
r2 = 0.01 
p = 0.57
r2 = 0.06 
p = 0.29
r2 = 0.02 
p = 0.57 -
r2 = 0.00
p = 0.80
a-CEHC/ 
24 h
r2 = 0.00
p = 0.81
r2 = 0.24 
p = 0.03
r2 = 0.00 
p = 0.89
r2 = 0.00
p = 0.80 -
a-T: a-tocopherol, C: cholesterol, PCV: packed cell volume, pro: protein
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Table 3.5 shows a correlation matrix for baseline y-tocopherol concentration in 
plasma, erythrocytes, platelets, lymphocytes and baseline urinary excretion of y- 
CEHC. There was a strong positive correlation between y-tocopherol concentration in 
plasma and erythrocytes. Urinary y-CEHC excretion did not correlate with any of the 
blood components measured.
Table 3.5 Correlation matrix for baseline y-tocopherol concentration in plasma, 
erythrocytes, platelets, lymphocytes and urinary y-CEHC excretion (n = 20)
Plasma 
y-T/ mmol C
Erythrocytes 
y-T/ PCV
Platelets 
y-T/ g pro.
Lymphocytes 
y-T/ g pro.
y-CEHC/ 
24 h
Plasma 
y-T/ mmol C -
r2 = 0.68
p < 0.01
r2 = 0.07
p = 0.26
r2 = 0.11 
p = 0.15
r2 = 0.00
p = 0.81
Erythrocytes 
y-T/ PCV
r2 = 0.68
p < 0.01 -
r2 = 0.14
p = 0.11
r2 = 0.18 
p = 0.07
r2 = 0.05 
p = 0.37
Platelets 
y-T/ g pro.
r2 = 0.07
p = 0.26
r2 = 0.14
p = 0.11 -
r2 = 0.07 
p = 0.29
r2 = 0.05 
p = 0.39
Lymphocytes 
y-TI g pro.
r2 = 0.11 
p = 0.15
r2 = 0.18 
p = 0.07
r2 = 0.07 
p = 0.29 -
r2 = 0.04 
p = 0.43
y-CEHC/ 
24 h
r2 = 0.00
p = 0.81
r2 = 0.05 
p = 0.37
r2 = 0.05 
p = 0.39
r2 = 0.04 
p = 0.43 -
y-T: a-tocopherol, C: cholestero , PCV: packed cell volume, pro: protein
3.4.3 a- and y-Tocopherol concentration 24 h post ingestion o f differing single doses 
o f a-tocopheryl acetate
Table 3.6 shows the mean a-tocopherol concentrations in plasma, erythrocytes, 
platelets and lymphocytes at baseline and 24 h post ingestion of varying single doses 
of a-tocopheryl acetate. Plasma and erythrocyte a-tocopherol concentrations 
significantly increased 24 h after ingestion of 195, 390 and 780 mg a-tocopheryl 
acetate. A non-significant increase was observed in a-tocopherol concentration within 
platelets and lymphocytes 24 h after the varying single doses of a-tocopheryl acetate.
Table 3.7 shows the mean y-tocopherol concentrations in plasma, erythrocytes, 
platelets and lymphocytes at baseline and 24 h post ingestion of varying single doses 
of a-tocopheryl acetate. y-Tocopherol concentration decreased in all blood 
components, although not significantly.
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Table 3.6 a-Tocopherol concentration at baseline and 24 h post ingestion of varying 
single doses of a-tocopheryl acetate
a-Tocopheryl 
acetate dose
Plasma
pmol/ mmol C
Erythrocytes
pmol/PCV
Platelets
pmol/ g protein
Lymphocytes
pmol/ g protein
130 mg Pre 5.10 + 0.38 4.01 + 0.28 1.29 ±0.24 2.46 ± 0.30
Post 6.05 + 1.04 4.67 + 0.55 1.15 + 0.22 3.05 ± 0.30
195 mg Pre 5.40 + 0.51 3.51 ±0.23 1.09 + 0.23 2.17 ±0.17
Post 6.89 + 0.46* 5.42 + 0.45* 1.13 + 0.20 2.42 + 0.26
390 mg Pre 4.92 + 0.41 3.70 + 0.41 1.24 + 0.25 2.34 ±0.16
Post 6.94 ± 0.97* 4.68 ± 0.47" 1.38 ±0.36 2.23 ±0.37
780 mg Pre 4.71 ± 0.49 3.72 + 0.36 1.10 ±0.21 2.75 ±0.38
Post 7.42 ± 0.87* 5.72 + 0.55* 1.40 ±0.29 3.09 ±0.35
Values expressed as mean ± SEM * Significantly different from baseline concentration, 
analysed by paired t-test (p < 0.05), "p = 0.06 C: cholesterol, PCV: packed cell volume 
n = 5 in each group except lymphocytes n = 4 due to insufficient sample
Table 3.7 y-Tocopherol concentration at baseline and 24 h post ingestion of varying 
single doses of a-tocopheryl acetate
a-Tocopheiyl 
acetate dose
Plasma
pmol/ mmol C
Erythrocytes
pmol/ PCV
Platelets
pmol/ g protein
Lymphocytes
pmol/ g protein
130 mg Pre 0.34 ± 0.04 0.37 ± 0.05 0.14 ±0.03 0.21 ±0.06
Post 0.30 ± 0.03 0.25 ± 0.04 0.14 ±0.05 0.19 ±0.05
195 mg Pre 0.33 ± 0.02 0.29 ± 0.04 0.09 ± 0.03 0.29 ± 0.05
Post 0.20 ± 0.02* 0.19 ±0.04 0.06 ± 0.02 0.23 + 0.03
390 mg Pre 0.34 ± 0.03 0.33 + 0.04 0.11 ±0.03 0.29 + 0.03
Post 0.32 + 0.04 0.25 + 0.03* 0.10 + 0.03 0.23 + 0.02
780 mg Pre 0.31 ±0.03 0.27 ± 0.03 0.08 ± 0.02 0.23 + 0.04
Post 0.27 ± 0.03 0.24 + 0.03 0.07 ± 0.02 0.21 ±0.02
Values expressed as mean ± SEM * Significantly different from baseline concentration, 
analysed by paired t-test (p < 0.05) C: cholesterol, PCV: packed cell volume 
n = 5 in each group except lymphocytes n = 4 due to insufficient sample
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Figure 3.2 illustrates the mean percentage increases in a-tocopherol 
concentration 24 h following ingestion of varying single doses of a-tocopheryl acetate 
in plasma, erythrocytes, platelets and lymphocytes. A larger percentage increase in a- 
tocopherol concentration was observed in plasma and erythrocytes compared with 
platelets and lymphocytes. A dose-response increase in a-tocopherol was not observed 
in any of the blood components. There was large inter-individual variation in the 
percentage change in a-tocopherol concentration, as illustrated by the large standard 
error bars in figure 3.2.
The percentage decrease in y-tocopherol did not correlate with the percentage 
increase in a-tocopherol concentration.
-20 J
i  130mga-TA
flj 195mga-TA 
390 mg a-TA 
□  780 mg a-TA
Plasma Eyrthrocytes Platelets Lymphocytes
Figure 3.2 Mean percentage changes in a-tocopherol concentrations within blood 
components between baseline and 24 h post ingestion of varying single doses of a- 
tocopheryl acetate.
Values expressed as mean ± SEM. No dose-response observed in percentage increase 
of a-tocopherol in plasma, erythrocytes, platelets or lymphocytes after varying single 
doses of a-tocopheryl acetate. a-TA: a-tocopheryl acetate dose ingested.
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3.4.4 Urinary a- and y-CEHC levels after varying single-doses o f  a-tocopheryl 
acetate
Individual urinary a-CEHC excretion profiles are shown in the following 
section to clearly illustrate the inter-individual differences in the excretion profiles.
Figure 3.3 illustrates the five individual and the mean urinary a-CEHC 
excretion profiles over five days when 130 mg a-tocopheryl acetate was ingested on 
day 3. There was no significant difference in a-CEHC excretion over time.
Days
Figure 3.3 Urinary excretion of a-CEHC over 5 days when 130 mg a-tocopheryl acetate 
was ingested on day 3.
There was no significant difference in a-CEHC excretion over time, analysed by 
repeated measures ANOVA
Figure 3.4 shows the five individual and mean urinary a-CEHC excretion 
profiles over five days when 195 mg a-tocopheryl acetate was ingested on day 3. 
There was a significant time effect in a-CEHC excretion (p = 0.024), with greater a- 
CEHC excretion on day 3 compared with days 1 and 2. One individual excreted a 
large amount of a-CEHC on days 3 and 4 as shown in figure 3.4.
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Days
Figure 3.4 Urinary excretion of a-CEHC over 5 days when 195 mg a-tocopheryl acetate 
was ingested on day 3.
There was a significant time effect in a-CEHC excretion (p = 0.024) analysed by repeated 
measures ANOVA. * Post hoc analysis showed greater a-CEHC excretion on day 3 compared 
with days 1 and 2.
Figure 3.5 illustrates the five individual and mean urinary a-CEHC excretion 
profiles over five days when 390 mg a-tocopheryl acetate was ingested on day 3. 
There was no significant difference in a-CEHC excretion over time.
Days
Figure 3.5 Urinary excretion of a-CEHC over 5 days when 390 mg a-tocopheryl acetate 
was ingested on day 3.
There was no significant difference in a-CEHC excretion over time, analysed by 
repeated measures ANOVA.
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Urinary a-CEHC excretion was lower after the 390 mg dose compared with 
the 195 mg dose. There were some subjects that did not excrete any more a-CEHC 
above baseline; this is illustrated by two flat profiles in both figures 3.3 and 3.5.
Figure 3.6 shows the five individual and mean urinary a-CEHC excretion 
profiles over five days when 780 mg a-tocopheryl acetate was ingested on day 3. 
There was a trend towards a significant time effect in a-CEHC excretion (p = 0.068). 
One individual excreted a large amount of a-CEHC on day 3 compared with the other 
subjects.
Overall there was a large inter-individual variation in the magnitude and 
pattern of urinary a-CEHC excretion in response to varying single doses of a- 
tocopheryl acetate.
Days
Figure 3.6 Urinary excretion of a-CEHC over 5 days when 780 mg a-tocopheryl acetate 
was ingested on day 3.
There was a trend towards a significant time effect in a-CEHC excretion (p = 0.068) 
analysed by repeated measures ANOVA.
There was no significant difference in the excretion of y-CEHC compared with 
baseline values post ingestion of the varying single doses of a-tocopheryl acetate.
Figure 3.7 illustrates the collective amount of a-CEHC excreted over baseline 
over 72 hours after ingestion of the varying single doses of a-tocopheryl acetate. 
There was large inter-individual variation in amount of a-CEHC excreted, illustrated
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by the very large standard error bars in figure 3.7. No dose-dependant increase in 
urinary a-CEHC excretion was observed.
uui
8
|
1
130 mg 195 mg 390 mg 780 mg
Figure 3.7 Collective urinary excretion of a-CEHC above baseline from days 3, 4 and 5.
There was no dose-dependant increase in urinary a-CEHC excretion
Table 3.8 shows the mean a-CEHC excreted above baseline and the calculated 
amount this would equate to as percentage of dose ingested. The calculated percentage 
dose of a-tocopheryl acetate excreted as a-CEHC was less than 1% after each dose.
Table 3.8 Urinary a-CEHC excretion up to 72 h after ingestion of varying doses of a- 
tocopheryl acetate
Group a- CEHC mg over baseline a- CEHC
a-T mean ± SEM range %
130 mg 0.42 ± 0.34 -0.30-1.29 0.33 ± 0.26
195 mg 1.63 ±0.65 0.47-4.12 0.84 ± 0.33
390 mg 0.51 ±0.12 0.22-0.85 0.13 ±0.03
780 mg 1.34 ±0.50 0.35-3.94 0.17 ±0.06
Values expressed as mean ± SEM. % dose = (100/ mg dose) x mg excreted over baseline
2.5 i
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3.4.4.1 Correlations after varying single doses of a-tocopheryl acetate
Table 3.9 shows a correlation matrix for a-tocopherol concentration in plasma, 
erythrocytes, platelets, lymphocytes 24 h post ingestion of varying doses of a- 
tocopheryl acetate and incremental AUC (iAUC) urinary a-CEHC excretion up to 72 
h post ingestion of a-tocopheryl acetate. There was a positive correlation between 
concentration of a-tocopherol in plasma and erythrocytes post 24 h with iAUC of a- 
CEHC excretion over baseline, and between platelets and eiythroctes. There were no 
correlations between platelets or lymphocytes with plasma or urinary a-CEHC 
excretion.
Table 3.9 Correlation matrix for a-tocopherol concentration in plasma, erythrocytes, 
platelets, lymphocytes 24 h following ingestion of varying single doses of a-tocoplieryl 
acetate and incremental AUC for urinary a-CEHC excretion up to 72 h post ingestion of 
a-tocopheryl acetate (n = 20)
Plasma 
a-T/ mmol C
Erythrocytes 
a-T/ PCV
Platelets 
a-T/ g pro.
Lymphocytes 
a-T/ g pro.
a-CEHC
iAUC
Plasma 
a-T/ mmol C -
r2 = 0.18
p = 0.06
r2 = 0.00 
p = 0.80
r2 = 0.09
p = 0.21
r2 = 0.36
p < 0.01
Erythrocytes 
a-T/ PCV
r2 = 0.18
p = 0.06 -
r2 = 0.36
p<0.01
r2 = 0,01 
p = 0.83
r2 = 0.36
p < 0.01
Platelets 
a-T/ g pro.
r2 = 0.00
p = 0.80
r2 = 0.36
p < 0.01 -
r2 = 0.00 
p = 0.91
r2 = 0.10 
p = 0.17
Lymphocytes 
a-T/ g pro.
r2 = 0.09
p = 0.21
r2 = 0.01 
p = 0.83
r2 = 0.00 
p = 0.91 -
r2 = 0.02 
p = 0.52
a-CEHC
iAUC
r2 = 0.36
p < 0.01
r2 = 0.36
p<0.01
r2 = 0.10 
p = 0.17
r2 = 0.02 
p = 0.52 -
a-T: a-tocopherol, C: cholesterol, PCV: packed cell volume, pro: protein, iAUC: incremental
AUC up to 72 h post ingestion of a-tocopheryl acetate.
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3.5 Discussion
Vitamin E is an important micronutrient, however, presently there is no 
adequate biomarker to assess vitamin E status. The uptake of vitamin E into blood 
cells and factors influencing the production of urinary a-CEHC are poorly understood. 
This study aimed to investigate the response of vitamin E concentration within 
plasma, erythrocyte, platelets and lymphocytes, and urinary excretion of a-CEHC to 
varying single doses of a-tocopheryl acetate.
Key findings;
1. There was an increase in a-tocopherol concentration in plasma and erythrocytes, 
and a non-significant increase in platelets and lymphocytes 24 hours post varying 
single doses of a-tocopheryl acetate. There was no dose-response increase in a- 
tocopherol concentration in plasma, erythrocytes, platelets or lymphocytes.
2. A transient increase in urinary a-CEHC excretion was observed after the 195 mg 
and 780 mg a-tocopheryl acetate doses. There was no dose-response in a-CEHC 
excretion.
3. Less than 1 % of a-tocopheryl acetate dose was excreted as urinary a-CEHC.
4. There was a positive correlation between percentage increase in a-tocopherol 
concentration in plasma and erythrocyte and mg a-CEHC excreted over baseline.
3.5.1 Baseline a- and y-tocopherol concentration in plasma, erythrocytes, platelets 
and lymphocytes, and a- and y-CEHC urinary excretion
Plasma vitamin E levels are often used as a biomarker for vitamin E status, 
however there are several confounding factors that cumulatively reduce the reliability 
of plasma vitamin E to predict vitamin E status. The current study utilises vitamin E 
concentration within a number of blood components to assess vitamin E response to 
supplemental a-tocopheryl acetate.
The baseline a - and y-tocopherol values for plasma are similar to previously 
published values (Galli et al., 2002; Galli et al., 2003; Traber et al., 1998a). Also, a - 
and y-tocopherol concentrations within erythrocytes were similar to those reported by 
Simon et al. (1997) and in the lower range of those reported Roxborough et a l (2000). 
a - and y-Tocopherol concentration in platelets reported in the current study were
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slightly greater than those previously published (Lehmann et a l, 1988; Saito et a l, 
1992; Vatasseiy et a l,  1983). Vitamin E within lymphocytes is less well documented. 
Lymphocyte a- tocopherol concentrations reported here are greater than those 
reported by Lehmann et al, (1988) and Lenton et a l (2000).
Baseline urinary a - and y-CEHC excretion were similar to published values by 
Lodge et a l (2000), Schuelke et a l (2000) and Traber et a l (1998a). However, this 
does not agree with the findings reported by Galli et a l (2002, 2003) whereby greater 
urinary excretion of a-CEHC compared with y-CEHC was observed. Urinary a - and 
y-CEHC excretion depends on the habitual diet of the population used in a study 
(Jiang et a l,  2001). a - and y-CEHC are specific metabolites formed from the 
metabolism of a - and y tocopherols (Schonfeld et a l, 1993; Wechter et a l,  1996) and 
tocotrienols (Lodge et a l, 2001) respectively. It is hypothesised that they are excreted 
into bile and reabsorbed via the intestine into the systemic circulation before urinary 
excretion (Hattori et a l, 2000; Lodge et a l, 2001).
3.5.1.1 Baseline correlations
Basal plasma a-tocopherol per mmol cholesterol did not correlate with a- 
tocopherol concentration in erythrocytes, platelets nor lymphocytes. It can be inferred 
from this finding that blood cell a-tocopherol concentrations are independent of 
plasma concentration, and that presumably active transfer processes regulate a- 
tocopherol concentration within these cells rather than passive diffusion. The lack of 
correlation also implies that plasma a-tocopherol is unable to reflect a-tocopherol 
concentration within platelets or lymphocytes and thus their functional status.
There have been conflicting findings on a correlation between plasma a- 
tocopherol corrected for lipids and platelets. Vatasseiy et a l (1983) found a positive 
correlation whereas Lehmann et a l (1988) found no correlation. The current study did 
not observe a correlation.
However, there was a positive correlation between y-tocopherol concentration 
in plasma and erythrocytes. This could be as a result of passive diffusion, whereas a- 
tocopherol binding activity in erythrocytes may redistribute a-tocopherol 
(Wimalasena et a l, 1982).
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There were no correlations between baseline urinary a-CEHC excretion with 
a-tocopherol concentration in plasma, platelets or lymphocytes. Interestingly, there 
was a negative correlation between a-tocopherol concentration in erythrocytes and 
urinary a-CEHC excretion. However, a physiological explanation for this finding 
could not be found.
The lack of correlation between plasma a-tocopherol concentration and 
urinary a-CEHC excretion implies that urinary a-CEHC excretion does not reflect a- 
tocopherol concentration within the systemic circulation. This is in agreement with the 
findings by Schuelke et al. (2000) who reported that patients with a defective a-TTP 
excreted large amounts of a-CEHC despite low plasma levels of a-tocopherol. Small 
amounts of a-tocopherol are metabolised to a-CEHC from vitamin E within the 
habitual diet, it is hypothesised that this is due to the non-specific catabolism of RRR- 
a-tocopherol and thus some R&R-a-tocopherol being inevitably metabolised to a- 
CEHC. a-TTP is believed to selectively remove ftR/Ga-tocopherol from the metabolic 
pathway within the liver. Urinary a-CEHC may reflect the inter individual variation in 
processes involved in the catabolism of vitamin E and excess from supplementation 
rather than vitamin E status per se.
3.5.2 Response to varying single-doses o f a-tocopheryl acetate in plasma, 
erythrocytes, platelets and lymphocytes
a-Tocopherol concentration increased in plasma and erythrocytes 24 hours 
after 195, 390 and 780 mg a-tocopheryl acetate, indicating that plasma and 
erythrocytes are responsive to, and therefore reflective of, short-term dietary intake, a- 
Tocopherol concentration increased non-significantly in platelets and lymphocytes. It 
is possible that platelets and lymphocytes only take up a small amount of newly 
absorbed a-tocopherol or have a slower uptake whereby at 24 h maximal uptake is not 
yet achieved. The uptake of newly absorbed a-tocopherol has not been investigated in 
platelets and lymphocytes; this information may provide an insight into the low uptake 
of a-tocopherol observed in the current study.
It was hypothesised that a dose-responsive increase in a-tocopherol would be 
observed in the blood components measured, however, this was not the case. The large
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inter-individual variation in response to supplemental vitamin E is well documented 
(Dimitrov et a l, 1991; Traber et a l, 1998b) and this may have contributed to the lack 
of dose-response observed. A within subject study designed would have reduced the 
confounding variation between dose groups as Roxborough et a l (2000) reported 
lower intra-individual variation. Dimitrov et a l (1991) measured plasma a-tocopherol 
response in three individuals after a single dose of 440, 880, and 1320 mg all rac-a- 
tocopherol using a within subject study design. They reported a dose-response in two 
of the three subjects.
In the current study and the one by Dimitrov et a l (1991) it was not possible to 
distinguish between newly absorbed a-tocopherol from the supplement and pre­
existing a-tocopherol within the body. It has previously been shown that newly 
absorbed a-tocopherol displaces pre-existing tocopherol in plasma (Burton et a l, 
1998; Traber et a l, 1994). It has not previously been investigated whether newly 
absorbed a-tocopherol also displaces pre-existing tocopherol in erythrocytes, platelets 
and lymphocytes, although it is probable. It is also possible that there was a dose- 
responsive appearance of newly absorbed a-tocopherol into the blood components, 
but it was masked by a decrease in pre-existing vitamin E. Traber et a l (1998b) 
administered volunteers with 15, 75 and 150 mg deuterium labelled &&R-a-tocopheryl 
acetate and they reported a dose-responsive increase in deuterium labelled a- 
tocopherol within plasma, but total tocopherol remained unchanged. Deuterium 
labelled a-tocopherol was not available when this study was conducted.
A multiple dose-response study conducted by Lehmann et a l (1988) reported a 
dose responsive increase in a-tocopherol concentration within plasma, erythrocytes, 
platelets and lymphocytes. However, due to the large inter-individual variation in a- 
tocopherol concentration it is unlikely that the significant dose-response reported 
would remain when the appropriate statistical test is applied (one-way ANOVA rather 
than multiple t-tests).
Twenty-four hours after varying single doses of a-tocopheryl acetate, y- 
tocopherol concentration was reduced in plasma and erythrocytes, but significantly 
only after 195 and 390 mg doses. Previously published studies have shown a- 
tocopherol supplementation to reduce y-tocopherol concentration in plasma due to 
newly absorbed a-tocopherol replacing pre-existing tocopherol (Baker et a l, 1986;
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Handelman et al., 1985; Traber et al., 1992a). The a-tocopheryl acetate capsules also 
contained y-tocopherol, presumably originating from the soya bean oil used which 
contains 80mg y-tocopherol per 100 g oil (Sheppard et a l, 1993). The decrease in y- 
tocopherol concentration was observed despite 4, 6, 12 and 24 mg y-tocopherol being 
administered with the 130, 195, 390 and 780 mg a-tocopheryl acetate doses, 
respectively. y-Tocopherol is rapidly metabolised to y-CEHC within the liver (Galli et 
al., 2001; Galli et a l, 2003), therefore, at 24 h post ingestion of the comparatively 
small amount of y-tocopherol would probably have returned to baseline, as shown by 
Galli et a l (2003) after a 100 mg dose of deuterium labelled y-tocopheryl acetate 
(Galli etal., 2 m ) .
3.5.3 Urinary a-CEHC excretion in response to varying single-doses o f  a-tocopheryl 
acetate
There was a transient increase in urinary a-CEHC excretion after ingestion of 
varying single doses of a-tocopheryl acetate (significant increase after the 390 mg 
dose only). This is in agreement with Himmelfarb et al. (2003) who reported a non­
significant increase in serum a-CEHC after a single dose of 600 mg RRR a- 
tocopherol. A dose-response increase in a-CEHC excretion was not observed after 
varying single doses of a-tocopheryl acetate. This could be due to selective retention 
of a-tocopherol within the liver and the large inter-individual variation.
Extensive dose responsive RRR-a-tocopherol metabolism may only occur once 
a-TTP is saturated. Schultz et a l (1995) administered increasing doses of a- 
tocopheryl acetate (0 - 800 mg) over four weeks, they reported a dose response 
increase once plasma a-tocopherol concentration exceeded 7 - 9  pM/ g total lipid 
following multiple a-tocopherol supplementation.
A large inter-individual variation was observed in the transient increase in 
urinary a-CEHC excretion up to 72 h after varying single doses of a-tocopheryl 
acetate. This was clearly shown by the range of mg a-CEHC excreted above baseline 
for each dose (Table 3.8). Some individuals did not increase their excretion of a - 
CEHC over baseline, whereas others excreted up to ten-fold the baseline values. 
Hepatic a-TTP is believed to remove RRR-a-tocopherol from the metabolic pathway.
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Hence the increase in urinary a-CEHC excretion observed maybe due to an excess of 
a-tocopherol greater than the capacity of a-TTP to transfer all the i?7?7?-a-tocopherol 
away from the metabolic pathway. It is likely that the a-TTP capacity to transfer a- 
tocopherol differs in individuals and therefore potentially resulting in the observed 
inter-individual variation in urinary a-CEHC excretion. a-CEHC is excreted into bile 
(Hattori et a l,  2000) and it is hypothesised that a proportion of the a-CEHC is 
reabsorbed into the systemic circulation from the intestine. The extent of reabsorption 
is also likely to vary between individuals, contributing to the inter-individual variation 
observed.
The absorption of vitamin E has been reported to be between 20 - 80 % 
(Blomstrand & Forsgren, 1968; Kelleher & Losowsky, 1970). The amount of a- 
tocopheryl acetate absorbed was not measured in the current study, however, a- 
tocopherol concentration at 24 h post ingestion of a-tocopheryl acetate positively 
correlated with urinary a-CEHC incremental AUC over 72 h. This suggests a possible 
relationship between the amount of a-tocopheryl acetate absorbed and the extent of 
urinary a-CEHC excretion.
Relatively recent publications reporting plasma or serum a - and y-CEHC, 
illustrate the potential of measuring metabolites in plasma rather than urine (Galli et 
a l, 2002; Radosavac et a l, 2002). The process of urine collection can deter people 
from volunteering for a study and there is the possibility of incomplete collections. 
Measurements of urinary metabolites also include a degree of variation in individuals’ 
kidney function, partly eliminated by correcting for creatinine values. The 
measurement of plasma a-CEHC may have provided further insight to the extent of a- 
tocopherol conversion to a-CEHC, however, the required methodology was not 
available to measure plasma a-CEHC in the current study.
The percentage of a-tocopheryl acetate dose excreted, as urinary a-CEHC was 
veiy low (< 1%) (calculated by mg a-CEHC excreted over baseline). This extremely 
low excretion of a-CEHC is in agreement with the low excretion of deuterium 
labelled a-CEHC following ingestion of 150 mg deuterium labelled RRR a-tocopherol 
reported by Traber et a l (1998a). Whereas, approximately 2 -6  % of a dose (125 or 
500 mg) of a- or y-tocotrienol was recovered as the respective urinary CEHCs (Lodge
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et al.,), the synthetic form of a-tocopherol was metabolised 2 fold greater than the 
RRR- form when ingested together (150 mg of each) (Traber et al., 1998a). y- 
Tocopherol has been found to undergo rapid metabolism with approximately 7 % of a 
dose (100 mg) of y-tocopherol recovered as urinary y-CEHC (Galli et al., 2003). The 
low urinary a-CEHC excretion was probably due to the preferential retention of RRR- 
a-tocopherol in the body rather than its metabolism. The current study shows that the 
body appears to be able to retain a single dose up to 780 mg RRR-a-tocopherol 
without substantial metabolism to a-CEHC. This agrees with the findings from 
Radosavac et al. (2002) whereby there was only a small increase in plasma a-CEHC 
after a single dose of 306 mg RRR a-tocopheryl acetate.
There are several factors involved in the production of urinary a-CEHC that 
are currently unknown; these includes the proportion of the a-tocopheryl acetate dose 
absorbed into the body, actual amount of a-tocopherol converted to a-CEHC and the 
fraction of a-CEHC reabsorbed from the intestine. These are important considerations 
when attempting to understand the significance of urinary a-CEHC excretion.
A positive correlation between plasma and erythrocyte a-tocopherol 
concentration 24 hour after ingestion of the varying single doses of a-tocopherol and 
urinary a-CEHC excretion above baseline was observed. This implies a relationship 
between plasma and erythrocyte a-tocopherol with a-CEHC excretion rather than 
dose given. Schultz et al. also reported a correlation between plasma a-tocopherol 
after supplementation and urinary a-CEHC excretion (Schultz et a l, 1995). This 
correlation only exists after a-tocopherol doses substantially greater than that 
obtainable form the diet are ingested. Hence, the role of urinary a-CEHC excretion in 
predicating vitamin E status appears to be limited.
3.5.4 Conclusions
The inter-individual variation in uptake of vitamin E into plasma could, in part, 
be due to differing amounts and rates of absorption from the intestine. The subjects 
were requested to consume a breakfast containing fat rather than being provided with a 
standard breakfast, the extent of variation introduced is not known, the food diaries 
indicated that the meals ranged from approximately 2.7 to 17.5 g fat (as analysed from
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The blood sample was taken 24 hours post ingestion of the a-tocopheryl 
acetate capsules, in order for the newly absorbed a-tocopherol to enter the blood 
components and for it be comparable to the 24 h collection of urine. The 
measurements were taken after the peak a-tocopherol concentration in plasma. 
Several blood samples, taken over a number of time-points to calculate area under the 
curve, would be a preferable measure of a-tocopherol uptake into the blood 
components.
In conclusion, following varying single doses of a-tocopheryl acetate up to 
780 mg, a-tocopherol is preferentially retained with in the body with less than 1 % of 
the dose recovered as a-CEHC in the urine. A dose responsive increase in a- 
tocopherol was not observed in blood components or urinary a-CEHC excretion.
The extent of inter-individual variation in absorption of a-tocopheryl acetate 
dose is an important area for future research as is the amount of fat required for 
maximal vitamin E absorption. Another important area of research is the uptake of a- 
tocopherol into platelets and lymphocytes, as both cell types are functionally affected 
by a-tocopherol. However, there is extremely limited information on how they acquire 
and regulate vitamin E.
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Chapter 4
4.1 Introduction
This chapter will investigate the effect of fat content and physical properties of 
food on vitamin E absoiption. Vitamin E is believed to enter the enterocytes by 
passive diffusion and is reliant on processes involved in lipid emulsification, 
hydrolysis and enterocyte uptake (Hollander et ah, 1975; Muralidhara & Hollander, 
1977; Traber et a l, 1993). Once within the enterocytes vitamin E is incoiporated into 
chylomicrons with lipids and released into the systemic circulation via the thoracic 
duct (Bisgaier & Glickman, 1983).
It is widely accepted that dietary fats enhance vitamin E absorption (Traber et 
a l,  1990b). Cohn et a l (1992b) demonstrated that mixed micelles are more efficient at 
incoiporating a-tocopherol than pure bile salt micelles not containing lipid products, 
in vitro. Furthermore, Cohn et a l (1997) reported that a-tocopherol absorption 
required the hydrophobic molecules of lipid hydrolysis at the brush border membrane 
to allow the diffusion of a-tocopherol. There are few human studies that have 
investigated the effect of different fat quantities on vitamin E absorption. Dimitrov et 
a l (1991) reported significantly greater plasma a-tocopherol levels in humans after 5 
days when given 800 mg all rac a-tocopherol with a high fat diet compared to a low 
fat diet. There are a few contradictory studies in rats, Brink et a l (1996) and Tijburg et 
a l (1997) both reported plasma a-tocopherol levels were similar after feeding vitamin 
E, irrespective of the fat content of the diet they were fed over a number of weeks. It 
has been proposed that the low fat diets contained sufficient fat for absorption of 
vitamin E (the low fat diets were 7 g fat/ kg feed or 15% energy). The amount of fat 
necessary for maximal vitamin E absorption is currently undetermined (Parks & 
Traber, 2000).
Despite the large number of vitamin E supplementation studies, the effect of 
different meals on the rate and magnitude of vitamin E absorption has not yet been 
investigated. This is the first post-prandial study to compare the uptake of a- 
tocopherol into plasma and chylomicrons after ingestion of a-tocopheryl acetate with 
meals containing different amounts of fat. The physical properties of food is known to 
affect gastric emptying, for example foods that are high in fibre, have high viscosity 
and the protein content protein (Low, 1990). These could in turn affect the rate of 
vitamin E uptake into enterocytes
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4.2 Aim and hypothesis
A large degree of variation was observed in the magnitude of vitamin E uptake 
into plasma in Chapter 3. In the study, volunteers were instructed to consume a 
breakfast containing fat with varying single doses of a-tocopheryl acetate. Food diary 
analysis indicated that breakfasts ranged from cereal and semi-skimmed milk to toast 
and butter, or both. It was hypothesised that some of the variation observed was due to 
the subjects consuming an un-standardised meal with their vitamin E capsules.
The current study aims to;
1. Determine the extent of variation in a-tocopherol absorption when a-tocopheryl 
acetate is ingested with semi-skimmed milk and cereal compared with toast and 
butter.
2. Establish whether the rate and magnitude of a-tocopherol absorption following a- 
tocopheryl acetate ingestion is affected by the fat content of the meal.
3. Discover if the physical properties of a meal, independently of its fat content, 
affect a-tocopherol absorption.
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4.3 Study design
Eight healthy volunteers were recruited from within the university. Selection 
criteria stated subjects must be non-smoking, not taking dietary supplements and with 
no gastrointestinal disorders as determined from a written questionnaire. Subjects with 
blood lipid abnormalities were excluded (selection criteria was cholesterol < 6 mmol/1 
and triacylglycerol <1.5 mmol/1).
A within-subject, repeated measures study design was used, with each subject 
serving as his or her own control. Each subject consumed 150 mg deuterium labelled 
(d6) KRK-a-tocopheryl acetate on four separate occasions, with each occasion 7 days 
apart. Each subject consumed the a-tocopherol acetate capsule with four test meals in 
a randomised order. The four test meals were: 1) toast and butter, 2) trill fat milk, 
single cream and cornflakes, 3) semi-skimmed milk and cornflakes, and 4) water. 
Table 4.1 shows the macronutrient content of the four test meals. The toast and butter 
meal and the low fat cereal meal were chosen to represent standard breakfasts 
consumed in the study detailed in Chapter 3. The high fat cereal breakfast was deigned 
to contain the same amount and type of fat as the cereal and toast breakfast as it has 
previously been shown that the type of fat can affect the rate of vitamin E absorption 
(Ohrall et al. 2001).
Table 4.1 Macroiiutrient composition of the four test ineals
Test meal Protein*
(g)
Fat*
(g)
CHO*
(g)
Energy*
(kcal)
2 slices white toast and 20 g butter 6.8 17.5 41.2 323
40 g cornflakes, 75 g full fat milk and 75 7.5 17.5 41.0 342g single cream
40 g cornflakes and 75 g semi-skimmed 
milk 8.1 2.7 41.9 213
Glass of water 0.0 0.0 0.0 0
*Values were calculated from Holland et al (1995)
The subjects were instructed to fast for 12 h before the study commenced. 
Figure 4.1 summarises the study protocol. Subjects arrived at the Clinical 
Investigation Unit at the University of Surrey between 07:15 and 07:45 h. A trained 
doctor inserted an intravenous cannula into an antecubital vein in the forearm under 
local anaesthetic. A 10 ml baseline blood sample was taken, before the subjects
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Subjects were only allowed water during the study period, and they consumed 
a standard lunch following the 6-hour blood sample. The standard lunch consisted of a 
sandwich and low fat yoghurt containing 23 g protein, 2.5 g fat, 59 g carbohydrate for 
a total energy content of 340 kcal.
150 mg d6 RRR  a-tocopheryl acetate with differing breakfast 
i Blood sample taken
8:00 8 3 0  97)0 9:30 1(L00 1 ljOO
1
14 17;00
< >
Standard lunch 
2.5g fat
Figure 4.1 Schematic figure of study protocol
10 ml blood samples were taken at baseline before ingestion of the a-tocopheryl acetate 
capsule, then 0.5, 1, 1.5, 2, 3, 6 and 9 hours after ingestion of the capsule and test meal.
Plasma was separated from the blood samples at each time point. 
Chylomicrons were then isolated from the plasma at the 0.5, 1, 1.5, 2, 3 and 6 h time 
points (the methods are described in sections 2.2.5 and 2.2.9.1). Plasma cholesterol 
and triacylglycerol, and chylomicron triacylglycerol and protein concentration were 
measured (as detailed in sections 2.210, 2.2.11 and 2.2.15). Deuterium labelled (d6) a- 
tocopherol was measured in plasma and chylomicron samples by LC/MS (as detailed 
in sections 2.2.19 and 2.2.21).
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4.4 Results
4.4.1 Subject characteristics
Eight healthy normolipidemic volunteers (5 female and 3 male) participated in 
the study. Table 4.2 shows the subject characteristics. During the study period no one 
reported any side effects or withdrew from the study.
Table 4.2 Subject characteristics (n = 8)
Mean ± SD
Age (years) 28 ±6
BMI (kgm"2) 23 ±4
d6 a-TA/ kg body weight (mg/ kg) 2.3 ±0.1
Cholesterol (mmol/ L) 4.2 ± 0.7
Triacylglycerol (mmol/ L) 0.95 + 0.2
Plasma a-tocopherol (pmol/ L) 23.6 ±2.2
Plasma a-T/ cholesterol (pmol/ mmol) 5.6 ±0.3
BMI: body mass index, a-T: a-tocopherol a-TA: d6 a-tocopheryl acetate
4.4.2 Plasma and chylomicron cholesterol and triacylglycerol concentrations 
following four test meals
The concentration of plasma cholesterol and triacylglycerol (TAG) did not 
differ significantly during the study period (see graph in appendix IV).
Figure 4.2 illustrates the concentration of TAG in chylomicrons over 6 hours 
following four test meals. There was a significant difference over time in the TAG 
concentration of chylomicrons (p = 0.025), with a trend towards a significant 
difference in the TAG concentration profile between test meals (p = 0.051). Figure 4.3 
illustrates the protein concentration in chylomicrons over 6 hours following four test 
meals. There was no significant difference in the protein content of chylomicrons over 
time or between test meals. A large inter-individual variation was observed in protein 
concentration up to 2 h, as shown by the large SEM bars in figure 4.3.
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Figure 4.2 Chylomicron triacylglycerol concentration following ingestion of 150 mg d6 
RRR-a-tocopheryl acetate with four test meals over 6 hours
Values expressed as mean ± SEM (n = 8). There was a significant difference over time (p = 
0.025) and a trend towards a difference between test meals (p = 0.051) analysed by two way 
repeated measures ANOVA
Toast and butter 
High fat cereal 
Low fat cereal 
Water
3 -
2 -
1 -
Toast and butter 
High fat cereal 
Low fat cereal 
Water
Time (hours)
Figure 4.3 Chylomicron protein following ingestion of 150 mg d6 RRR-a-tocopheryl 
acetate with four test meals over 6 hours
Values expressed as mean ± SEM (n = 8). There was no significant difference over time as 
analysed by two way repeated measures ANOVA
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4.4.3 Plasma and chylomicron uptake o f  d6-RRR-a-tocopherol post ingestion o f a- 
tocopheryl acetate with four test meals
On six occasions d6 a-tocopherol was detected (< 2 pM) in baseline plasma 
samples, it was present from a previous study day. The plasma d6 a-tocopherol values 
were corrected for baseline d6 a-tocopherol concentration and used in the analysis.
Figure 4.4 shows the plasma d6 a-tocopherol concentration over 9 hours. d6 
a-Tocopherol increased from 2-3 h with the toast and butter and high fat cereal meals. 
There was a significant difference in d6 a-tocopherol concentration over time (p < 
0.001) and between the four test meals (p < 0.001), per litre plasma or per mmol 
cholesterol (data not shown). There was greater d6-a-tocopherol absorption when the 
a-tocopheryl acetate was ingested with toast and butter compared with the low fat 
cereal meal and the water (p < 0.001) and there was a trend towards a greater d6 a- 
tocopherol absorption with toast and butter compared with the high fat cereal meal (p 
= 0.065). There was also significantly greater d6-a-tocopherol absorption when the a- 
tocopheryl acetate was ingested with the high fat cereal meal compared with the low 
fat cereal meal or water (p < 0.05)
0 1 2 3 4 5 6 7 8 9
Time (hours)
Figure 4.4 Plasma d6-a-tocopherol concentration, following ingestion of 150 mg d6 RRR- 
a-tocopheryl acetate with 4 different meals over 6 hours
Values expressed as mean ± SEM (n = 8). There was significant difference over time and 
between test meals (p < 0.001) analysed by two way repeated measures ANOVA
•*— Toast and butter 
*— High fat cereal 
-♦— Low fat cereal 
— Water
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Figures 4.5 and 4.6 show chylomicron d6 a-tocopherol concentration per 
mmol TAG and per g protein. d6 a-Tocopherol increased from 1.53 h with the toast 
and butter and 2 h with the high fat cereal meal. There was a significant difference in 
d6 a-tocopherol concentration mmol TAG and per g protein over time (p < 0.001) and 
between the four test meals (p < 0.001). There was greater d6-a-tocopherol absorption 
when the a-tocopheryl acetate was ingested with toast and butter compared with the 
high fat cereal, low fat cereal and water meals (p < 0.03).
Less inter-individual variation was observed in d6 a-tocopherol per mmol 
TAG compared with per g protein, as illustrated by the large SEM bars in figure 4.6
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Figure 4.5 Chylomicron d6-a-tocopherol per mmol triacylglycerol (TAG) following 
ingestion of d6 a-tocopheryl acetate with four test meals over 6 hours
Values expressed as mean ± SEM (n = 8). There was significant difference over time (p < 
0.001) and between test meals (p < 0.001) analysed by two-way repeated measures ANOVA
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-•— High fat cereal 
-♦— Low fat cereal
— Water
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Figure 4.6 Chylomicron d6-a-tocopherol per g protein following ingestion of d6 a- 
tocopheryl acetate with four test meals over 6 hours
Values expressed as mean ± SEM (n = 8). There was significant difference over time (p < 
0.001) and between test meals (p < 0.05) analysed by two way repeated measures ANOVA
4.4.4 Inter-individual variation in uptake o f d6-RRR-a-tocopherol
A  large degree of inter-individual variation was observed in the uptake of d6 
a-tocopherol in chylomicrons and plasma, after ingestion of 150 mg d6 RRR-a- 
tocopheryl acetate with the same test meal. Figure 4.7 shows the individual plasma d6 
a-tocopherol absorption after following the ingestion of d6 a-tocopheryl acetate with 
the toast and butter meal. Individuals vary in the time course and magnitude of d6 a- 
tocopherol absorption. One individual differed from the other in that plasma d6 a- 
tocopherol decreased sharply at 9 h.
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Figure 4.7 Individual d6 a-tocopherol plasma concentration profiles after ingestion of 
150 mg d6-a-tocopheryl acetate with the toast and butter meal.
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4.5 Discussion
The aim of this study was to determine if the absorption of a-tocopheryl 
acetate was affected by the fat content and physical properties (independent of fat 
content) of the meal it was consumed with. Deuterium labelled RRR a-tocopheryl 
acetate was used to trace the uptake of newly absorbed a-tocopherol into plasma and 
chylomicrons.
Key findings;
1. The fat content of a meal (2.7 compared with 17.5 g fat) significantly influenced 
the rate and magnitude of a-tocopherol uptake into plasma and chylomicrons over 
9 hours.
2. The absorption of a-tocopherol was significantly greater over 9 hours, when a- 
tocopheryl acetate was ingested with toast and butter compared with full fat milk, 
single cream and cereal (both meals contained 17.5 g fat). This indicates that the 
physical properties of the meal affect the rate and magnitude of a-tocopherol 
absorption.
3. A large inter-individual variation in the rate and magnitude of a-tocopherol 
absorption was observed when a-tocopheryl acetate was ingested with the same 
meal.
There are very few studies that have investigated the absorption of vitamin E in 
humans. This may be due to the inherent difficulty in measuring absorption and the 
requirement of labelled vitamin E in order to distinguish between existing and newly 
absorbed a-tocopherol within the body. This study measured the uptake profiles of 
deuterium labelled a-tocopherol in plasma and chylomicrons to compare the effects of 
different test meals on a-tocopherol absorption. The study was not designed to 
measure the amount of a-tocopherol absorbed from 150 mg d6 a-tocopheryl acetate 
capsule.
The large inter-individual variation observed in Chapter 3 was hypothesised to 
be partially due to the fact that the vitamin E capsules were consumed with meals 
varying in fat content. The extent of variation this may have caused was thus 
investigated in the current study.
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4.5.1 Absorption o f  d6 a-tocopheryl acetate following four test meals
The uptake of a-tocopherol into plasma and chylomicrons was determined 
following the ingestion of d6 a-tocopheryl acetate with two common breakfasts that 
subjects consumed in the study detailed in Chapter 3, these were a) semi-skimmed 
milk and cereal, b) and toast and butter. There was significantly greater uptake of d6 
a-tocopherol, over 9 hours, when the capsule was consumed with toast and butter 
compared with semi-skimmed milk and cereal. The uptake of d6 a-tocopherol when 
ingested with the semi-skimmed milk and cereal was not statistically different to 
water.
The reason for the differences observed in a-tocopherol uptake into plasma 
and chylomicrons could be due to the greater fat content of the toast and butter 
compared with the semi-skimmed milk and cereal (17.5 g compared to 2.7 g 
respectively). However, the two test meals also differed greatly in their physical 
properties, which may impact on the absorption of vitamin E. In plasma there was a 
significantly greater d6 a-tocopherol absorption with the high fat cereal meal 
compared with the low fat cereal meal and a trend towards a significantly greater 
absorption with toast and butter compared with high fat cereal meal. This suggests that 
both the fat content and the physical properties of a meal influence a-tocopherol 
absorption.
4.5.1.1 The effect of fat content on the absorption of q-toconherol
It is generally accepted that vitamin E requires mixed micelles and a 
hydrophobic environment at the brush border membrane of the enterocytes for optimal 
absorption (Cohn et a l, 1992b; Cohn, 1997). There was significantly greater a- 
tocopherol uptake into plasma and chylomicrons when a-tocopheryl acetate was 
ingested with high fat cereal meal (17.5 g fat) compared with low fat cereal meal (2.7 
g fat), over 9 hours. Therefore, the vitamin E uptake profiles observed in this study are 
in agreement with the current understanding of vitamin E absorption.
Previously published studies have provided different amounts of fat when 
investigating the effects of supplemental vitamin E (Cheeseman et a l,  1995; Traber et 
a l,  1998b). This was the first post-prandial study to investigate whether the amount of 
dietary fat effects vitamin E absorption in humans. It showed that a-tocopheryl acetate
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consumed with 17.5 g fat was absorbed to a greater extent over 9 hours compared with 
a-tocopheryl acetate consumed with 2.7 g fat (Figure 4.4).
Traber et a l (1998) gave 150 mg d3 RRR-a-tocopheryl acetate with a meal 
containing 30 g fat and reported plasma d3 a-tocopherol concentration to be 
approximately 7 pM at 9 hours. In the current study the mean d6 a-tocopherol 
concentration at 9 hours was 6 and 10 pM, following high fat cereal and toast and 
butter meals, respectively. It is therefore possible that 17.5 g fat is sufficient for 
optimal absorption of 150 mg a-tocopheryl acetate, as Traber did not report a greater 
absorption following ingestion with 30 g fat. Traber et a l (1998) also measured a- 
tocopherol uptake into chylomicrons, however the data cannot be compared as they 
express a-tocopherol per litre plasma, whereas in the current study the a-tocopherol 
within chylomicrons is expressed as per mmol chylomicron TAG or per gram 
chylomicron protein. The current study did not report a-tocopherol concentration in 
lipoproteins per litre plasma due to the limitations in the methodology used to isolate 
the lipoproteins (method detailed in section 2.2.9).
Chronic a-tocopherol and lipid feeding studies have investigated the influence 
of fat on plasma vitamin E levels; collectively the results are inconclusive. Brink et a l
(1996) fed rats a high (190 g fat/ kg feed) or low fat (7 g fat/ kg feed) diet over 3 
weeks and vitamin E absorption was determined by intake minus faecal excretion. 
They reported no significant difference in the absorption of vitamin E between the two 
diets (Brink et a l, 1996). This finding was replicated when Tijburg et a l (1997) fed 
rats either 15 or 30 % fat diets and concluded that the low fat diet contained sufficient 
fat for significant absorption of vitamin E. A study in humans also revealed that 
plasma a-tocopherol concentration was similar following 7 days of 50 mg a- 
tocopherol consumed with a low fat (< 6.5 g fat) or high fat (~ 45 g fat) meal 
(Roodenburg et a l, 2000). Furthermore, Hayes et a l (2001) reported that milk 
enhanced vitamin E uptake, irrespective of fat content. Their conclusions were based 
on a similar percentage increase in plasma a-tocopherol after 4-week supplementation 
with fat-soluble version of vitamin E dispersed in 1 % fat milk, and a water-soluble 
form of vitamin E in skimmed milk (0.1 % fat). The 1 % fat milk used had a much 
lower fat content (~ 5 g fat ingested) compared with the high fat cereal meal used 
within the current study (17.5 g fat), therefore Hayes et a l (2001) were unable to take
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into account if  a higher fat content milk would increase vitamin E absorption. 
However, Dimitrov et al. (1991) reported a significantly greater plasma uptake of a- 
tocopherol in humans fed a high fat diet (~ 115 g fat per day) compared to a low fat 
diet (~ 51 g fat per day) over a five day supplementation with 800 mg all rac a- 
tocopheryl acetate. Likewise, Iuliano et a l (2001) reported greater plasma a- 
tocopherol concentration after 15 days when 300 mg a-tocopheryl acetate was 
consumed with a meal compared with an ‘empty stomach’.
It is possible that a small amount of a-tocopherol is absorbed without dietary 
fat. In the current study there was a small increase in plasma d6 a-tocopherol at 9 
hours and Dimitrov et al (1991) also reported a small increase in plasma a-toeopherol 
after a fat free meal, the mechanisms for this are unclear. It is possible that the 
enterocytes contain a pool of lipid from the previous meal and this may aid 
chylomicron formation and vitamin E incorporation.
The current study confirms that fat is required for vitamin E absorption, 
however, the minimal amount of dietary fat necessary for optimal vitamin E 
absorption remains undetermined. Future dose-response studies to investigate the 
different amounts of fat are necessary to determine the minimum amount of fat 
required for optimal absorption. The amount of dietary fat required may also vary with 
the amount of a-toeopherol ingested.
4.5.1.2 The effect of meal physical properties on the absorption of a-tocopherol
The uptake of vitamin E was investigated after the ingestion of 150 mg d6 - 
RRR-a-tocopheryl acetate with two meals identical in fat content (17.5 g fat) but 
different in physical properties; full fat milk, single cream and cereal (high fat cereal) 
compared with toast and butter. The physical properties of toast and butter compared 
to high fat milk and cereal meal produced a greater uptake profile of d6 a-tocopherol 
in the plasma and chylomicrons over 9 and 6 hours respectively. There have been no 
previous suggestions within the literature that the physical properties of a meal 
vitamin E is consumed with affects its absorption. The physical properties of food are 
known to affect gastric emptying, foods that are high in fibre, viscosity and protein 
slow gastric emptying (Low, 1990). These could in turn affect the rate of vitamin E 
uptake into enterocytes.
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The total amount of a-tocopherol absorbed from the a-tocopheryl acetate 
capsule was not determined in this study, therefore, it is not known whether the 
amount absorbed when consumed with an isocaloric cereal and milk meal is less than 
toast and butter or simply delayed. Further investigations would be interesting and 
longer sampling time may help to elucidate whether there is a difference in amount 
absorbed. The inherent difficulties in measuring total absorption of vitamin E, either 
by lymph duct cannulation or faecal excretion, means that these studies are unlikely to 
be carried out.
The reduced absorption of d6 a-tocopherol into plasma and chylomicrons over 
9 hours following a high fat cereal meal may be due to delayed gastric emptying. The 
high fat cereal meal had a greater volume compared with the toast and butter meal. 
Low et al. (1990) reported that the meal volume and proportions of solid and liquid 
within a meal have different gastric emptying patterns (Low, 1990). Additionally the 
high fat cereal meal contained casein, a milk protein, has been shown to delay gastric 
emptying (Low, 1990). A delayed gastric emptying of the high fat cereal meal 
compared with the toast and butter would have increased the time required for the 
lipids and a-tocopherol to reach the enterocytes.
4.5.2 Inter-individual variation in the absorption of a-tocopheryl acetate
A large inter-individual variation in the magnitude and time of d6-a- 
tocopherol uptake within plasma and into chylomicrons was observed, illustrated by 
the large SEM bars and the individual uptake profiles after toast and butter. 
Roxborough et al. (2000) and Cheeseman et al. (1995) have also reported large inter­
individual variation in the absorption of d6 jRjR/Ga-tocopherol in plasma up to 51 
hours. Roxborough et al. (2000) reported a low intra individual variation in the uptake 
of d6 RRR-a-tocopherol in to plasma, which may imply a genetic influence in the inter 
individual variation observed. This observed inter-individual variation is probably due 
to a number of factors including the gastrointestinal handling of lipids, processes 
involved in the packaging of tocopherol into chylomicrons and their release into the 
systemic circulation. Variation in the secretion of bile and pancreatic lipases would 
impact on the handling of lipids and consequently effect vitamin E uptake.
114
Chapter 4
It is not known how vitamin E is packaged into chylomicrons. Arita et al.
(1997) speculated that a-tocopherol is associated with VLDL after it is secreted, 
which may also be the case for a-tocopherol incorporation into chylomicrons. There 
are a number of genetic polymorphisms involved in lipoprotein regulation (Ye & 
Kwiterovich, 2000). For example, polymorphism in apo B or the chylomicron 
assembly protein, microsomal transfer protein, may influence the rate of chylomicron 
secretion and therefore appearance of newly absorbed a-tocopherol in the systemic 
circulation (Bergeron & Havel, 1997; Hussain, 2000; Peacock et al., 1995)
It is important to gain an understanding of the extent of inter-individual 
variation in uptake of vitamin E in healthy individuals for designing future studies 
investigating different sub groups within the population.
4.5.3 Study design
The time points for the current study were chosen to identify the initial stages 
of a-tocopherol uptake in chylomicrons and plasma. Borel et al. (1997) reported a- 
tocopherol within chylomicrons to be significantly greater than baseline after 1 hour. 
In the current study none was detected in the chylomicrons before 1.5 hours. The 
washout period between study dates was 7 days, however, d6 a-tocopherol was 
detected in some of the baseline plasma samples. Therefore, the time between the 
study days needed to be longer to allow the d6 a-tocopherol to reach negligible level 
within the plasma before administering another dose.
The current study was designed to measure the uptake profile of a-tocopherol 
in chylomicrons and plasma and therefore blood sampling stopped at 9 hours. If some 
d6 a-tocopherol remained in the enterocyte until the next meal, this would enrich the 
second influx of chylomicrons with d6 a-tocopherol and the study would be unable to 
distinguish between the first or second phase of chylomicron absorption. Additionally 
there would be transfer of tocopherol between lipoproteins, confounding the 
concentrations of d6 a-tocopherol taken up from the intestine. Further time points 
would have strengthened the results in determining the total amount of d6 a- 
tocopherol absorbed.
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The evening meal of the subjects was not standardised and therefore may have 
influenced the postprandial response the test meals, increasing the inter individual 
variation observed
4.5.4 Conclusions and future work
In conclusion this study has presented important findings in the post-prandial 
handling of a-tocopherol following meals containing high or low fat (17.5 or 2.7 g fat) 
and the influence of the physical properties of the meal. Clinical trials with vitamin E 
have not proved conclusive towards a benefit for vitamin E, to obtain maximal 
absorption vitamin E must be consumed with a certain amount of fat, this should be 
taken into consideration for the design of future studies investigating vitamin E 
uptake.
A dose-response investigation into the amount of fat required for maximal 
vitamin E absorption at differing vitamin E doses ingested is an important area for 
future research.
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5.1 Introduction
Vitamin E biokinetics within the systemic circulation is governed by plasma 
lipoprotein kinetics. Chylomicrons carry newly absorbed vitamin E, whilst circulating 
they transfer lipids and vitamin E to peripheral tissue during lipid hydrolysis (Traber 
et a l, 1985). Excess chylomicron surface area is consequently produced and along 
with vitamin E it is transferred to HDL (Traber & Kayden, 1989a). The resultant 
chylomicron remnants are taken up into to the liver and RRR a-tocopherol is packaged 
into VLDL and then secreted into the blood (Traber et a l, 1993). VLDL is catabolised 
to LDL and during this process vitamin E is transferred to HDL (Kayden & Traber, 
1993). Vitamin E is also taken up into peripheral tissues via LDL receptors (Traber & 
Kayden, 1984). Whilst lipoproteins are circulating there is a constant flux of vitamin E 
between them (Traber et a l, 1992b).
The uptake and distribution of newly absorbed a-tocopherol has previously 
been reported for plasma, lipoproteins and erythrocytes, but not together within the 
same individuals (Cheeseman et a l, 1995; Roxborough et a l, 2000; Traber et a l, 
1998b). This chapter will focus on the uptake and distribution profiles of newly 
absorbed a-tocopherol into erythrocytes, platelets and lymphocytes in healthy people. 
The uptake and biokinetics of newly absorbed a-tocopherol into platelets and 
lymphocytes has previously not been investigated.
Vitamin E within erythrocytes is membrane bound and they obtain vitamin E 
via tocopherol binding proteins (Kitabchi & Wimalasena, 1982b). Lymphocytes have 
LDL receptors and are thought to obtain their vitamin E by internalisation of LDL. It 
is currently unknown how platelets obtain their vitamin E. Both platelets and 
lymphocytes are functionally affected by vitamin E and therefore vitamin E 
concentration within these cells may represent a functional biomarker of vitamin E. 
Vitamin E regulation and distribution between the aforementioned blood components 
is poorly understood. Investigating the biokinetics of a-tocopherol will help towards 
elucidating how they acquire their a-tocopherol.
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5.2 Aim and hypothesis
The objective of this research was to investigate the response of vitamin E 
concentration within blood components to supplemental a-tocopherol in healthy 
subjects. The study aimed to establish the uptake and distribution profile in response 
to a single dose of stable isotope labelled a-tocopherol in plasma, lipoproteins, 
erythrocytes, platelets and lymphocytes. The uptake profile of newly absorbed a- 
tocopherol into platelets and lymphocytes is currently unknown.
It was hypothesised that an increase in newly absorbed a-tocopherol would be 
observed first in the plasma, followed by erythrocytes, platelets and lymphocytes as 
they acquire the newly absorbed a-tocopherol from the circulating lipoproteins. It was 
also hypothesised that the greater the d6 a-tocopherol uptake in to plasma the greater 
the uptake will be into blood cells.
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5.3 Study design
Twelve healthy males were recruited from the general population by an 
advertisement in local newspapers. Selection criteria stated subjects must be non­
smoking, not taking dietary supplements and with no gastrointestinal disorders as 
determined from a written questionnaire. Subjects with blood lipid abnormalities were 
excluded (selection criteria was cholesterol < 6 mmol/ 1 and triacylglycerol < 1.5 
mmol/ 1).
Subjects arrived at the C linical Investigation Unit at the University of Surrey at
7.45 am, having been requested to fast from 8 pm the night before the study. Figure
5.1 summarises the study protocol. The subjects consumed a standard breakfast 
containing 40g fat (2 croissants and 20 g butter); investigators ensured the capsule, 
containing 150 mg deuterium labelled (d6) RRR a-tocopheryl acetate, was taken mid­
w ay through the meal. The breakfast contained 40g fat to maxim ise vitamin E 
absorption. The time the capsule was consumed was taken as 0 hours and blood 
sampling was timed from this point. A suitable trained person drew 20 ml blood 
samples from the antecubital vein in the forearm at 3, 6, 9, 12, 24 and 48 h hours after 
ingestion of the capsule (illustrated in figure 5.1). Subjects were only allowed water 
and a standard meal at 12:00 until 15:00 on day 1, and then they were allowed to eat 
ad libitum.
From the blood samples plasma, erythrocytes, platelets and lymphocytes were 
freshly isolated. Chylomicrons, VLDL, LDL and HDL were isolated from frozen 
plasma at a later date, procedures detailed in sections 2.2.4 -  9. dO and d6 a -  
tocopherol were measured in all blood component (method detailed in section 2.2.21).
Standard lunch 
15g fat
08:00 11:00 14:00 17:00 20:00 08:00 08:00
■ ■ ■ i K  i  , ____________I
D A Y  1 D A Y  2 D A Y  3
150 mg d6 RRR a-tocopheryl acetate with 40 g fat |  Blood sample taken
Figure 5.1 Schematic diagram of study protocol
150 mg RRRa-tocopheryl acetate capsule was taken with a meal containing 40 g fat. 20 ml 
blood was taken at 3, 6, 9, 12, 24 and 48 h after ingesting the capsule.
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5.4 Results
5.4.1 Subject information
Twelve healthy normolipidemic males participated in the study. During the 
study period no one reported any side effects or withdrew from the study. Table 5.1 
outlines the characteristics of the subjects who participated in the study. The mean 
body mass index was slightly higher than the recommended ideal range of 20 -  25 
kgm"2 (WHO, 1998). Dosage of d6 a-tocopheryl acetate was calculated per kg body 
weight (table 5.1), there was a coefficient of variation of 10 % between subjects.
Table 5.1 Subject characteristics (n = 12)
Mean ± SD range
Age (years) 48 ±10 31-58
BMI (kgm'2) 25.6 ±2.5 23.1 -32.1
d6 a-TA/ kg body weight (mg/ kg) 1.9 ±0.2 1.7-2.2
Total cholesterol (mmol/ L) 5.0 ±0.6 3.88-5.84
Triacylglycerol (mmol/ L) 1.2 ±0.3 0.76-1.49
BMI; body mass index, a-TA; d6 a-tocopheryl acetate
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5.4.2 Plasma and lipopro te in  a -tocophero l p ro files
Plasma cholesterol concentrations were not statistically different during 
the study period. However, there was a trend towards a significant difference in 
triacylglycerol (TAG) concentration over time (p = 0.06) (see graph in appendix IV).
Table 5.2 shows d6 a-tocopherol area under curve (AUC), maximum 
concentration (C max) and time of C max for plasma, chylomicrons, VLDL, LDL and 
HDL. These parameters give an indication of the extent of inter-individual variation in 
uptake of newly absorbed d6 a-tocopherol. There was a larger inter-individual 
variation in chylomicron d6 a-tocopherol per g protein compared with d6 a- 
tocopherol per mmol TAG, as determined by lower coefficient of variation for AUC 
and C max as shown in table 5.2.
Table 5.2 Area under curve (AUC), maximum concentration (C max) and time of C max 
for d6 a-tocopherol in plasma and lipoproteins
AUC C max Time C max(hours)
Plasma
pmol/L.
Chylomicrons
pmol/ g protein
Chylomicrons
pmol/ mmol TAG
VLDL
pmol/ g protein 
LDL
pmol/ g protein 
HDL
pmol/ g protein
Mean ± SEM 678 ± 92 21.4 ± 2.4 13.9 + 2.3
(range) (2 3 3 -  1140) (7 .7 -3 0 .9 ) (9 -  24)
% CV 38 % 32% 48 %
Mean ± SEM 226 + 59 22.5 ± 6.2 6.3 ±0.3
(range) (6 4 -6 0 2 ) (4 .2 -6 0 .2 ) ( 6 - 9 )
% CV 74% 78 % 15%
Mean ± SEM 101 + 20 7.7 ±1.3 6.9 ±0.5
(range) (3 6 -2 2 0 ) (4.1 -  13.8) ( 6 - 9 )
% CV 58 % 50% 21 %
Mean + SEM 874 ± 96 28.5 ±3.5 12.6 ± 2.2
(range) (260 -  1250) (6.7 -  44.6) ( 6 - 2 4 )
% CV 31 % 34% 50%
M e a n t  SEM 556 ± 96 17,3 + 3.1 15.0 ±2.6
(range) (218 -  1022) (7 .1 -3 1 .4 ) ( 6 - 2 4 )
% CV 49 % 51 % 49 %
Mean ± SEM 45.5 ±4.7 1.4 ±0.1 14.7 ± 2.2
(range) (2 1 .5 -6 3 .7 ) (0 .7 -  1.9) (9 -  24)
% CV 29 % 29 % 42%
Plasma; n = 12, lipoproteins; n = 11 there was insufficient plasma to isolate lipoproteins. 
TAG: triacylglycerol, CV: coefficient of variation
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Figure 5.2 illustrates the mean total, pre existing (dO) and newly absorbed (d6) 
a-tocopherol profiles in plasma over 48 h. d6 a-Tocopherol concentration increased 
significantly over time (p < 0.0001), there was a peak in concentration at 9 h, then it 
plateaued until 24 h whereby the concentration started to decline. There was a 
significant increase in total tocopherol up to 9 h and an initial decrease in dO a- 
tocopherol concentration to 12 h (p < 0.001). The time of d6 a-tocopherol Cmax 
ranged from 9 to 24 h (Table 5.2). At 12 h Cmax in plasma was 18.0 ± 2.3 pmol/L, 
with a coefficient of variation of 37 %.
Total a-tocopherol 
dO a-tocopherol 
*— d6 a-tocopherol
Time (hours)
Figure 5.2 Plasma total (dO + d6), dO and d6 a-tocopherol concentration profile over 48 h 
after ingestion of 150 mg d6 RRR-a-tocopheryl acetate
Values expressed as mean ± SEM. (n = 12). Total and d6 a-tocopherol concentration 
increased significantly over time and dO a-tocopherol decreased over time (p < 0.0001) as 
analysed by repeated measures ANOVA.
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Figure 5.3 illustrates the mean uptake profile of d6 a-tocopherol into 
chylomicrons. The uptake of d6 a-tocopherol was significantly different over time (p 
< 0.0001). There was a sharp increase from 3 to 6 h and d6 a-tocopherol concentration 
peaked at 6 h (there was relatively little variation in the time of d6 a-tocopherol Cmax 
in chylomicrons shown by a coefficient of variation of only 15 % shown in table 5.2). 
There was a large inter-individual variation in the magnitude of d6 a-tocopherol 
uptake into chylomicrons, as illustrated by the large SEM bars at 6 h in figure 5.3 and 
the coefficient of variation for Cmax was 78 %, as shown in table 5.2. There was less 
inter-individual variation in Cmax and AUC for d6 a-tocopherol per mmol TAG in 
chylomicrons as shown in table 5.2. At 48 h d6 a-tocopherol concentration was only 1 
pM/ g protein.
Time (hours)
Figure 5.3 Chylomicron d6 a-tocopherol per g protein profile over 48 h after ingestion of 
150 mg d6 /f/?/?-a-tocopheryl acetate
Values expressed as mean ± SEM. (n = 11; insufficient plasma to isolate lipoproteins from one 
subject). d6 a-Tocopherol concentration increased significantly over time (p < 0.0001) as 
analysed by repeated measures ANOVA.
Figures 5.4A and B illustrate the mean d6 and dO a-tocopherol concentration 
in VLDL, LDL and HDL over 48 h. There was a significant increase in d6 a- 
tocopherol concentration over time in all lipoproteins (p < 0.0001). d6 a-Tocopherol 
peaked at 12 h in VLDL and then started to decline, whereas there was a plateau in d6 
a-tocopherol concentration between 12 and 24 h in LDL and HDL.
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There was a decrease in dO a-tocopherol concentration in VLDL, LDL and 
HDL up to 12 h post ingestion of the d6 a-tocopheryl acetate (p < 0.003). There was 
substantially less inter-individual variation in d6 a-tocopherol AUC and Cmax in 
VLDL, LDL and HDL (CV = 30 -  50 %) compared with d6 a-tocopherol in 
chylomicrons (CV > 70 %), as shown in table 5.2.
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Figures 5.4 A. and B: VLDL, LDL and HDL d6 and dO a-tocopherol per g protein over 
48 h after ingestion of 150 mg d6 RRR-a-tocopheryl acetate, respectively
Values expressed as mean ± SEM (n = 11). There was a significant increase in d6 a -  
tocopherol concentration over time in VLDL, LDL and HDL (p < 0.0001) analysed by 
repeated measures ANOVA.
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Figure 5.5 shows the d6 a-tocopherol percentage of total tocopherol in 
chylomicrons, VLDL, LDL and HDL over 48 h. In chylomicrons the percentage d6 a- 
tocopherol peaked at 6 h then declined to approximately 15 % at 48 h. Whereas, the 
percentage d6 a-tocopherol uptake in VLDL, LDL and HDL were very similar with a 
peak atl2 h and a decline from 24 h. The maximum percentage of d6 a-tocopherol 
within chylomicrons was 55% (range 2 2 -7 6  %), whereas the maximum percentage of 
d6 a-tocopherol in VLDL, LDL and HDL was 36% (range 29 -  57 %).
20 30
Time (hours)
chylomicrons
VLDL
LDL
HDL
Figure 5.5 Percentage d6 a-tocopherol uptake profiles for chylomicrons, VLDL, LDL 
and HDL over 48 h after ingestion of 150 mg d6 /?/?/?-a-tocopheryl acetate
Values expressed as mean ± SEM (n = 11).
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5.4.3 a-Tocopherol profiles fo r  erythrocytes, platelets and lymphocytes
Table 5.3 shows d6 a-tocopherol AUC, C max and time of C max for plasma, 
erythrocytes, platelets and lymphocytes. The extent of inter-individual variation in 
AUC and Cmax was similar for d6 a-tocopherol in plasma and erythrocytes, platelets 
and lymphocytes, as determined by % CV. The variation in time of C max was 
substantially greater in platelets and plasma compared with erythrocytes and 
lymphocytes as determined by coefficient of variations shown in table 5.3.
Table 5.3 Area under curve (AUC), maximum concentration (C max) and time of C max 
for d6 a-tocopherol in plasma and blood cells
AUC C max Time C max(hours)
Plasma
pmol/L
Mean ± SEM 678 ± 92 21.4 + 2.4 11.2 + 1.6
(range)
%CV
(233-1140)
38%
(7.7-30.9)
32%
(9-24)
40%
Erythrocytes
pmol/PCV
Mean ± SEM 
(range) 
%CV
118 + 11 
(58-190) 
32%
4.9 ± 0.4 
(2.6-7.9) 
29%
22.9 ±1.1 
(12-24) 
16%
Platelets
pmol/ g protein
Mean ± SEM 15.5 + 1.5 0.49 + 0.04 30 + 4.7
(range)
%CV
(6.5-2.4) 
34%
(0.23-0.69)
29%
(6-48)
50%
Lymphocytes
pmol/ g protein
Mean ± SEM 10.2 + 0.9 0.33 + 0.03 44.8 ±2.0
(range)
%CV
(5.7-18.3)
36%
(0.19-0.52)
34%
(24-48)
19%
n = 12 apart from lymphocytes n = 11 there was insufficient plasma to isolate lymphocytes 
from one subject. PCV: packed cell volume, CV: coefficient of variation
Figure 5.6 illustrates the mean d6 a-tocopherol concentration in erythrocytes 
up to 48 h, with the plasma d6 a-tocopherol uptake profile in grey shown for 
comparison. Erythrocyte d6 a-tocopherol concentration significantly increased over 
time (p < 0.0001), it peaked at 24 hours then started to decline at 48 h. At 24 h C max 
in erythrocytes was 4.76 ± 0.43 pmol/ PCV, with a coefficient of variation of 30 %. 
There was no dO a-tocopherol data available for erythrocytes due to methodological 
problems detailed in section 2.2.21.
There was a positive correlation between d6 a-tocopherol AUC in erythrocytes 
and HDL (r2 = 0.55, p = 0.006) and plasma (r2 = 0.46, p = 0.03), however, there were 
no correlations between d6 a-tocopherol AUC for chylomicrons, VLDL or LDL with 
erythrocyte d6 a-tocopherol AUC.
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Figure 5.6 Erythrocyte d6 a-tocopherol corrected for packed cell volume (PCV) over 48 
h after ingestion of 150 mg d6 RRR-a-tocopheryl acetate. Plasma d6 a-tocopherol in grey 
shown for comparison
Values expressed as mean ± SEM (n = 12). There was a significant increase in d6 a- 
tocopherol concentration over time in erythrocytes (p < 0.0001) analysed by repeated 
measures ANOVA.
Figure 5.7 illustrates the mean total, dO and d6 a-tocopherol concentration in 
platelets over 48 h. d6 a-Tocopherol concentration significantly increased over time, 
while dO a-tocopherol decreased (p < 0.0001), there was no significant difference in 
total a-tocopherol concentration. Subjects were classified into two groups, those that 
had a biphasic uptake of d6 a-tocopherol and those that did not. Figure 5.8 illustrates 
the mean dO and d6 a-tocopherol over 48 h in four subjects who exhibited a biphasic 
response in contrast to the other eight subjects. Subjects who did not have a biphasic 
uptake gradually incorporated d6 a-tocopherol from 3 h and plateaued between 24 and 
48 h. Whereas, in the biphasic group d6 a-tocopherol peaked at 6 h then declined at 9 
h, then there was a gradual uptake similar to the subjects that did not exhibit a biphasic 
response. dO a-Tocopherol profiles were similar in both groups, as shown in figure 
5.8. Figure 5.9 shows the initial d6 a-tocopherol peak at 6 hours, in subjects who 
exhibited a biphasic uptake, which coincided with the d6 a-tocopherol peak in 
chylomicrons.
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Figure 5.7 Total (dO + d6), dO and d6 a-tocopherol in platelets per g protein over 48 h 
after ingestion of 150 mg d6 ARR-a-tocopheryl acetate
Values expressed as mean ± SEM (n = 12). d6 a-Tocopherol concentration increased 
significantly over time and dO a-tocopherol decreased over time (p < 0.0001) as analysed by 
repeated measures ANOVA.
d6 a-T (n = 4) 
dO a-T (n = 4) 
d6 a-T (n = 8) 
dO a-T (n = 8)
Time (hours)
Figure 5.8 d6 and dO a-tocopherol profile in four subjects that had a biphasic uptake of 
d6 a-tocopherol and eight subjects who had a gradual d6 a-tocopherol uptake profile 
over 48 h after ingestion of 150 mg d6 jRJWf-a-tocopheryl acetate
Values expressed as mean ± SEM. a-T: a-tocopherol
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Time (hours)
Figure 5.9 Biphasic uptake of d6 a-tocopherol in platelets per g protein in 4 subjects 
(and chylomicron d6 a-tocopherol in grey shown for comparison) over 48 h after 
ingestion of 150 mg d6 /f/f/f-a-tocopheryl acetate
Values expressed as mean ± SEM
There was a significant correlation between d6 a-tocopherol AUC for platelets 
and LDL (r2 = 0.51, p = 0.04), however, there were no correlations between d6 a- 
tocopherol AUC for plasma, other lipoproteins or erythrocytes. There was a significant 
correlation between d6 a-tocopherol AUC for platelets and lymphocytes (r2 = 0.57, p 
= 0.009).
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Figure 5.10 illustrates the mean total, dO and d6 a-tocopherol concentration in 
lymphocytes over 48 h. Lymphocyte d6 a-tocopherol concentration significantly 
increased over time and dO a-tocopherol decreased (p < 0.0001) and there was no 
difference in total a-tocopherol concentration. From 6 hours a gradual uptake of d6 a- 
tocopherol into lymphocytes was observed and d6 a-tocopherol concentration 
continued to increase at 48 h.
There was a trend towards a significant correlation between d6 a-tocopherol 
AUC in lymphocytes and LDL (r2 = 0.49, p = 0.06), however, there were no 
correlations between d6 a-tocopherol AUC for plasma, other lipoproteins or 
erythrocytes. There was a significant correlation between d6 a-tocopherol AUC for 
lymphocytes and platelets (r2 = 0.57, p = 0.009).
—•— Total a-tocopherol
• o dO a-tocopherol 
—♦— d6 a-tocopherol
Time (hours)
Figure 5.10 Lymphocytes total (dO + d6), dO and d6 a-tocopherol per g protein over 48 h 
after ingestion of 150 mg d6 /?/?/?-a-tocopheryl acetate
Values expressed as mean ± SEM. d6 a-Tocopherol concentration increased significantly over 
time and dO a-tocopherol decreased over time (p < 0.0001) as analysed by repeated measures 
ANOVA.
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5.5 Discussion
This study aimed to determine the uptake and distribution profile of a single 
dose of deuterium labelled a-tocopherol into plasma, lipoproteins, erythrocytes, 
platelets and lymphocytes in healthy subjects. The uptake profile of newly absorbed 
a-tocopherol into platelets and lymphocytes had not previously been investigated.
Key findings;
1. The uptake profile of newly absorbed (d6) a-tocopherol was determined in 
platelets and lymphocytes. A third of subjects exhibited a biphasic uptake profile 
of d6 a-tocopherol in platelets. d6 a-Tocopherol concentration gradually increased 
from 6 h in lymphocytes up to 48 h.
2. The magnitude of d6 a-tocopherol uptake into plasma did not correlate with that in 
platelets or lymphocytes.
3. Pre existing (dO) a-tocopherol concentration decreased in all blood components 
measured
5.5.1 Uptake o f newly absorbed d6 a-tocopherol in plasma and lipoproteins
Plasma a-tocopherol concentrations represent the combined total of a- 
tocopherol within circulating lipoproteins. Following a single dose of 150 mg d6 RRR 
a-tocopheryl acetate plasma d6 a-tocopherol concentration increased from 3 h, 
plateaued between 9 and 24 h and then started to decline, this was similar to 
previously published studies (Cheeseman et a l , 1995; Roxborough et a l, 2000; 
Traber et a l,  1998b). These studies are outlined in table 5.4.
Chylomicron d6 a-tocopherol peaked at 6 h then decreased, this pattern of 
uptake was in agreement with published studies (Traber et a l,  1990a; Traber et a l, 
1992a). Once the chylomicrons entered the systemic circulation the newly absorbed d6 
a-tocopherol was rapidly incorporated into all lipoproteins. d6 a-Tocopherol uptake 
into VLDL peaked at 12 h then started to decline, whereas there was a plateau in d6 a- 
tocopherol concentration between 12 and 24 h in LDL and HDL before d6 a- 
tocopherol concentration started to decline. These observations were similar to 
previously published studies (Traber et a l,  1990a; Traber et a l,  1992a; Traber et a l, 
1998b).
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Table 5.4 Studies investigating labelled a-tocopherol biokinetics
n = Dosagea-TA Fat *
Blood components 
measured
Cheeseman et al 
(1995)
Traber et al 
(1998)
14
5
100 mg
15, 75 and 
150 mg
~ 17 g 
30 g
Plasma and erythrocytes 
Plasma and lipoproteins
Roxborough et al 
(2000) 30 75 mg ~ 17 g Plasma and erythrocytes
Current study 12 150 mg 40 g Plasma, lipoproteins and blood cells
a-TA: deuterium labelled RRR a-tocopheryl acetate. * The amount of fat a-TA was ingested 
with
Interestingly, chylomicrons were enriched by 54 % deuterium labelled a- 
tocopherol (range 22 -  76 %) in the current study, whereas Traber et a l (1998) 
reported an average enrichment o f 70 % after 150 mg deuterium labelled a-tocopheryl 
acetate, thus implying greater deuterium labelled a-tocopherol absorption. However, 
the current study observed a greater uptake of d6 a-tocopherol into plasma, as 
measured by AUC, compared with Traber et a l (1998). It should be noted that 
fractional absorption of dose was not measured in either study.
The current study did not report a-tocopherol concentration in lipoproteins per 
litre plasma due to the limitations in the methodology used to isolate the lipoproteins 
(method detailed in section 2.2.9). Consequently, a direct comparison between the 
uptake of deuterium labelled a-tocopherol into chylomicrons or other lipoproteins in 
the current study and the one reported by Traber et a l (1998) could not be established.
There was significantly greater uptake of d6 a-tocopherol in VLDL compared 
with LDL per g protein, this is consistent with previously published supplementation 
studies (Goulinet & Chapman, 1997; Perugini et a l , 2000). VLDL and LDL would 
have acquired d6 a-tocopherol via hepatic regulation and via exchange from other 
circulating lipoproteins; it was not possible to determine the proportion of d6 a- 
tocopherol obtained via these mechanisms. LDL is formed from VLDL metabolism 
and consequently contains the same apolipoprotein Bioo moiety, consequently d6 a- 
tocopherol per g protein in VLDL and LDL is directly comparable. The lower amount 
of d6 a-tocopherol within LDL was presumably due to the transfer of d6 a-tocopherol
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to HDL and uptake into peripheral tissues from VLDL (Perugini et al., 2000; Traber et 
a l, 1992b).
5.5.1.1 Inter-individual variation in the uptake of d6 a-tocopherol into plasma and 
lipoproteins
There was a large inter-individual variation in the magnitude of d6 a- 
tocopherol uptake into chylomicrons. This was presumably due to a combination of 
factors, including; the gastrointestinal handling of lipids whereby differing secretion 
of bile and pancreatic lipases would impact on the handling of lipids and consequently 
affect vitamin E absorption. It is not known how vitamin E is packaged into 
chylomicrons, however, processes involved in the packaging of tocopherol into 
chylomicrons and their release into the systemic circulation would impact upon 
vitamin E appearance in the systemic circulation. For example, genetic 
polymorphisms involved in chylomicron secretion such as, polymorphism in apo B or 
the chylomicron assembly protein, microsomal transfer protein, may influence the rate 
of chylomicron secretion (Bergeron & Havel, 1997; Hussain, 2000; Peacock et al., 
1995).
There was greater inter-individual variation in d6 a-tocopherol Cmax in 
chylomicrons per g protein (CV = 78 %) compared with d6 a-tocopherol per mmol 
TAG (CV = 58 %). A possible explanation for this difference is the increase in fat 
content of chylomicrons during absorption, with relatively little difference in protein 
(Hussain, 2000). Vitamin E follows fat absorption (Traber et a l, 1990b), therefore it is 
probable that there was more d6 a-tocopherol in larger chylomicrons compared with 
smaller chylomicrons.
Inter-individual variation was not only observed in the magnitude of d6 a- 
tocopherol uptake, but also in the time of maximum concentration (Cmax). There was 
larger inter-individual variation in plasma and lipoprotein d6 a-tocopherol Cmax 
compared with erythrocytes and lymphocyte, as determined by coefficient of variation 
(shown in Tables 5.2 and 5.3). The observed inter-individual variation in the 
biokinetics of d6 a-tocopherol within lipoproteins can, in part, be attributed to inter­
individual variation in lipoprotein metabolism. There are several genetic 
polymorphisms in the apolipoproteins moiety of the lipoproteins, the lipid processing
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enzymes and lipoprotein receptor uptake that are known to influence lipoprotein 
metabolism (Ye & Kwiterovich, 2000). For example, a polymorphism in the 
lipoprotein lipase gene is associated with plasma TAG and HDL concentration 
(Clifton & Abbey, 1997). Variation in lipoprotein metabolism would affect the uptake 
of d6 a-tocopherol in peripheral tissues and the liver, as well as the length of time 
circulating within the systemic circulation.
The studies detailed in Chapters 3 and 4 reported large inter-individual 
variation in response to supplemental a-tocopheryl acetate, in these studies male and 
female subjects participated. The current study only recruited males to reduce the 
external inter-individual variation. Variation in body size and hence blood volume 
would also have influenced the biokinetics of d6 a-tocopherol, as the amount 
absorbed would be diluted in blood components accordingly. The dose of d6 a- 
tocopheiyl acetate per body weight ranged from 1.7 to 2.2 mg per kg, this is similar to 
the range used by Traber et a l (1998) used, but was not reported by Roxborough et al 
(2000) or by Cheeseman et a l (1995).
In the current study the coefficient of variation in plasma d6 a-tocopherol 
concentration at 12 hours was 38 %, this was similar to the 40 % following the 
consumption of 100 mg dose reported by Cheeseman et a l (1995). However, 
Roxborough et a l (2000) reported a 60 % coefficient of variation at 12 hours. A 
possible reason for this inconsistency in reported inter-individual variation could be 
the different fat content of the meal consumed with the a-tocopherol capsules, as 
shown in table 5.4. In the current study the subjects were provided with 40 g fat 
whereas Cheeseman et a l (1995) and Roxborough et al (2000) reported the subjects 
ate lightly buttered toast, which contains approximately 17 g fat (Ministry of 
Agriculture, 1993). The amount of fat needed for optimal absorption of vitamin E has 
not been established, if  sufficient fat was not available for maximal vitamin E 
absorption, greater variation may be observed. Different populations were used in the 
studies and there was a larger subject group in the study carried out by Roxborough, 
however, the reasons for this disparity remains unclear.
The biokinetic uptake of newly absorbed a-tocopherol within lipoproteins 
helps in the understanding of a-tocopherol uptake into blood cells and peripheral 
tissues.
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5.5.2 Uptake o f  d6 a-tocopherol into erythrocytes, platelets and lymphocytes
Erythrocyte d6 a-tocopherol concentration peaked at 24 hours then started to 
decline at 48 h, this was similar to that reported by Cheeseman et al. (1995) and 
Roxborough et al. (2000). The current study reported a coefficient of variation of 32 
% for d6 a-tocopherol AUC, like plasma, this was a lot lower than the 60 % 
coefficient of variation reported by Roxborough et al. (2000).
The correlation found between d6 a-tocopherol AUC in plasma and 
erythrocytes agrees with the findings reported by Roxborough et a l (2000). There was 
also a correlation between erythrocyte and HDL d6 a-tocopherol AUC, but not with 
the other lipoproteins. This may be explained by the more efficient transfer of a- 
tocopherol from HDL to erythrocytes compared with other lipoproteins (Kayden & 
Bjomson, 1972; Kostner et a l , 1995).
The uptake of newly absorbed d6 a-tocopherol into platelets was particularly 
interesting. A gradual increase in d6 a-tocopherol concentration from 3 h was 
observed in eight subjects, however, a distinct biphasic uptake was observed in the 
other four subjects (Figure 5.9). Presently it is not known how platelets acquire 
vitamin E. The initial peak in d6 a-tocopherol concentration in subjects with a 
biphasic response coincided with the d6 a-tocopherol peak in chylomicrons at 6 h. It 
is hypothesised that this flux of d6 a-tocopherol in and out of the platelets was 
through uncontrolled diffusion, and the predominant source of d6 a-tocopherol was 
from chylomicrons. Vitamin E is transferred between lipoproteins as they collide with 
each other whilst circulating, it is hypothesised that this occurred with platelets, as a- 
tocopherol concentrations decreased in chylomicrons the platelets released d6 a- 
tocopherol along the concentration gradient.
These interesting findings deserve further investigation into how platelets 
obtain their vitamin E and the cause of this biphasic response. For example, it would 
be interesting to establish if there is a threshold of a-tocopherol in plasma before 
platelets rapidly take up newly absorbed a-tocopherol. The gradual uptake of d6 a- 
tocopherol into platelets from 9 hours in all subjects suggests controlled uptake, 
however, the mechanisms involved are unknown. Kitabchi et a l (1982) suggested, 
from preliminary work, that there are no tocopherol binding proteins and Kaempf et al
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(1994) stated that there are no LDL receptors in platelets. A controlled uptake of d6 a- 
tocopherol and the correlation between d6 a-tocopherol AUC for platelets and LDL 
suggests that platelets may have LDL receptors and this could be the controlled uptake 
mechanism.
d6 a-Tocopherol uptake into lymphocytes was gradual, appearing after 6 hours 
and continuing to increase up to 48 h, suggesting a controlled uptake mechanism. 
There was also a trend towards a significant correlation between d6 a-tocopherol 
AUC for lymphocytes and LDL. Lymphocytes contain LDL receptors, and therefore 
presumably acquire vitamin E via this mechanism.
d6 a-Tocopherol first appeared in plasma and the platelets of subjects with a 
biphasic pattern, then in erythrocytes and a gradual increase in lymphocytes and 
platelets of subjects without a biphasic response. It was hypothesised that the greater 
the initial absorption the greater the uptake into blood cells. However, unlike 
erythrocytes, the magnitude of d6 a-tocopherol uptake into platelets and lymphocytes, 
as determined by AUC, did not correlate with the magnitude of d6 a-tocopherol 
uptake in plasma. This further suggests controlled a-tocopherol uptake mechanisms 
into these blood cells, rather than passive diffusion.
Both platelets and lymphocytes are potentially useful functional biomarkers of 
vitamin E status. The results presented from this study help to elucidate the biokinetics 
of newly absorbed a-tocopherol into these blood cells. The current study findings of 
newly absorbed d6 a-tocopherol uptake profiles into blood cells have provided a 
useful insight into the possible mechanisms of tocopherol uptake.
5.5.3 Decrease in pre-existing unlabelled (dO) a-tocopherol in all blood components
A  number of studies have shown that newly absorbed RRR a-tocopherol 
displaces pre existing tocopherol within plasma (Handelman et a l,  1985; Radosavac 
et a l,  2002; Traber et al., 1992a). Traber et a l (1994) calculated the fractional 
disappearance rate of RRR a-tocopherol to be 0.4 ±0.1 pool per day, suggesting that 
tocopherol rapidly leaves plasma, but RRR a-tocopherol is returned to plasma via 
hepatic secretion of VLDL. A decrease in y-tocopherol concentration after varying 
single doses of a-tocopheryl acetate, was also observed in erythrocytes, platelets and 
lymphocytes in Chapter 3, although non-significant. In addition to this, the current
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study showed a significant decrease in pre-existing (dO) a-tocopherol in lipoproteins, 
platelets and lymphocytes, similar to the known phenomenon in plasma whereby 
newly absorbed d6 a-tocopherol replaces the existing tocopherol (Traber et al., 1994). 
This has previously not been shown to occur in platelets and lymphocytes. It is 
hypothesised that this was also the case for erythrocytes. dO a-TocopheroI was not 
measured in erythrocytes due to problems in methodology (detailed in section 2.2.21).
5.5.4 Study design
The time points for the current study were chosen to measure d6 a-tocopherol 
uptake, peak and decline within blood components without being too invasive for the 
subjects, additionally they are similar to the time points chosen by Cheeseman et al.
(1995) and Roxborough et al (2000). No baseline vitamin E measurement was taken, 
as the focus of this study was the uptake profile of newly absorbed d6 a-tocopherol. 
None of the subjects had previously been involved in a study involving the ingestion 
of deuterium labelled tocopherol.
The appearance of deuterium labelled a-tocopherol metabolite, a-CEHC, in 
plasma was not measured because the assay to measure deuterium labelled a-CEHC 
by LC/MS had not been developed within the laboratory. It would have been of 
interest to measure d6 and dO a-tocopherol metabolism by the appearance of d6 and 
dO a-CEHC in plasma to determine the time course and extent of metabolism of newly 
absorbed a-tocopherol compared with pre-existing tocopherol. The study detailed in 
Chapter 3 and Traber et al. (1998a) reported a small increase in a-CEHC excretion as 
RRR a-tocopherol is preferentially retained within the body. Radosavac et al (2002) 
reported a transient increase in serum a-CEHC following supplementation with 300 
mg unlabelled RRR a-tocopherol, however they could not distinguish a-CEHC from 
the pre-existing a-tocopherol and the newly absorbed a-tocopherol. Whereas, when 
Galli et al (2003) gave subjects 100 mg deuterium labelled (d2) y-tocopherol, there 
was a sharp increase in plasma d2 y-CEHC at 9 h and a smaller increase in dO y- 
CEHC. It is hypothesised that a transient increase in dO a-CEHC and d6 a-CEHC 
excretion would be observed, following ingestion of d6 a-TA, dO a-CEHC formed 
initially from the displacement of tocopherol from blood components. The extent of
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d6 a-CEHC excretion would also provide an indication to the amount of dose retained 
within the body.
5.5.5 Conclusions andfuture work
The study detailed in Chapter 3 only reported a significant increase in total a- 
tocopherol concentration in plasma after varying single doses of unlabelled a- 
tocopheryl acetate. The replacement of existing a-tocopherol with newly absorbed d6 
a-tocopherol in all blood components whilst total a-tocopherol concentration did not 
change significantly, as observed in the current study, in part explains the lack of 
significance in Chapter 3.
The uptake of a-tocopherol into platelets could be further investigated ex vivo 
whereby d6 a-tocopherol enriched chylomicrons are placed with platelets; the uptake 
of d6 a-tocopherol into platelets could then be measured. Also the vitamin E status of 
platelets may affect their ability to take up a-tocopherol.
In conclusion this study has revealed the uptake profile of newly absorbed a- 
tocopherol into platelets and lymphocytes to be strikingly different to plasma and 
erythrocytes, implicating different uptake mechanisms. The a-tocopherol uptake 
mechanism(s) for platelets and lymphocytes are hypothesised to include LDL 
receptors and requires further investigation. A better understanding of a-tocopherol 
uptake and regulation within blood cells and peripheral tissues is needed to further 
elucidate better ways to assess vitamin E status.
The extent of inter-individual variation in the uptake and distribution of newly 
absorbed a-tocopherol is important to ascertain for the design of future studies 
comparing healthy individuals with those who may have an altered vitamin E status. 
Interestingly Roxborough et al. (2000) showed that intra individual variation in the 
uptake of newly absorbed labelled a-tocopherol was relatively consistent.
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6.1 Introduction
This chapter investigates the biokinetics of a-tocopherol in the blood 
components of normolipidemic people compared with hyperlipidemic people. It is 
currently unknown whether vitamin E status in people with raised lipids differs to 
normolipidemic people.
Raised plasma low-density lipoprotein (LDL) cholesterol is a risk factor for 
Cardiovascular disease (CVD) (Martin & et al, 1986; Rose & Shipley, 1986), a 
suggested ideal level for LDL is < 3.0 mmol per litre plasma (Wood et al., 1998). 
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the 
Western world. CVD is a chronic, multi-factorial disease and the aetiology can be 
attributed to the accumulation of risk factors.
LDL, which may be oxidatively modified, is an important factor in inducing 
endothelial dysfunction, which occurs in the early stages of atherosclerosis 
(Griendling & Alexander, 1997; Stokes et a l, 2002b). Furthermore, LDL can become 
trapped within the arterial wall, whereby oxidatively modified LDL are internalised 
into macrophages leading to the formation of foam cells (Steinberg et a l, 1989). LDL 
are heterogeneous, and have been classified into sub populations; a predominance of 
small dense LDL is considered more atherogenic than large, buoyant LDL (Berneis & 
Krauss, 2002; Griffin et a l, 1994).
Hypercholesterolemia may result from an increased production of LDL 
cholesterol and/ or reduced clearance from the systemic circulation. Polygenic 
hypercholesterolemia is the most common cause of raised plasma LDL cholesterol 
(Wilding & Williams, 1997). There are several genetic polymorphisms in lipoprotein 
metabolism including the apolipoproteins moiety of the lipoproteins, the lipid 
processing enzymes and lipoprotein receptor uptake (Ye & Kwiterovich, 2000). For 
example, the Apo E phenotype influences the uptake of lipoproteins via interactions 
with LDL receptor and hepatic chylomicron remnant receptor (Weintraub et a l, 
1987a).
Vitamin E is transported within lipoproteins whilst circulating in the blood. As 
a consequence, individuals with raised plasma cholesterol usually have increased 
concentrations of plasma vitamin E (Horwitt et a l, 1972; Lambert & Mourot, 1984; 
Simon et a l, 1997; Thurnham et al., 1986). The implications of raised plasma vitamin 
E concentration on vitamin E status are poorly understood. It has been previously
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shown that vitamin E concentration within erythrocytes is lower in 
hypercholesterolemic subjects, the authors speculated that there was preferential 
retention of a-tocopherol within the lipoproteins (Simon et al., 1997).
The antioxidant properties of vitamin E have been implicated in the prevention 
of CVD for a number of years (Gey et al., 1991; Steinberg, 1989), more recently 
vitamin E has been shown to inhibit cells crucial in the progression of atherosclerosis 
both directly and via the inhibition of LDL oxidation (Azzi & Stocker, 2000). An 
altered vitamin E status may contribute to the increased risk of CVD associated with 
raised plasma LDL cholesterol.
The biokinetics of newly absorbed a-tocopherol has not previously been 
investigated in subjects with raised plasma lipids. This chapter investigates the uptake 
and distribution profiles of newly absorbed labelled a-tocopherol into plasma, 
lipoproteins and blood cells (erythrocytes, platelets and lymphocytes) in 
normolipidemic and hypercholesterolemic subjects.
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6.2 Aim and hypothesis
The study aims to determine whether there is a difference in the uptake and 
distribution biokinetics of newly absorbed a-tocopherol in plasma, lipoproteins and 
blood cells (erythrocytes, platelets and lymphocytes) in hypercholesterolemic subjects 
compared with normolipidemic subjects.
It is hypothesised that individuals with raised plasma LDL cholesterol have 
altered vitamin E biokinetics, more specifically, individuals with raised plasma LDL 
will retain more of the newly absorbed a-tocopherol within the LDL. It was also 
proposed that a decreased rate of disappearance from plasma and a reduced uptake 
into other blood components might be observed. LDL is heterogeneous; the study also 
investigates whether the uptake of newly absorbed a-tocopherol into LDL sub 
fractions differs between normolipidemic and hypercholesterolemic subjects.
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6.3 Study design
Eight normolipidemic males were recruited from an advertisement in local 
newspapers and eight asymptomatic hypercholesterolemic males were recruited from 
general practitioners and through a lipid clinic at Royal Surrey County hospital. 
Selection criteria stated subjects must be non-smoking, not taking dietary supplements 
and with no gastrointestinal disorders, as determined from a written questionnaire. 
Subjects with fasting triacylglycerol concentrations greater than 1.5 mmol/ L were 
excluded. Additional selection criteria for normolipidemic subjects was; cholesterol < 
5.7 mmol/ 1 and LDL cholesterol < 3 . 5  mmol/ 1, and for hypercholesterolemic 
subjects; > 6 mmol/ 1 and LDL cholesterol > 3.5 mmol/1.
Subjects arrived at the C linical Investigation Unit at the University of Surrey at
7.45 am, having been requested to fast from 8 pm the night before the study. The 
subjects consumed a standard breakfast containing 40g fat (2 croissants and 20 g 
butter); investigators ensured the capsule, containing 150 mg deuterium labelled (d6) 
RRR a-tocopheryl acetate, was taken m id-way through the meal. 40g Fat was chosen 
to maxim ise vitamin E absorption. The time the capsule was consumed was taken as 0 
hours and blood samplings were timed from this point. A suitable trained person drew 
20 ml blood samples from the antecubital vein in the forearm at 3, 6, 9, 12, 24 and 48 
h hours after ingestion o f the capsule (illustrated in figure 6.1), an additional 10 ml 
blood was taken at 12 and 24 h. Subjects were only allowed water and a standard meal 
at 12:00 until 15:00 on day 1, and then they were allowed to eat ad libitum.
Plasma, erythrocytes, platelets and lymphocytes were isolated from the blood 
samples. LDL subclasses were isolated from plasma at 12 and 24 hours. 
Chylomicrons, VLDL, LDL and HDL were isolated from frozen plasma at a later date.
Standard lunch 
15g fat
08:00 11:00 14:00 17:00 20:00 08:00 08:00
■ 1 1 I X ■■■ I  3 ____________I
D A Y  1 D A Y  2 D A Y 3
150 mg d6 RRR a-tocopheryl acetate with 40 g fat |  Blood sample taken
Figure 6.1 Schematic diagram of study protocol
150 mg RRR a-tocopheryl acetate capsule was taken with a meal containing 40 g fat. 20 ml 
blood was taken at 3, 6, 9, 12, 24 and 48 h after ingestion of the capsule; an additional 10 ml 
blood was taken at 12 and 24 h.
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6.4 Results
6.4.1 Subject information
Eight normolipidemic (NL) and eight hypercholesterolemic (HC) males 
participated in the study. During the study period no one reported any side effects or 
withdrew from the study. Table 6.1 shows the subject characteristics for NL and HC 
subjects, they were age matched and the dose of d6 -a-tocopheryl acetate per body 
weight was similar for each group.
The HC subjects had significantly greater total cholesterol (p < 0.001), LDL 
cholesterol (p < 0.001) and HDL cholesterol (p = 0.03) compared with NL subjects 
(Table 6.1). Both groups had similar fasted plasma triacylglycerol levels.
Table 6.1 Subject characteristics for normolipidemic and hypercholesterolemic subjects
Normolipidemic 
n= 8
Hypercholesterolemic 
n = 8 p value*
Age (years) 46.8 + 9.5 47.1 ± 10.2 0.87
BMI (kgm2) 26.1+3.0 25.6 ±2.4 0.64
d6 a-TA1 kg body wt 1.9 ±0.2 1.9 ±0.2 0.71
Total cholesterol (mmol/ L) 4.8+ 0.5 7.0 ±0.6 < 0.001
LDL cholesterol (mmol/ L) 3.2 ±0.5 4.4 ±0.8 < 0.001
HDL cholesterol (mmol/ L) 1.1 ±0.2 1.3 ±0.2 0.03
Triacylglycerol (mmol/ L) 1.2 ±0.3 1.4 ±0.2 0.12
Values expressed as mean ± SEM. BMI; body mass index, a-TA; a-tocopheryl acetate 
* as analysed by unpaired t-test
6.4.2 Plasma and lipoprotein a-tocopherol profiles
Plasma cholesterol concentrations did not differ significantly over time for NL 
and HC subjects. However, in HC subjects there was a significant decrease in 
triacylglycerol (TAG) concentration over time (p <0.001), a lower concentration was 
observed at 24 and 48 h when some subjects were fasted (see Appendix IV).
Table 6.2 shows the area under the curve (AUC) for d6 a-tocopherol uptake 
into plasma and lipoproteins over 48 hours following ingestion of 150 mg RRR a- 
tocopheryl acetate. There was a significantly lower d6 a-tocopherol AUC in HC than 
NL subjects in LDL per g protein (p = 0.008).
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Table 6.2 Mean d6 a-tocopherol area under curve (AUC), in plasma and lipoproteins 
over 48 hours following ingestion of 150 mg RRR a-tocoplieryl acetate
normolipidemic 
(n = 8)
hypercholesterolemic . *p value*(n = 8)
Plasma
pmol/L. h 666 ± 86 724 ± 83 0.64
Plasma
jumol/ mmol cholesterol, h 144 ±17 130 + 12 0.50
Chylomicrons
pmol/ g protein, h 217 + 46 208 ±38 0.84
Chylomicrons
pmol/ mmol TAG. h 107 ±20 81 + 12 0.29
VLDL
pmol/ g protein, h 893 ±110 763 + 140 0.48
LDL
pmol/ g protein, h 688 + 89 400 + 21 0.008
HDL
qmol/ g protein, h 50.8 ±3.4 49.8 + 4.5 0.39
Values expressed as mean ± SEM.* as analysed by unpaired t-test TAG: triacylglycerol
Figure 6.2 A) shows the mean dO and d6 a-tocopherol concentration per litre 
plasma in NL and HC subjects and figure 6.2 B) shows dO and d6 a-toeopherol 
concentration per mmol cholesterol. There was a significant increase in the mean d6 
a-tocopherol concentration over time in both groups (p<0.001), d6 a-tocopherol 
peaked at approximately 9 h and then declined from 12 h. There were no significant 
differences in d6 a-tocopherol profiles per litre plasma or per mmol cholesterol in NL 
and HC subjects. Percentage d6 a-tocopherol uptake profiles were also similar in NL 
and HC subjects (data not shown).
Pre-existing dO a-tocopherol concentration decreased from 3 h to 24 h in both 
groups (p<0.001). dO a-Tocopherol profile per litre plasma in HC was greater than in 
NL subjects, but lower per mmol cholesterol as shown in figures 6.2 A) and B), 
although neither were significantly different.
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Figure 6.2 (A) Plasma dO and d6 a-tocopherol for NL and HC subjects (B) dO and d6 a- 
tocopherol per mmol cholesterol for NL and HC subjects over 48 hours following 
ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase in d6 
a-tocopherol and decrease in dO a-tocopherol in both groups / L plasma and per mmol 
cholesterol (p < 0.01), analysed by repeated measures ANOVA. There was no significant 
difference in d6 or dO a-tocopherol biokinetic profiles in NL versus HC subjects 
a-T: a-tocopherol, HC: hypercholesterolemic, NL: normolipidemic
Figures 6.3 A) and B) illustrate the mean chylomicron d6 a-tocopherol 
concentration per g protein and per mmol TAG in NL and HC subjects over 48 h. d6 
a-Tocopherol concentration peaked sharply at 6 h then quickly decreased. The uptake 
of d6 a-tocopherol into chylomicrons was not significantly different for NL and HC 
subjects per mmol TAG (Figure 6.3B). However, the uptake of d6 a-tocopherol per g 
protein in HC subjects appeared greater compared with NL subjects, although it was
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not significant (Figure 6.3A). There was large inter-individual variation in d6 a- 
tocopherol per g protein in both groups; illustrated by the large SEM bars at 6 hours in 
figures 6.3 A. There was less inter- individual variation was observed in d6 a- 
tocopherol per mmol TAG as shown in figure 6.3 B.
Time (hours)
Time (hours)
Figure 6.3 (A) Chylomicron d6 a-tocopherol per g protein for NL and HC subjects (B) 
Chylomicron d6 a-tocopherol per mmol TAG for NL and HC subjects over 48 hours 
following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase in d6 
a-tocopherol in both groups per g protein and mmol TAG (p < 0.01), analysed by repeated 
measures ANOVA. There was no significant difference in d6 a-tocopherol biokinetic profiles 
in NL versus HC subjects
TAG: triacylglycerol HC: hypercholesterolemic, NL: normolipidemic
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Figure 6.4 illustrates VLDL dO and d6 a-tocopherol per g protein in NL and 
HC subjects over 48 h. d6 a-Tocopherol concentration plateaued between 6 and 12 h 
then started to decline in NL and HC subjects, there was no significant difference in 
d6 a-tocopherol uptake profiles. However, dO a-tocopherol concentration was 
consistently lower in the HC group compared with NL group over 48 h, although not 
significantly. There was a large inter-individual variation in dO a-tocopherol 
concentration in VLDL for both groups illustrated by the large SEM bars in figure 6.4.
The d6 a-tocopherol per mmol TAG and percentage d6 a-tocopherol uptake 
profiles were also similar in NL and HC subjects (data not shown).
Time (hours)
Figure 6.4 VLDL dO and d6 a-tocopherol per g protein in for NL and HC subjects over 
48 hours following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase 
in d6 a-tocopherol and decrease in dO a-tocopherol in both groups (p < 0.01), analysed by 
repeated measures ANOVA. There was no significant difference in d6 or dO a-tocopherol 
biokinetic profiles in NL versus HC subjects 
a-T: a-tocopherol, HC: hypercholesterolemic, NL: normolipidemic
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Figure 6.5 shows the mean LDL dO and d6 a-tocopherol concentration per g 
protein in NL and HC subjects over 48 h. d6 a-Tocopherol concentration increased up 
to 12 h then started to decrease in both NL and HC subjects. However, there was a 
significantly lower uptake of d6 a-tocopherol per g protein in HC subjects compared 
with NL subjects (p = 0.004). The d6 a-tocopherol per g protein AUC was also lower 
in HC than NL subjects, as shown in table 6.2 (p = 0.008). d6 a-tocopherol per mmol 
cholesterol over 48 h was also lower in HC compared with NL, however not 
significantly. The percentage d6 a-tocopherol uptake profiles were similar in NL and 
HC subjects (data not shown).
dO a-Tocopherol concentration was consistently lower in the HC group 
compared with NL group over 48 h (p = 0.03) as illustrated in figure 6.5.
There was a larger inter-individual variation in the uptake of d6 a-tocopherol 
in NL subjects compared with the HC subjects, illustrated by the larger SEM bars in 
figure 6.5.
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Figure 6.5 LDL dO and d6 a-tocopherol per g protein for NL and HC subjects over 48 
hours following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase 
in d6 a-tocopherol and decrease in dO a-tocopherol in both groups (p < 0.01), analysed by 
repeated measures ANOVA. Significantly less dO and d6 a-tocopherol per g protein in HC 
compared with NL (p = 0.03 and 0.004, respectively). 
a-T: a-tocopherol, HC: hypercholesterolemic, NL: normolipidemic
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Figure 6.6 illustrates the mean HDL dO and d6 a-tocopherol per g protein in 
NL and HC subjects over 48 h. d6 a-tocopherol plateaued between 9 and 24 h and 
then decreased at 48 h. The uptake and distribution profile of d6 a-tocopherol within 
HDL for HC was similar to that observed for NL and percentage d6 a-tocopherol 
uptake profiles were also similar in NL and HC subjects (data not shown). dO a- 
tocopherol concentration was consistently higher in NL compared with HC, although 
not significantly.
Time (hours)
Figure 6.6 HDL dO and d6 a-tocopherol per g protein for NL and HC subjects over 48 
hours following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase 
in d6 a-tocopherol and decrease in dO a-tocopherol in both groups (p < 0.01), analysed by 
repeated measures ANOVA. There was no significant difference in dO or d6 a-tocopherol 
biokinetic profiles in NL versus HC subjects. 
a-T: a-tocopherol, HC: hypercholesterolemic, NL: normolipidemic
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6.4.3 Erythrocyte, platelet and lymphocyte a-tocopherol profiles
Table 6.3 shows the mean area under the curve (AUC) for d6 a-tocopherol 
uptake into erythrocytes, platelets and lymphocytes over 48 hours following ingestion 
of 150 mg RRR a-tocopheryl acetate for NL and HC subjects. There was a trend 
towards a significantly lower d6 a-tocopherol AUC in HC subjects compared with NL 
in erythrocytes, platelets and lymphocytes.
Table 6.3 Mean d6 a-tocopherol area under curve (AUC) in erythrocytes, platelets and 
lymphocytes over 48 hours following ingestion of 150 mg RRR a-tocopheryl acetate
normolipidemic
(n=8)
hypercholesterolemic 
(n = 8) p value*
Erythrocytes 
pmol/ PCV 
Platelets
182 + 15 149+11 0.09
18.5 + 1.0 15.1 + 1.4 0.08pmol/ g protein
Lymphocytes
pmol/ g protein 12.6 ± 0.9 10.6 + 0.8 0.13
Values expressed as mean ± SEM. PCV: packed cell volume * analysed by unpaired t test
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Figure 6.7 shows the mean d6 a-tocopherol concentration in erythrocytes in 
NL and HC subjects. d6 a-tocopherol concentration peaked at 24 h then decreased at 
48 h. There was a greater uptake of d6 a-tocopherol into erythrocytes of NL subjects 
compared with HC subjects, although not significant (p = 0.17). There was a also 
trend towards a significantly larger AUC for d6 a-tocopherol/ PCV.h in NL subjects 
versus HC subjects as shown in table 6.3 (p = 0.09).
There was no dO a-tocopherol data for erythrocytes, due to methodological 
limitations (detailed in section 2.2.21).
There was a trend towards a significant correlation between d6 a-tocopherol 
AUC in erythrocytes and HDL in NL group (r2 = 0.43, p = 0.08), however, this was 
not evident in the HC group (r2 = 0.21, p = 0.25).
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Figure 6.7 Erythrocyte d6 a-tocopherol corrected for PCV for NL and HC subjects over 
48 hours following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase 
in d6 a-tocopherol over time in both groups (p < 0.01), analysed by repeated measures 
ANOVA. There was a non-significantly lower d6 a-tocopherol uptake in HC compared with 
NL (p = 0.17). PCV: packed cell volume HC: hypercholesterolemic, NL: normolipidemic
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Figure 6.8 shows the mean platelet dO and d6 a-tocopherol concentration per g 
protein for NL and HC subjects over 48 h. The d6 a-tocopherol uptake profile into 
platelets appeared quite different in HC versus NL, although they were not 
significantly different. Six HC and two NL subjects exhibited a biphasic response, 
whereby there was a sharp increase in d6 a-tocopherol concentration at 6 h. The other 
subjects had a gradual increase in d6 a-tocopherol up to 48 h.
There was a lower d6 a-tocopherol concentration at 24 hours in the HC group 
compared with the NL group (p = 0.01) and a trend towards a lower d6 a-tocopherol 
uptake in HC, as measured by AUC in the HC group (p = 0.08) as shown in table 6.3.
dO a-Tocopherol concentration was higher in NL compared with HC over 48 
h, although not significantly.
Time (hours)
Figure 6.8 Platelets d6 a-tocopherol per g protein for NL and HC subjects over 48 hours 
following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase 
in d6 a-tocopherol and decrease in dO a-tocopherol in both groups (p < 0.01), analysed by 
repeated measures ANOVA. There was non-significant difference in dO and d6 a-tocopherol 
biokinetic profiles in NL versus HC subjects. * Significantly greater concentration of d6 a- 
tocopherol at 24 h in NL compared with HC (p = 0.01) as analysed by unpaired t test. 
a-T: a-tocopherol, HC: hypercholesterolemic, NL: normolipidemic
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Figure 6.9 illustrates the mean dO and d6 a-tocopherol per g protein in 
lymphocytes of NL and HC subjects over 48 h, d6 a-tocopherol is on a second axis to 
clarify the NL and HC profiles. There was as gradual increase in d6 a-tocopherol 
concentration up to 48 h, this was similar in NL and HC subjects. However, there was 
a slightly lower d6 a-tocopherol concentration at 24 and 48 hours in the HC group 
compared with the NL group, although not significant. d6 a-Tocopherol AUC was not 
significantly different in HC and NL subjects (table 6.3). One HC subject exhibited a 
biphasic response, with an initial peak at 6 hours.
dO a-Tocopherol concentration was similar at 3 h then higher in NL compared 
with HC, although not significantly.
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Figure 6.9 Lymphocyte dO and d6 a-tocopherol per g protein for NL and HC subjects 
over 48 hours following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was a significant increase in d6 
a-tocopherol and decrease in dO a-tocopherol in both groups (p < 0.01), analysed by repeated 
measures ANOVA. There was non-significant difference in dO and d6 a-tocopherol biokinetic 
profiles in NL versus HC subjects.
a-T : a-tocopherol, HC: hypercholesterolemic, NL: normolipidemic
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6.4.4 d6 a-tocopherol uptake into LDL sub fractions
Figures 6.10 A and B illustrate the mean d6 a-tocopherol concentration in 
LDL sub fractions taken 12 h following 150 mg RRR a-tocopheryl acetate in NL and 
HC subjects. There was no difference in d6 a-tocopherol concentration or percentage 
uptake at 12 or 24 h (data not shown). The uptake of d6 a-tocopherol per mmol 
cholesterol was similar in NL and HC subjects as shown in figure 6.10 A. There was 
more d6 a-tocopherol in the lightest fraction per mmol cholesterol compared with the 
other fractions in both groups (p <0.05).
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Figure 6.10 A d6 a-Tocopherol in LDL sub fractions at 12 hours for NL and HC per 
fraction, and 6.10 B d6 a-Tocopherol in LDL sub fractions at 12 hours for NL and HC 
per mmol cholesterol following ingestion of 150 mg RRR a-tocopheryl acetate
Values expressed as mean ± SEM, n = 8 in each group. There was no significant 
difference in d6 a-tocopherol concentration in NL versus HC. * There was significantly 
greater d6 a-tocopherol in the first fraction compared with the dense fractions 6, 7 and 8 per 
mmol cholesterol in both groups (p < 0.05). HC: hypercholesterolemic, NL: normolipidemic
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6.5 Discussion
The aim of this study was to compare the uptake and distribution biokinetics of 
newly absorbed a-tocopherol between hypercholesterolemic (HC) and 
normolipidemic (NL) subjects. It was hypothesised that raised plasma LDL 
cholesterol would result in altered a-tocopherol biokinetics in the HC group.
Vitamin E is beneficial in the prevention of CVD (Azzi et al., 2003) and thus 
an altered vitamin E status may contribute to the increased risk of CVD associated 
with raised plasma LDL cholesterol (Rose & Shipley, 1986; Steinberg, 1989).
Key findings;
1. The uptake of d6 a-tocopherol into plasma was similar in NL and HC subjects, 
however, there was a significantly lower uptake of d6 a-tocopherol in LDL per g 
protein in HC subjects compared with NL subjects.
2. There was a trend towards a significantly lower uptake of d6 a-tocopherol into 
erythrocytes, platelets and to a lesser extent lymphocytes in EIC subjects.
3. d6 a-Tocopherol uptake was significantly greater in the lightest LDL fraction per 
mmol cholesterol compared with the denser fractions. There was no difference in 
d6 a-tocopherol uptake in NL and HC subjects.
6.5.1 Plasma and lipoprotein a-tocopherol profiles
The pre-existing (dO) a-tocopherol concentration, at 3h and before significant 
uptake of d6 a-tocopherol, was higher per litre plasma and lower per mmol cholesterol 
in HC subjects compared with NL subjects, although not significant. This finding was 
similar to published studies (Lambert & Mourot, 1984; Regnstrom et al., 1996; Simon 
etal., 1997).
In the current study HC subjects had significantly less dO a-tocopherol per g 
protein in LDL compared with NL subjects, at 3 h, before significant uptake of d6 a- 
tocopherol. Lambert and Mourot (1984) who reported lower LDL vitamin E per litre 
serum in patients with raised LDL cholesterol compared to normolipidemic subjects 
and Regnstrom et al. (1996) reported significantly lower vitamin E per g protein in 
LDL from a heterogeneous group of hyperlipidemic men who had survived a 
myocardial infarction.
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There was similar dO a-tocopherol concentration per g protein in HDL for NL 
and HC subjects, at 3 h, before significant uptake of d6 a-tocopherol. This is in 
agreement with the findings of Lambert and Mourot (1984) reported similar HDL 
vitamin E per litre serum in patients with raised LDL cholesterol and Simon et al 
(2000) who reported similar steady-state vitamin E per mmol HDL in NL and 
hyperlipidemic subjects.
6.5.1.1 Uptake profile of newly absorbed (d6i a-tocopherol
Following a single dose of 150 mg d6 RRR a-tocopheryl acetate plasma d6 a- 
tocopherol concentration increased from 3 h and plateaued between 9 and 12 h before 
decreasing in NL and HC subjects, this profile was similar to previously published 
studies in NL subjects (Cheeseman et a l, 1995; Roxborough et a l,  2000; Traber et a l, 
1998b). The magnitude of d6 a-tocopherol uptake into plasma was similar in NL and 
HC subjects, this suggests that there was no difference in d6 a-tocopherol absorption 
(illustrated in figure 6.2). The study did not measure the amount of a-tocopherol 
absorbed from 150 mg d6 a-tocopheryl acetate capsule nor could it report a - 
tocopherol concentration in lipoproteins per litre plasma due to the limitations in the 
methodology used to isolate the lipoproteins (method detailed in section 2.2.9).
The uptake of d6 a-tocopherol into chylomicrons was similar in NL and HC 
subjects per mmol TAG. However, there appeared to be greater uptake of d6 a- 
tocopherol per g protein in HC subjects, although not significant. This may suggest 
that the chylomicrons formed are larger and more TAG rich in HC subjects compared 
with NL subjects. No studies were found that explored whether there are differences in 
chylomicron formation in hypercholesterolemia, as suggested in the current study.
The uptake of d6 a-tocopherol into VLDL plateaued between 6 and 12 h in NL 
and HC subjects and to a similar magnitude. Therefore, HC subjects did not differ in 
their ability acquire newly absorbed a-tocopherol per g protein or per mmol TAG in 
VLDL. VLDL are enriched with a-tocopherol within the liver and from other 
lipoproteins whilst circulating, the current study suggests that neither of these process 
are impaired in hypercholesterolemia. Pre-existing (dO) a-tocopherol concentration 
appeared lower in HC over 48 h (Figure 6.4), however there was large inter-individual 
variation and the difference was not significant.
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d6 a-Tocopherol increased up to 12 h in LDL, then started to decrease from 24 
h in both NL and HC subjects. There was a significantly lower uptake of d6 a- 
tocopherol per g protein of LDL in HC subjects compared with NL subjects. This 
presumably was due to the greater volume of LDL in the plasma of HC subjects and as 
a consequence the d6 a-tocopherol available per particle was less compared with NL 
(as similar d6 a-tocopherol absorption was observed). The pre-existing dO a- 
tocopherol was also significantly lower in HC subjects (illustrated in figure 6.5). LDL 
is formed from VLDL metabolism, in the current study d6 a-tocopherol in VLDL was 
similar in NL and HC over 48 h. This suggests that the difference observed in LDL 
occurs within the systemic circulation, after hepatic secretion. It is possible that in 
hypercholesterolemia, LDL is circulating for a longer time and therefore more a- 
tocopherol may be transferred to peripheral tissues. Interestingly the percentage uptake 
of d6 a-tocopherol in LDL was similar in NL and HC subjects.
There was no difference in the d6 a-tocopherol uptake profile for HDL 
between NL and HC subjects. This implies that high circulating LDL levels do not 
impair the transfer of newly absorbed a-tocopherol to HDL. Simon et al (2000) 
suggested that a-tocopherol in HDL was retained to a greater extent in HC subjects, 
however, in the current study the disappearance rate of d6 a-tocopherol also appeared 
similar in NL and HC groups.
The total amount of d6 a-tocopherol circulating within the plasma was similar 
in NL and HC subjects, therefore, any differences observed in the uptake of d6 a- 
tocopherol into blood cells may be attributed to the differing d6 a-tocopherol in 
lipoproteins between NL and HC groups.
It was hypothesised that HC subjects would retain a greater amount of newly 
absorbed d6 a-tocopherol within lipoproteins, illustrated by a slower disappearance of 
d6 a-tocopherol from lipoproteins. In hindsight more frequent time points were 
needed in the current study to ascertain the disappearance rate of d6 a-tocopherol 
from plasma and lipoproteins.
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tocopherol into blood cells may be attributed to the differing d6 a-tocopherol in 
lipoproteins between groups.
6.5.2 Uptake o f d6 a-tocopherol into erythrocytes, platelets and lymphocytes
Erythrocyte d6 a-tocopherol concentration peaked at 24 hours then started to 
decline at 48 h in NL and HC subjects, which was similar to previously published 
studies in normolipidemic subjects (Cheeseman et al., 1995; Roxborough et al., 2000). 
There was a trend towards a lower uptake of d6 a-tocopherol into erythrocytes of HC 
subjects compared with NL subjects, as measured by d6 a-tocopherol AUC over 48 h. 
Erythrocyte dO a-tocopherol concentration was not measured in the current study due 
to methodological problems, however, previous studies have reported lower steady- 
state vitamin E levels in erythrocytes of hyperlipidemic rats and humans compared to 
NL controls (Nishida et al., 1982; Simon et a l, 1997). The reduced vitamin E 
concentration in erythrocytes has physiological consequences; Simon et a l (1998) 
showed that erythrocytes from HC subjects were more susceptible to oxidation ex vivo 
compared with those from NL subjects.
Chapter 5 investigated a-tocopherol biokinetics in healthy subjects and 
reported a strong correlation between the d6 a-tocopherol AUC of erythrocytes and 
HDL and in the current study there was a trend towards a significant correlation 
between d6 a-tocopherol AUC of erythrocytes and HDL in NL subjects. However, 
there was no correlation between d6 a-tocopherol AUC of erythrocytes and HDL in 
HC subjects. The transfer of a-tocopherol to erythrocytes from HDL is more efficient 
compared with other lipoproteins (Kayden & Bjomson, 1972; Kostner et a l,  1995). 
Simon et al. (2000) reported that erythrocytes from hyperlipidemic and NL subjects 
were equally able to accept a-tocopherol from donor HDL ex vivo and suggested that 
HDL may preferentially transfer a-tocopherol to LDL rather than erythrocytes. It is 
possible that if erythrocytes have lower vitamin E concentration in HC compared with 
NL people there may also be less vitamin E distributed to other blood cells and 
peripheral tissues.
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A distinct biphasic uptake in d6 a-tocopherol was observed in a proportion of 
both NL and HC, whereby d6 a-tocopherol concentration sharply increased from 3 h 
to 6 h, then a gradual uptake from 9 h, this was similar to what was observed in 
healthy subjects Chapter 5. A gradual increase in d6 a-tocopherol concentration from 
3 h was observed in the other NL and HC subjects. A greater percentage of HC 
subjects exhibited a biphasic uptake of d6 a-tocopherol into platelets compared with 
NL subjects. However, as discussed in Chapter 5, the reasons for the biphasic uptake 
of a-tocopherol are not clear. The NL and HC biphasic and non-biphasic subjects 
were not compared due to the low subject numbers in each group. Whether or not lipid 
status affects the uptake of a-tocopherol into platelets remains to be elucidated. Very 
little is known regarding the mechanisms for a-tocopherol uptake and regulation 
within platelets. It was hypothesised in Chapter 5 that there is passive diffusion and 
controlled uptake of a-tocopherol into platelets, possibly via LDL receptors, whilst 
circulating within the blood.
Some hypercholesterolemic subjects have reduced binding activity of LDL 
receptors (Ye & Kwiterovich, 2000), in these individuals there may be a lower a- 
tocopherol uptake in cells that acquire vitamin E via LDL receptors. There was a trend 
towards a significantly lower uptake of d6 a-tocopherol into platelets of HC subjects 
compared with NL subjects, as measured by d6 a-tocopherol AUC. Additionally dO 
a-tocopherol concentration was lower in HC subjects at 3 h compared with NL 
subjects, albeit non significantly (illustrated in figure 6.8).
Platelet adhesion and aggregation is a key factor in thrombosis and CVD 
pathogenesis (Handin, 1996), and it has been shown that there is greater platelet- 
endothelial adhesion in hypercholesterolemic animals and humans (Davi et a l , 1997; 
Scalia et al, 1998). Additionally a-tocopherol has been shown to modulate platelet 
adhesion and aggregation in supplementation studies and ex vivo experiments 
(Calzada et al, 1997; Steiner, 1991; Steiner, 1999). Therefore, if HC subjects had less 
a-tocopherol within their platelets, as suggested by the current study, this could 
contribute to the altered platelet function observed in HC subjects.
d6 a-Tocopherol uptake into lymphocytes was gradual, appearing after 6 hours 
and continuing to increase up to 48 h in NL and HC subjects, this was similar to what 
was observed healthy subjects in Chapter 5. Chapter 5 suggested a controlled uptake
161
Chapter 6
of newly absorbed a-tocopherol into lymphocytes. Since lymphocytes have LDL 
receptors, they are thought to obtain vitamin E via this process (Kaempf et a l,  1994). 
As hypothesised with the uptake of tocopherol in platelets, if  there is reduced activity 
of LDL receptors in HC you would predict a lower uptake of LDL and therefore a- 
tocopherol.
Peripheral lymphocytes are involved in the pathogenesis of atherosclerosis 
(Bach et a l, 1997; Hansson, 1997; Song et a l, 2001) and lymphocyte function in HC 
animals has been shown to be different compared with NL animals (Stokes et a l, 
2002b; Stokes et a l, 2002a). a-Tocopherol has been shown to enhance lymphocyte 
differentiation and proliferation in vitro and ex vivo (Meydani et a l,  1990; Meydani et 
a l, 1986). Therefore, if  HC subject have less a-tocopherol within their lymphocytes, 
as hypothesised from the findings in the current study, this could contribute to the 
altered lymphocytes function observed in HC subjects
The current study findings of newly absorbed d6 a-tocopherol uptake profiles 
into blood cells of HC subjects has provided a useful insight into the possibility that a- 
tocopherol regulation is different to that in NL subjects and that the delivery of a- 
tocopherol to peripheral tissues may also be impaired in HC subjects.
6.5.3 Uptake o f  d6 a-tocopherol into LDL sub fractions
LDL are heterogeneous, and have been classified into sub populations; large 
buoyant, intermediate or small, dense LDL. A predominance of small dense LDL is 
considered more atherogenic than large, buoyant LDL (Bemeis & Krauss, 2002; 
Griffin et a l, 1994).
Previous studies have reported less a-tocopherol in small dense LDL 
compared with large buoyant LDL (Chancharme et a l, 2002; Goulinet & Chapman, 
1997; Tribble et a l, 1995). The current study obseived significantly greater d6 a- 
tocopherol uptake per mmol cholesterol in the lightest LDL sub fraction compared 
with the denser fractions, this may help towards explaining the lower a-tocopherol 
levels in small dense LDL. There was no difference in d6 a-tocopherol uptake per 
mmol cholesterol between NL and HC subjects, however there was a lower, albeit 
non-significant, d6 a-tocopherol uptake in total LDL per mmol cholesterol in HC.
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The uptake of newly absorbed d6 a-tocopherol into LDL sub fractions was 
similar at 12 and 24 hours, this agrees with the plateau in d6 a-tocopherol per g 
protein in total LDL, shown in figure 6.5. The current study did not measure uptake of 
d6 a-tocopherol per g protein in LDL sub fractions, and therefore cannot conclude 
whether there is a difference in uptake per LDL molecule. d6 a-Toeopherol into total 
LDL was significantly greater at 12 and 24 hours in NL subjects compared with HC 
subjects per g protein.
6.5.4 Conclusions and future work
The initial study protocol estimated fourteen subjects in each group would 
provide a reasonable chance of observing a true difference between biokinetics of 
newly absorbed a-tocopherol in HC and NL subjects. However, there was great 
difficulty in recruiting HC subjects, which resulted in only eight subjects in each 
group completing the study. Power calculation from the current study revealed that 
thirty subjects within each group would be required to find a significant difference in 
the uptake of d6 a-tocopherol into blood cells.
No baseline vitamin E measurement was taken, as the focus of this study was 
the uptake profile of newly absorbed d6 a-tocopherol. However, a steady-state dO a- 
tocopherol concentration for lipoproteins or blood cells would have been beneficial as 
there is very limited data on vitamin E status in dyslipidemia within the literature.
In conclusion HC and NL subjects absorbed d6 a-tocopherol to a similar 
extent, however, HC had a reduced uptake of newly absorbed d6 a-tocopherol per g 
LDL. This may impact upon the uptake of a-tocopherol into blood cells and peripheral 
tissues, as shown by the trend towards significantly lower uptake of newly absorbed 
d6 a-tocopherol into erythrocytes, platelets and lymphocytes. Hypercholesterolemia is 
a risk factor for CVD; the current study reveals that it may also contribute to an altered 
vitamin E regulation that may further predispose HC people to a higher risk of CVD.
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Future work to investigate the biokinetics o f a-tocopherol in people with an 
atherogenic lipoprotein phenotype, with raised plasma TAG and a predominance of 
small dense LDL, would be of interest to determine whether vitamin E regulation 
differs. It is hypothesised that they may retain more newly absorbed a-tocopherol 
within VLDL and subsequently reduce the transfer of newly absorbed a-tocopherol to 
HDL and peripheral tissues.
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Chapter 7
V i t a m i n  E  s t a t u s  i n  c i g a r e t t e  s m o k e r s  a n d
n o n - s m o k e r s
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7.1 Introduction
This chapter investigates the steady-state vitamin E status in cigarette smokers 
compared with non-smokers. Cigarette smoking has been identified as an independent 
risk factor for carcinogenesis, pulmonary and cardiovascular diseases (Chow, 1993; 
Doll et a l, 1994; Lykkesfeldt et a l, 1997; Peto et a l, 1992). Cigarette smokers are 
exposed to sustained free radical attack both from those present in the cigarette smoke 
and those formed endogenously through the inflammatory-immune response (Alberg, 
2002; Cross & Traber, 1997). Cigarette smoke contains alkenes, nitrosamines, 
aromatic and heterocyclic carbons and amines (Church & Pryor, 1985), these 
compounds are a known source of reactive oxygen species. Cigarette smoking causes 
an acute inflammatory reaction characterised by the accumulation of neutrophils and 
macrophages within the lungs, that generate an increased number of reactive oxygen 
species (Duthie et a l,  1991; Jay et a l, 1986; Kalra et a l, 1991; Piyor, 1993; van 
Antwerpen et a l, 1995).
Cigarette smokers are exposed to greater oxidative stress, this is characterised 
by greater lipid peroxidation of membranes and lipoproteins and oxidative DNA 
damage in smokers (Frei et a l, 1991; Harats et a l, 1990; Husgafvel-Pursiainen et a l, 
1984; Loft et a l, 1992; Miro et a l,  1999; Morrow et a l, 1995). Antioxidants are 
crucial in the body’s defence against oxidative damage from cigarette smoke (Alberg, 
2002). Cigarette smoke has been shown to deplete plasma carotenoids, ascorbic acid 
and vitamin E in vitro (Eiserich et a l, 1995; Handelman et a l, 1996), and several 
studies have shown cigarette smokers have lower plasma ascorbic acid and 
carotenoids levels in vivo (Marangon et a l, 1998; Mezzetti et a l, 1995; Stryker et a l, 
1988). A review by Alberg (2002) clearly demonstrated that unlike ascorbic acid and 
carotenoids, measurements of plasma vitamin E are, in general, not lower in cigarette 
smokers compared with non-smokers.
The lower plasma antioxidants of cigarette smokers have been attributed to 
both increased oxidative stress and a lower dietary intake of antioxidants (Dietrich et 
a l, 2003). Cigarette smokers tend to have a lower dietary intake of fruit and 
vegetables, which results in a lower intake of antioxidant micronutrients 
(Dallongeville et a l,  1998; Ma et a l, 2000; Wei et a l, 2001).
It has however been reported that cigarette smokers have a lower concentration 
of vitamin E in alveolar fluid (Pacht et a l, 1986) and a higher concentration in arterial
166
Chapter 7
tissue (Mezzetti et a l, 1995), compared with non-smokers. Increased levels of vitamin 
E were observed in the lungs of cigarette-smoked animals (Airriess et a l, 1988; Chow 
et a l, 1989). Furthermore, it has been proposed that vitamin E is mobilised to the lung 
tissue of cigarette smokers via ‘protein oxidation-generating bioactive molecules’ 
(Elsayed, 2001). These bioactive molecules can activate signal transduction pathways 
to mobilise vitamin E towards the site of increased oxidative stress (Suzuki et a l, 
1997). Biokinetie studies in humans have also indicated that cigarette smokers have an 
altered vitamin E uptake and utilization in plasma (Munro et a l,  1997; Traber et a l, 
2001). Together, these studies put a strong case forward for the existence of an altered 
vitamin E status in cigarette smokers.
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7.2 Aim and hypothesis
Cigarette smokers are exposed to higher levels of free radicals and oxidative 
stress compared with non-smokers. It is conceivable that cigarette smokers have a 
higher requirement for vitamin E and therefore they may have an altered vitamin E 
status compared with non-smokers. This study aims to report steady-state levels of 
vitamin E status within a number of blood components and the urinary excretion of a- 
and y-tocopherol metabolites (a- and y-CEHC) in cigarette smokers compared with 
non-smokers. A combination of vitamin E biomarkers are utilised since vitamin E 
regulation and distribution between cells is not fully understood and plasma steady- 
state levels are inadequate, as detailed in section 1.9.
It is hypothesised that cigarette smokers may have different levels of a- or y- 
tocopherol within blood cells due to exposure to more free radicals and hence greater 
oxidative stress. Platelet and lymphocyte functions are affected by vitamin E status 
and therefore may represent a functional biomarker of vitamin E status. Previous to 
this investigation the vitamin E status in platelets and lymphocytes have not been 
measured in cigarette smokers.
It is also hypothesised that reduced urinary excretion of a-CEHC would be 
observed in cigarette smokers, compared with non-smokers, due to an increased 
vitamin E utilisation.
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7.3 Study design
Thirty volunteers (15 cigarette smokers and 15 non-smokers) were recruited. 
Selection criteria stated subjects must not be taking dietary supplements and not have 
gastrointestinal disorders as determined from a written questionnaire. Subjects with 
blood lipid abnormalities were excluded (selection criteria was cholesterol < 6 mmol/1 
and triacylglycerol < 1.5 mmol/ 1). Additionally, non-smokers could not have 
previously smoked and cigarette smokers must have smoked at least 10 cigarettes a 
day, for greater than 5 years. Cigarette smokers were instructed to maintain their 
habitual smoking pattern during the study period.
Volunteers completed a 7-day food diary and collected two 24 h urine 
production. The 7-day food diaries were analysed for average nutrient intake per day, 
as detailed in section 2.2.2. The urine samples were utilised for the measurement of a- 
and y-CEHC, creatinine and cotinine; the methods are detailed in sections 2.2.3 and 
2.2.22 -  24. A fasted 20 ml blood sample was taken by a suitably trained person. 
Blood samples were used for the measurement of cholesterol, triacylglycerol, ascorbic 
acid and vitamin E in plasma, erythrocytes, platelets and lymphocytes; the methods 
are detailed in sections 2 .24-8 .
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7.4 Results
7.4.1 Subject characteristics and dietary intake
Table 7.1 shows the subject characteristics of cigarette smokers and non- 
smokers that participate in the study. The fifteen cigarette smokers and non-smokers 
were of similar age, body mass index (BMI) and plasma cholesterol and triglyceride 
concentrations. Self reported smoking status, expressed as pack-years, was confirmed 
by detection of urinary cotinine in cigarette smokers, whereas cotinine was not 
detected in non-smokers (limit of detection of 10 pg/ L; (Greaves et al. 2001). 
Cigarette smokers were relatively young and had not been smoking for longer than 15 
years.
Table 7.1 Subject characteristics for cigarette smokers and non-smokers
Characteristic Cigarette smokers Non-smokers(n= 15) (n= 15)
Gender (male/ female) 8/7 8/7
Age (years) 27.5 + 2.0 30.9 + 1.9
BMI (kgm"2) 24.4+1.0 23.0 + 0.9
Cholesterol 4.3 ± 0.2 4.5 + 0.2(mmol/1)
Triglycerides 
(mmol/1) 1.0 ±0.1 1.0+ 0.1
Pack-years# 6.1 ±3.4
(range) (2.5-15.0)
Urinary cotinine 1144 ±162 non detected(ng/ mg creatinine)
Values expressed as mean ± SEM. BMI; body mass indexn Pack years = packs of cigarettes 
smoked per day x number of years smoked * Analysed by two-tailed unpaired t-test
There were no significant differences between a- or y-tocopherol 
concentrations in males and female cigarette smokers and non-smokers, therefore, the 
collated data are presented throughout the chapter.
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Table 7.2 shows the average nutrient intake per day for cigarette smokers 
compared with non-smokers. Analysis of habitual dietaiy intake revealed the cigarette 
smokers and non-smokers have a similar intake of energy and macronutrients. 
Cigarette smokers reported a significantly greater intake of alcohol compared with 
non-smokers (p = 0.035). Dietary intake of antioxidants vitamins A, C and E and 
selenium, were not significantly different between cigarette smokers and non-smokers.
Table 7.2 Average nutrient intake per day for cigarette smokers and non-smokers
Average nutrient Cigarette smokers Non-smokers
intake/ day (n = 15) (n = 15)
Energy (kcal) 2232 ± 165 2158 + 106
Fat (g) 79.2 ± 7.4 82.8 ± 6.7
PUFA (g) 14.5 + 1,5 15.5 ±1.7
Carbohydrate (g) 255.5 + 33.0 270.1 ± 18.4
Protein (g) 68.7 ±3.9 73.8 + 4.2
Alcohol (g) 28.1+4.1 15.1 ±4.1*
Vitamin A intake (mg) 650 ± 98 766 + 68
Vitamin C intake (mg) 90.5 ± 24.2 104.0+16.2
Vitamin E intake (mg) 5.9 + 0.7 6.6 ± 0.7
Selenium (jig) 57.4 + 4.9 64.3 + 11.1
Values expressed as mean ± SEM. * p = 0.035 analysed by unpaired t-test 
PUFA; polyunsaturated fatty acids
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7.4.2 Plasma ascorbic acid and vitamin E concentration in plasma, erythrocytes, 
platelets and lymphocytes
Plasma ascorbic acid concentrations were lower, but not significantly, in 
cigarette smokers compared with non-smokers; mean ± SEM were 36.9 ± 4.8 and 42.9 
±4.0 pM respectively (p = 0.36).
Figure 7.1 illustrates the mean plasma a- and y-tocopherol concentrations per 
mmol cholesterol in cigarette smokers and non-smokers, a- and y-Tocopherol plasma 
concentrations were similar in cigarette smokers and non-smokers. However, a- 
tocopherol per litre plasma was significantly lower in cigarette smokers compared 
with non-smokers (22.1 ±1.0 and 25.2 ±1.0 pM respectively; p = 0.03).
The ratio of a-tocopherol : y-tocopherol in plasma of cigarette smokers and 
non smokers were similar (mean ± SEM; 15.9 ± 1.4 and 16.1 ± 0.6).
Figure 7.1 Plasma a- and y-tocopherol concentration per mmol cholesterol in cigarette 
smokers and non-smokers
Values expressed as mean ± SEM (n = 15 in each group), a- and y-Tocopherol concentration 
did not differ significantly between cigarette smokers and non-smokers. Analysed unpaired t 
test.
| a-Tocopherol 
|  y-Tocopherol
Cigarette smokers Non-smokers
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Figure 7.2 shows the mean a- and y-tocopherol concentration in erythrocytes 
corrected for packed cell volume in cigarette smokers and non-smokers. a-Tocopherol 
concentration was slightly lower in the erythrocytes of cigarette smokers compared 
with non-smokers, however, this difference was not significant (p = 0.10). y- 
Tocopherol concentration did not differ between cigarette smokers and non-smokers 
(1.59 ±0.18 and 1.50 ± 0.07 pM /1 packed cell volume respectively).
The ratio of a-tocopherol : y-tocopherol in erythrocytes of cigarette smokers 
and non smokers were similar (mean ± SEM; 10.5 ± 1.1 and 12.5 ± 0.7).
a-Tocopherol 
y-Tocopherol
Smokers Non-smokers
Figure 7.2 Erythrocyte a- and y-tocopherol concentration corrected for packed cell 
volume in cigarette smokers and non-smokers
Values expressed as mean ± SEM (n = 15 in each group). a-Tocopherol concentration was 
slightly lower in the erythrocytes of cigarette smokers compared with non-smokers, however, 
this difference was not significant (p = 0.10). y-Tocopherol concentration did not differ 
significantly between cigarette smokers and non-smokers. Analysed using unpaired t test.
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Figure 7.3 illustrates the mean a- and y-tocopherol concentration in platelets 
per g protein in cigarette smokers and non-smokers. Platelet a-tocopherol 
concentration was significantly lower in cigarette smokers compared with non- 
smokers (p = 0.014), whereas y-tocopherol concentration was similar in cigarette 
smokers and non-smokers.
The ratio of a-tocopherol : y-tocopherol in platelets was significantly lower in 
cigarette smokers compared with non smokers (mean ± SEM; 7.4 ± 0.6 and 13.0 ± 2.1,
p = 0.02).
.E1Q.
00
oL.uf
* p = 0.014
a-Tocopherol
y-Tocopherol
Smokers Non-smokers
Figure 7.3 Platelet a- and y-tocopherol concentration per g protein in cigarette smokers 
and non-smokers
Values expressed as mean ± SEM (cigarette smokers; n = 15, non smokers n = 14, one sample 
had to be discarded). a-Tocopherol concentration was significantly lower in the platelets from 
cigarette smokers compared with non-smokers (p = 0.014). y-Tocopherol concentration in 
platelets was similar in cigarette smokers and non-smokers. Analysed using unpaired t test.
* Significantly lower than to non-smokers.
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Figure 7.4 shows the mean lymphocyte a- and y-tocopherol per g protein in 
cigarette smokers and non-smokers. There was a significantly lower a- and y- 
tocopherol concentration within lymphocytes from cigarette smokers compared with 
non-smokers (p = 0.002 and p = 0.031, respectively).
The ratio of a-tocopherol : y-tocopherol in lymphocytes of cigarette smokers 
and non smokers were similar (mean ± SEM; 7.0 ± 0.5 and 7.6 ± 1.0).
p = 0.002
a-Tocopherol 
y-Tocopherol
* p = 0.031
Smokers Non-smokers
Figure 7.4 Lymphocyte a- and y-tocopherol concentration per g protein in cigarette 
smokers and non-smokers
Values expressed as mean ± SEM (n = 15 in each group), a- and y-Tocopherol concentration 
were significantly lower in the platelets from cigarette smokers compared with non-smokers 
(p = 0.002 and p = 0.031 respectively). Analysed using unpaired t test. * Significantly lower 
than non-smokers.
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7.4.3 Urinary excretion o f  a- and y-CEHC
Figure 7.5 illustrates the mean urinary excretion of a- and y-CEHC in cigarette 
smokers and non-smokers. Urinary excretion of a-CEHC did not differ between 
cigarette smokers and non-smokers. However, y-CEHC excretion was significantly 
greater in cigarette smokers compared with non-smokers (p = 0.036). No correlation 
was observed between a- or y-CEHC excretion and cotinine.
The ratio of a-CEHC : y-CEHC urinary excretion was significantly lower in 
cigarette smokers compared with non smokers (mean ± SEM; 0.40 ± 0.04 and 0.84 ±
0.14, p = 0.007).
Cigarette smokers Non-smokers
Figure 7.5 Urinary excretion of a- and y-CEHC excretion corrected for creatinine in 
cigarette smokers and non-smokers
Values expressed as mean ± SEM (n = 15 in each group). Urinary excretion of y-CEHC was 
significantly greater in cigarette smokers compared with non-smokers (p = 0.036). a-CEHC 
excretion was similar in cigarette smokers and non-smokers. Analysed using unpaired t test. 
* Significantly higher than non-smokers.
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7.5 Discussion
Cigarette smoking causes severe oxidative stress within the lungs, disruption 
of the antioxidant homeostasis and a probable increased requirement of antioxidants 
(Alberg, 2002; van Antwerpen et a l, 1995). The aim of this investigation was to 
determine whether cigarette smokers have an altered vitamin E status compared with 
non-smokers by measuring a number of steady-state biomarkers. Previous studies 
have reported inconsistent values for plasma and erythrocyte vitamin E concentrations 
in cigarette smokers and non-smokers (Brown et al, 1998; Liu et al, 1998). Cigarette 
smokers are likely to have an altered vitamin E status due to the greater oxidative 
stress and therefore higher utilisation of vitamin E acting as an antioxidant.
Key Findings;
1. Plasma a- and y-tocopherol concentrations corrected for cholesterol and 
erythrocyte a- and y-tocopherol concentrations were similar in cigarette smokers 
and non-smokers
2. Cigarette smokers had a lower concentration of a-tocopherol in their platelets and 
lymphocytes, compared with non-smokers
3. Cigarette smokers also had a lower concentration of y-tocopherol in their 
lymphocytes, compared with non-smokers
4. The urinary excretion of a-CEHC was similar in cigarette smokers and non- 
smokers. However, cigarette smokers excreted a greater amount of urinary y- 
CEHC compared with non-smokers.
7.5.1 a- and y-Tocopherol within blood components
This study observed a similar concentration of a- and y-tocopherol per mmol 
cholesterol in the plasma of cigarette smokers and non-smokers. This agrees with the 
majority of studies which have compared vitamin E levels in cigarette smokers with 
non-smokers (Dietrich et al, 2003; Duthie, 1993; Marangon et al, 1998; Mezzetti et 
al., 1995; Ross et al., 1995). Liu et al (1998) reported significantly lower plasma a- 
tocopherol (corrected for total lipid) in volunteers older than 35 years, but not in 
younger volunteers. A small study conducted by Munro et al (1997) also reported 
significantly lower plasma a-tocopherol (corrected for cholesterol). Interestingly a
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limited number of studies have reported higher y-tocopherol concentration in cigarette 
smokers’ plasma although the reasons for these observations remain unclear (Dietrich 
et al., 2003; Lykkesfeldt et al., 2000). From this information, it implies that there is 
little difference in vitamin E status between cigarette smokers and non-smokers.
A limited number of studies have investigated the plasma biokinetics of newly 
absorbed a-tocopherol in cigarette smokers compared with non-smokers using 
deuterium labelled a-tocopherol. Munro et al (1997) reported a lower uptake of 
newly absorbed a-tocopherol into plasma in cigarette smokers compared with non- 
smokers and Traber et al (2001) demonstrated a trend towards a faster removal of a- 
tocopherol from plasma in cigarette smokers compared with non-smokers. These 
studies demonstrate that cigarette smokers probably utilise vitamin E differently 
compared with non-smokers and this difference cannot be detected in steady-state 
plasma vitamin E levels. These differences may not be detected because plasma 
vitamin E is strongly associated with lipoprotein concentration and is homeostatically 
regulated (Iiorwitt et a l , 1972; Traber, 1994).
Erythrocytes from cigarette smokers are more susceptible to oxidation ex vivo 
compared with non-smokers (Brown et a l, 1997; Codandabany, 2000). However, 
studies that have compared vitamin E concentration within erythrocytes have 
concluded that there is little, if any, difference between cigarette smokers and non- 
smokers (Brown et al., 1997; Brown e t al, 1998; Duthie e t a l, 1991). Bellizzi et al 
(1996) reported lower a-tocopherol levels within erythrocytes from cigarette smokers. 
The current study found a non-significant lower erythrocyte a-tocopherol 
concentration from cigarette smokers compared with non-smokers. However, 
retrospective power calculations revealed that at least 35 subjects were required within 
each group to statistically establish whether there was a difference. Erythrocytes have 
tocopherol binding proteins (Kitabchi & Wimalasena, 1982a), and Bellizzi et al 
(1996) showed a reduced binding activity in the erythrocytes of cigarette smokers 
compared with those from non-smokers, although there was no correlation between 
uptake activity and vitamin E concentration within the erythrocytes.
Platelet adhesion and aggregation are influenced by vitamin E (Calzada et al, 
1997; Steiner, 1991). These are important processes in the pathology of cardiovascular 
disease. The concentration of vitamin E within platelets may represent a functional
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biomarker to detect sub optimal vitamin E status. Platelet vitamin E concentration has 
not previously been investigated in cigarette smokers. This study showed that steady- 
state a-tocopherol concentrations are lower in platelets from cigarette smokers 
compared with non-smokers, y-tocopherol concentrations were similar. A number of 
researchers have shown that cigarette smoking increased platelet aggregation 
(Bierenbaum et al, 1978; Lehr et a l, 1997; Rival et al, 1987). There are several 
proposed mechanisms which include; reduced platelet-derived nitric oxide formation 
(Ichiki et al, 1996), increased surface density of thromboxane receptors on platelets of 
smokers (Rangemark & Wennmalm, 1996), increased response to external stimuli and 
formation of platelet activating factor-like lipid(s) in smokers (Imaizumi et a l , 1991). 
The lower levels of a-tocopherol may contribute towards the increased aggregation of 
platelets that has been shown in cigarette smokers. A possible reason for reduced a- 
tocopherol concentration in platelets could be due to greater activation and therefore 
greater oxidative stress.
The current study showed that cigarette smokers also had lower a-and y- 
tocopherol concentration within their lymphocytes compared with non-smokers. This 
was the first study to report the vitamin E concentration of lymphocytes in cigarette 
smokers. Several researchers have observed increased lipid peroxidation and oxidative 
DNA damage within lymphocytes from cigarette smokers compared with non- 
smokers (Asami et a l, 1996; Miro et al, 1999; Piperakis et a l, 1998; Schneider et al, 
2001). Cigarette smoking has also been associated with altered lymphocyte 
responsiveness and function (Ekberg-Jansson A et a l, 2000; Moszczynski et a l, 2001; 
Schaberg et a l, 1997). Vitamin E has been shown to protect lymphocytes from 
oxidative damage (Brennan et al, 2000; Schneider et a l, 2001) and enhance 
lymphocyte differentiation and proliferation ex vivo (Beharka et al, 1997; Brennan et 
a l, 2000; Meydani et al, 1990). It is, therefore, possible that in cigarette smokers 
there is greater oxidation of vitamin E within the lymphocytes, which may result from 
chronic inflammation known to occur within cigarette smokers (Hunninghake et a l, 
1979). It would have been of interest to measure tocopherylquinone in plasma, 
erythrocytes, platelets and lymphocytes as a measure of tocopherol oxidation. It is 
probable that the a-tocopheryl radical is regenerated to a-tocopherol by ascorbic acid 
in lymphocytes. Due to the small amount of sample collected it was not possible to
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measure ascorbic aid content of lymphocytes. Such measurements may have helped 
towards the understanding of why cigarette smokers have lower vitamin E levels 
within their lymphocytes.
It is well documented that cigarette smokers have lower plasma ascorbic acid 
concentrations (Chow et al., 1986; Pelletier, 1970; Ross et al, 1995; Van Resnburg et 
al., 1989). It is also generally accepted that ascorbic acid is important in the 
regeneration of vitamin E in vivo (Halliwell & Gutteridge, 1999; Hamilton et al, 
2000). Therefore, it is conceivable that the reduced ascorbic acid levels could limit the 
regeneration of the tocopheroxyl radical to tocopherol within platelets and 
lymphocytes. However, in the current study, the plasma ascorbic acid concentration of 
cigarette smokers was not significantly lower than non-smokers.
The lower y-tocopherol concentration found in lymphocytes from cigarette 
smokers compared with non-smokers, could have been due to an increased utilisation 
in neutralising reactive oxygen and nitrogen species. Cigarette smoke produces 
reactive nitrogen species (Norman & Keith, 1965) and y-tocopherol is superior to a- 
tocopherol at neutralising the compounds (Cooney et al, 1993). Additionally Leonard 
et al (2003) reported increased levels of 5-nitro-y-tocopherol in plasma from cigarette 
smokers compared with non-smokers.
7.5.2 Urinary excretion o f  a- and y-CEHC
Urinary a-CEHC excretion has been suggested as a useful biomarker to 
determine adequate vitamin E status (Schuelke et al, 2000; Schultz et al, 1995). The 
regulation of a-CEHC production is not frilly understood, it is hypothesised that the 
extent of a-CEHC metabolism, in people with functioning a-tocopherol transfer 
protein (a-TTP), may represent the amount of vitamin E exceeding the requirements 
of the body. Baseline vitamin E urinary metabolites, a- and y-CEHC, have not 
previously been measured in cigarette smokers. It was hypothesised that if there were 
increased utilisation of a-tocopherol in cigarette smokers, regulation pathways would 
ensure the retention of a-tocopherol at the expense of metabolism to a-CEHC. 
However, this study found urinary a-CEHC excretion to be similar in cigarette 
smokers and non-smokers. It may be questionable as to how sensitive a biomarker 
urinary excretion of a-CEHC is at baseline values. Plasma a- and y-CEHC was not
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measured in the current study, these measurements may be more sensitive as the inter­
individual variation in kidney function would have been removed (Galli et a l, 2002).
Radosavac et a l (2002) observed that the concentration of a-CEHC in plasma 
of cigarette smokers was higher than non-smokers after a-tocopherol supplementation. 
Whereas Bruno et al (2003) reported lower urinary excretion of a-CEHC in cigarette 
smokers after a-tocopherol supplementation. The contradictory results emphasise the 
gaps in knowledge in a-CEHC regulation.
Interestingly urinary y-CEHC excretion was greater in cigarette smokers 
compared to non-smokers. y-Tocopherol metabolism to y-CEHC is believed to be the 
major route of elimination for y-tocopherol (Galli et a l, 2003; Swanson et a l, 1999), 
its metabolism involves one or more P450 cytochrome enzymes within the liver 
believed to include CYP 4F2 (Songtag & Parker, 2002). It has been widely reported 
that induction of one P450 cytochrome enzyme can affect induction of others and it is 
possible this is the case in cigarette smokers (Pelkonen et a l, 1998). Cigarette 
smoking induces CYP1A, an effect which has been attributed to the polycyclic 
aromatic hydrocarbon class of compounds (Pelkonen et a l, 1998). In the current study 
cigarette smokers also had greater alcohol consumption compared with non-smokers 
(Table 7.2), in accordance with reports by other researchers (Dallongeville et a l, 
1998) ethanol has been shown to induce cytochrome P450 enzyme CYP2E1 (Fraser, 
1997). Thus, in addition to the possible effect of smoking it is plausible that induction 
of enzymes by ethanol could have influenced vitamin E metabolism as well. However, 
if this were the case an increased urinary a-CEHC excretion would have been 
observed as well.
y-CEHC has been described as a powerful natriuretic factor (Wechter et a l, 
1996) and it is able to inhibit COX-2 in macrophages (Jiang et a l, 2000), implying a 
specific role for this metabolite. The increase in urinary y-CEHC excretion may have a 
specific role in cigarette smokers rather than merely a consequence of y-tocopherol 
metabolism. More research is required in the area of y-CEHC regulation in order to 
fully understand the observed increased y-CEHC excretion in cigarette smokers.
It is also possible that the increase y-CEHC excretion was in part due to a 
higher dietary intake of y-tocopherol in cigarette smokers; dietary analysis showed 
similar vitamin E intake but could not distinguish between different vitamin E forms.
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7.5.3 Conclusions andfuture work
In the current study the cigarette smokers were relatively light smokers, thus 
highlighting the particularly detrimental effects cigarette smoking may have on 
vitamin E status. These data suggest that in smokers platelet and lymphocyte a- 
tocopherol are useful biomarkers, showing an affect prior to changes in other oxidative 
stress markers, such as plasma ascorbic acid.
Further investigation in to vitamin E status in older volunteers that have 
smoked for a longer period of time is needed to understand if these findings 
underestimate the extent of changes in vitamin E metabolism and status. Cigarette 
smoking is a risk factor for CVD, the altered vitamin E status in platelets and 
lymphocytes may contribute to the early stage of the disease.
Measurement of tocopherylquinone would have been of particular interest 
within the blood cells to establish whether there is greater free radical scavenging in 
the blood components of cigarette smokers and therefore conversion of a-tocopherol 
to tocopherylquinone.
The current study demonstrates the importance of measuring vitamin E 
concentration in multiple blood cells to assess vitamin E status. Using steady-state 
plasma vitamin E concentrations may lead to the misinterpretation of the involvement 
of vitamin E in disease states. Further work is needed to determine the biokinetic 
profile of a- and y-tocopherol in erythrocytes, platelets and lymphocytes and whether 
uptake and turnover differ in cigarette smokers compared with non-smokers.
The current study has demonstrated that steady-state vitamin E status is altered 
in cigarette smokers, although the case for increased requirements has not been 
established. More research is required into how cigarette smokers utilise their vitamin 
E and whether combined supplementation of vitamin E and C can provide optimal 
protection against reactive oxygen and nitrogen species.
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C h a p t e r  8
General discussion and conclusions
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8.1 Research problem
Vitamin E is involved in preventing the pathogenesis of cardiovascular disease 
(CVD), both as an antioxidant (Steinberg, 1997) and at a molecular level (Azzi & 
Stocker, 2000). The previous chapters detail studies that have contributed to the 
understanding of vitamin E status in healthy people and those with an increased risk of 
CVD. The studies have also demonstrated the value of using a combination of 
biomarkers to gain a more accurate assessment of vitamin E status.
It is important to understand and be able to assess vitamin E status when 
investigating possible factors relating to disease risk. At present there is no adequate 
biomarker to reliably and accurately assess vitamin E status. This is, in part, due to the 
lack of information about the mechanisms that regulate the transfer of a-tocopherol 
both within and between cells and tissues. Steady-state plasma a- and y-tocopherol 
concentrations are frequently used to assess vitamin E status, however, plasma vitamin 
E is hepatically regulated (Traber et a l, 1990a; Traber & Kayden, 1989a), saturable 
(Dimitrov et a l, 1991; Jialal et a l, 1995), influenced by plasma lipids (Horwitt et a l, 
1972; Thumham et a l, 1986) and there is limited evidence to show that it is not 
sensitive to altered vitamin E concentrations within cells or tissues (Mezzetti et al, 
1995; Simon et a l, 1997). Additionally the relationship between plasma concentration 
and tissue levels is not fully understood. A number of other steady-state and functional 
biomarkers have been suggested (Morrissey & Sheehy, 1999), although these have not 
been properly standardised and are not universally accepted.
8.1.1 The response o f vitamin E concentration within blood components and urinary 
excretion o f vitamin E metabolites to supplemental a-tocopherol in healthy volunteers
Vitamin E status was assessed, using a variety of biomarkers, following 
supplementation with a-tocopheryl acetate. Measurement of plasma, erythrocyte, 
platelet and lymphocyte E concentrations were chosen for a number of reasons, 
plasma vitamin E concentration is the combined total of vitamin E within lipoproteins 
and therefore reflects vitamin E transport within the systemic circulation. Erythrocytes 
have been proposed as a possible biomarker of vitamin E status and the oxidative 
susceptibility of their membranes is directly related to vitamin E status (Miyake et al, 
1991; Simon et a l, 1997). Platelets and lymphocytes are functionally affected by 
vitamin E (Lehr et a l, 1998; Moriguchi & Muraga, 2000; Steiner, 1999), it was
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therefore proposed that vitamin E concentration may represent a functional biomarker 
of vitamin E status. Lymphocytes are known to have LDL receptors, a mechanism by 
which vitamin E is taken up into peripheral tissues (Traber & Kayden, 1984), and 
therefore may reflect peripheral tissues. Urinary excretion of a- CEHC has been 
proposed as an indicator of adequate vitamin E status in people with a functioning a- 
tocopherol transfer protein (a-TTP)(Schuelke et al., 2000; Schultz et a l, 1995).
The single dose-response study detailed in Chapter 3 found no clear dose- 
response in a-tocopherol concentration in plasma, erythrocytes, platelets or 
lymphocytes, 24 h after ingestion of varying single doses of a-tocopheryl acetate up to 
780 mg. This was, in part, the inability to distinguish between newly absorbed a- 
tocopherol and a-tocopherol already within the blood components and it has 
previously been shown that newly absorbed a-tocopherol replaces the existing 
tocopherol in plasma, which results in no significant difference in total tocopherol 
concentration (Traber et a l, 1994; Traber et a l, 1998b). Therefore, it is conceivable 
that a similar* displacement process occurred within the erythrocytes, platelets and 
lymphocytes. The biokinetic study detailed in Chapter 5 described a decrease in dO a- 
tocopherol within these blood components after a single dose of 150 mg d6 RRR-a- 
tocopheryl acetate, thus supporting the displacement hypothesis. The observations of 
a-tocopherol uptake and the displacement of existing a-tocopherol in platelets and 
lymphocytes within healthy individuals is a step towards a better understanding of a- 
tocopherol uptake and regulation in these important cells that are functionally affected 
by vitamin E.
The results of the single dose-response study contribute to the understanding of 
the specific vitamin E urinary metabolites a- and y-CEHC in relation to a- and y- 
tocopherol concentration in plasma, erythrocytes, platelets and lymphocytes. Baseline 
urinary a- and y-CEHC excretion did not correlate with a- or y-tocopherol 
concentrations in plasma, erythrocytes, platelets or lymphocytes. This therefore 
questions whether urinary a- and y-CEHC excretion accurately reflects vitamin E 
status within the body. There was a correlation between plasma a-tocopherol, 
corrected for cholesterol, and erythrocyte a-tocopherol at 24 h with IAUC of urinary 
a-CEHC excreted up to 72 h after varying single doses of a-tocopheryl acetate. If 
a-CEHC is only excreted in large quantities when a-TTP is saturated the results from
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Chapter 3 suggest that urinary a-CEHC excretion reflects a-TTP capacity rather than 
vitamin E status.
Schultz et al (1995) proposed urinary a-CEHC excretion as a potential 
biomarker for vitamin E status. However, there is limited information on the exact 
metabolic pathways and details on the proportion of ingested a-tocopherol converted 
to a-CEHC are unknown. The single dose-response study reported in Chapter 3 
showed no clear dose-response in urinary excretion of a-CEHC of up to 781 mg a- 
tocopheryl acetate ingested. a-TTP is thought to selectively remove RRR-a- 
tocopherol from the metabolic pathway. It is hypothesised that the metabolism of a- 
tocopherol to a-CEHC may only be observed in a dose dependant manner when a- 
TTP is saturated. Less than 1 % of the ingested RRR a-tocopheryl acetate doses were 
excreted as urinary a-CEHC, which was lower than that observed when other vitamin 
E forms are ingested (Galli et a l , 2003; Lodge et a l, 2001; Traber et a l, 1998a), 
suggesting selective retention within the body. It is therefore important to consider the 
uptake and distribution of the newly absorbed a-tocopherol into the blood and 
subsequent tissues and other routes of metabolite excretion.
The uptake profile of newly absorbed deuterium labelled a-tocopherol has 
previously been reported in plasma and erythrocytes (Cheeseman et a l, 1995; 
Roxborough et a l, 2000). However, the study reported in Chapter 5 was novel in 
describing the uptake of newly absorbed deuterium labelled a-tocopherol into platelets 
and lymphocytes. Interestingly in platelets a biphasic uptake of newly absorbed a- 
tocopherol was observed in some individuals, the initial peak in a-tocopherol uptake 
was suggestive of passive diffusion, however the more gradual uptake observed after 9 
h suggested a more controlled uptake process. The subjects who did not exhibit a 
biphasic uptake had a gradual increase in newly absorbed a-tocopherol after 3 h, it 
remains unknown why individuals differ in their uptake of a-tocopherol into platelets. 
In lymphocytes there was also a gradual uptake of newly absorbed a-tocopherol. It 
was probable that the controlled uptake of a-tocopherol was by LDL internalisation 
via LDL receptors in lymphocytes and may be platelets too, although the possible 
presence of tocopherol binding proteins has not been properly investigated. Kitabchi 
and Wimalasena (1982a) reported from their preliminary studies that platelets do not 
have tocopherol binding proteins.
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A large inter-individual variation was observed in response to the varying 
single doses of vitamin E in the study detailed in Chapter 3. External variation was 
introduced in the study protocol, which could, in part, be attributed to the subjects 
consuming a non-standardised breakfast with their vitamin E capsules. The results 
shown in Chapter 4 indicate that the fat content and physical properties of the meal 
with which supplemental a-tocopheryl acetate is consumed affect the rate and 
magnitude of a-tocopherol appearance in plasma. This may have important 
implications in the design of future studies when trying to provide a standard vitamin 
E dose. The studies detailed in Chapters 4 and 5 illustrate the large inter-individual 
variation in the magnitude and rate of deuterium labelled a-tocopherol entering the 
systemic circulation when external confounding factors are minimised.
8.1.2 Vitamin E concentration in blood components o f subjects with increased risk o f 
cardiovascular disease
A research objective was to investigate the biokinetics of newly absorbed a- 
tocopherol in hypercholesterolemic volunteers compared with normolipidemic 
volunteers, which to date has previously been unexplored. Raised plasma cholesterol 
is a risk factor for CVD and may also impact upon vitamin E regulation as it is 
transported within lipoproteins. Vitamin E has also been shown to be important in the 
prevention of CVD.
The biokinetic study detailed in Chapter 6 investigated the uptake and 
distribution profiles of newly absorbed deuterium labelled a-tocopherol within a 
number of blood components. Lipoproteins were separated to observe the possible 
difference in a-tocopherol transport within plasma that may have otherwise been 
disguised if plasma concentrations alone were measured. Newly absorbed a- 
tocopherol uptake into plasma was similar in normolipidemic and 
hypercholesterolemic subjects, but there was there was a lower uptake of deuterium 
labelled a-tocopherol into LDL, and non-significant lower uptake into erythrocytes 
and lymphocytes in hypercholesterolemic subjects compared with normolipidemic 
subjects. These data suggest that hypercholesterolemics do not incorporate a- 
tocopherol into blood cells as efficiently as normolipidemics. A greater number of 
hypercholesterolemic subjects than normolipidemic subjects exhibited a biphasic
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profile in the uptake of d6 a-tocopherol into platelets, the significance of which is 
unknown, but may be a worthwhile area of future investigation. Hypercholesterolemia 
is a risk factor for CVD and the study detailed revealed that it also contributes to an 
altered vitamin E regulation, which may further predispose hypercholesterolemic 
people to a higher risk of CVD.
Cigarette smoking is also considered a risk factor for CVD and cigarette 
smokers are exposed to sustained increased oxidative stress. Similar steady-state 
plasma and erythrocyte vitamin E concentrations have previously been reported in 
cigarette smokers and non-smokers. However, the study detailed in Chapter 7 
demonstrated that cigarette smokers had a lower concentration of a-tocopherol in their 
platelets and lymphocytes compared with non-smokers and cigarette smokers also had 
a lower concentration of y-tocopherol in their lymphocytes, compared with non- 
smokers. The lower vitamin E levels may contribute towards the increased platelet 
aggregation that has been observed in cigarette smokers (Lehr et a l , 1997). These 
findings imply that cigarette smokers have an altered vitamin E status, but the 
implications of the lower vitamin E levels remain to be understood. Additionally 
cigarette smokers excreted more urinary y-CEHC compared with non-smokers, whilst 
a-CEHC excretion was similar, a- and y-Tocopherol metabolism to a- and y-CEHC 
involves hepatic cytochrome P450 enzymes, the activity of these can be influenced by 
smoking, however more research is required in the area of y-CEHC regulation in order 
to understand the observed increase in y-CEHC excretion. Tocopherylquinone levels 
were not measured, this would have been beneficial to assess the extent of vitamin E 
utilisation in the cigarette smokers. Likewise, ascorbic acid levels within platelets and 
lymphocytes may have been of interest as its capacity to recycle the a-tocopheroxyl 
radical to a-tocopherol may influence vitamin E concentration within the cells.
The alterations observed in vitamin E regulation in cigarette smokers is of 
particular interest as the subjects were relatively young and not heavy smokers, 
consequently the data suggest that in smokers platelet and lymphocyte a-tocopherol 
are useful biomarkers, showing an affect prior to changes in other oxidative stress 
markers, such as plasma ascorbic acid.
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8.1.3 Limitations o f research detailed in thesis
There was large inter-individual variation in response to supplemental vitamin 
E observed throughout the research described, this is in agreement with previously 
published studies (Dimitrov et a l, 1991; Traber et a l, 1998a; Traber et a l, 1998b). 
The inter-individual variation observed increased the calculated number of subjects 
required for each study to provide significance. The studies detailed in this thesis 
however, involved relatively small subject numbers and the power of the results 
discussed would be increased with larger subject numbers. An ongoing problem 
throughout the studies was the difficulty in recruiting subjects, in particular those with 
altered lipid status and cigarette smokers and as a consequence some results are not 
conclusive. The studies have however provided some interesting avenues for future 
work.
The benefits of using deuterium labelled vitamin E are well recognised and it 
is evident in the study detailed in Chapter 3 that the use of non-labelled vitamin E is 
limited. However, deuterated tocopherols are not commercially available and are very 
expensive thereby potentially limiting their availability for usage in studies.
Method development to analyse plasma a- and y-CEHC, both deuterated and 
non-deuterated, was not possible in the timescale available for the current research 
project. It would have been interesting to assess plasma a- and y-CEHC to observe the 
extent and rate of production of newly absorbed a-tocopherol in Chapters 5 and 6.
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8.2 Recommendations for future work
The work that has been carried out for this thesis has provided some important 
findings and in the process has prompted further questions. These questions may form 
the basis of future research and suggestions for further studies are outlined below.
1. The uptake of newly absorbed a-tocopherol into platelets exhibited a biphasic 
response in some individuals, with a greater proportion in the 
hypercholesterolemic population. The a-tocopherol uptake and retention 
mechanisms into platelets are unknown, but it has been proposed in this thesis that 
passive diffusion and active transport may be involved. Experiments to investigate 
the possible processes for a-tocopherol uptake into platelets and to investigate if 
different lipoproteins are better donors than others are needed.
2. This thesis illustrated that vitamin E status was altered in cigarette smokers 
compared with non-smokers and it was hypothesised that these differences were 
due to a greater utilisation of vitamin E in the cigarette smokers. To investigate the 
formation of metabolites, measurement of both CEHC and tocopherylquinone are 
required to assess the turnover of vitamin E in a biokinetic study with deuterium 
labelled a-tocopherol and y-tocopherol. A study investigating the effect of vitamin 
C status on vitamin E levels within platelets and lymphocytes with respect to its 
ability to recycle tocopherylquinone to tocopherol would be of particular interest.
3. A large degree of inter-individual variation was observed in the response to 
vitamin E supplementation throughout the studies documented. Reasons for this 
variation point towards variation in absoiption, genetic polymorphisms that 
influence lipoprotein metabolism and the uptake of vitamin E into peripheral 
tissues. These are important areas for future research, a better understanding of the 
sources of variation and the magnitude of effect will help towards designing 
studies to investigate vitamin E status in subpopulations with altered vitamin E 
regulation.
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Personal Information Sheet
APPENDIX I
Please complete all sections.
All information given will be held in the strictest confidence.
Surname: Contact address:
Forenames:
Date of birth: Gender: Contact telephone:
E-mail address:
Yes/No Dates and details
Have you ever suffered from fits, blackouts, 
or fainting?
Are you currently on any long-term 
medication?
Do you suffer from any gastrointestinal 
disorder (e.g. chrohns disease, irritable 
bowel syndrome)
Do you smoke?....................If yes, how many cigarettes per day?
Do you follow a special diet or have any dietary restrictions? 
If yes, please give details:
Do you take any type of dietary supplement? 
If yes, please give details:
How many units of alcohol do you consume per week on average? 
(One unit = % pint lager, 1 measure spirits, or 1 glass wine).
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APPENDIX II
1. Density solutions used in the separation of lipoproteins by sequential 
ultracentrifugation
V0d0 4- A' = d(vQ + vx) 
x(l -  dv ) = v0 (d  -  d0)
x  = amount of KBr in grams 
Vo = initial volume in ml 
do = initial density 
d  -  final density
v = specific volimie of KBr at the final density 
Density solution 1.006 g / ml
11.4 g NaCl + 0.1 g EDTA Na2 + 500 ml H20  + 1 ml 1M NaOH 
Dissolve solids and make up to 1000 ml 
0.195 M NaCl
Density solution 1.182 g/ml
24.98 g NaBr +100 ml 1.006 g/ ml solution
0.195 M NaCl
2.44 M NaBr
Density solution 1.019ml 
8 ml 1.182 g/ ml +100 ml 1.006 g/ ml
Density solution 1,063ml
1.006 g/ m l: 1.182 g/ ml 
1 2
2. Equation for relative centrifugal force (g)
g = coir 
980
g = relative centrifugal force
r = the distance between the particle and centre of the rotation in cm (70.1 Ti radius
min 40.5 max 82)
co = rotor speed rad/ sec
co = rev/ min x 2 tc = rev/ min x (0.10472)
60
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An individual cholesterol profile o f LDL sub fractions
APPENDIX III
LDL sub fractions, an individual profile of cholesterol content of fractions. Fractions 2 
- 17 were used and adjacent fractions were pooled together for vitamin E analysis.
itSlM
&o
LDL sub fractions from light to dense
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APPENDIX IV
Triacylglycerol concentration in plasma for studies detailed in Chapters 4, 5 and 6
— Toast and butter 
to— High fat cereal 
to— Low fat cereal 
to— Water
150 mg a -  
tocopheiyl acetate 
and breakfast
0. 4 i i 1----------1----------1----------1----------1----------1----------1----------1
-1 0 1 2 3 4 5 6 7 8 9
Time (hours)
Chapter 4. Plasma triacylglycerol (TAG) concentration following ingestion of 150 mg d6 
RRR-a-tocopheryl acetate with four test meals over 6 hours
Values expressed as mean ± SEM (n = 8). There was a no significant difference over time
2.2 -|
2.0 -
1.8 -
O
£  1.6-
^  1.4 -0
1 1-2 -
1.0 -
0.8 -
0.6 -  
0
Chapter 5. Plasma triacylglycerol (TAG) concentration following ingestion of 150 mg d6 
RRR-a-tocopheryl acetate with 40g fat over 48 hours
Values expressed as mean ± SEM (n = 12). There was a trend towards a significant difference 
over time (p = 0.06)
- 1--------------1-------------- 1-------------- 1-------------- 1
10 20 30 40 50
Time (hours)
2 3 1
Time (hours)
Chapter 6. Plasma triacylglycerol (TAG) concentration following ingestion of 150 mg d6 
RRR-a-tocopheryl acetate with 40g fat over 48 hours in normolipidemic (NL) and 
hypercholesterolemic (HC) subjects
Values expressed as mean ± SEM (n = 8 in each group). There was a significant difference 
over time in the TAG concentration profile in NL and HC subjects (p < 0.05) and a significant 
difference between groups (p < 0.05).
